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1 Introduction 
 
 
The immune system is a remarkably adaptive defense system that has evolved in vertebrates to 
protect them from invading pathogens and cancer. It is able to generate an enormous variety of 
cells and molecules capable of specifically recognizing and eliminating an apparently limitless 
variety of foreign invaders. These cells and molecules act together in an exquisitely adaptable, 
dynamic and complex network. 
Immunity has both non-specific and specific components, which work in a synchronized manner 
that provides an effective biological defense. Innate, or non-specific immunity refers to the basic 
resistance to disease that comprises four types of defensive barriers: anatomic, physiologic, 
endocytic and phagocytic, and inflammatory. Acquired, or specific, immunity reflects the 
presence of a functional immune system that is capable of specific and selective immune 
responses: humoral and cell-mediated. Generation of an effective humoral immune response 
requires cell interactions between macrophages, TH cells and B cells leading to the production of 
large numbers of antibody molecules specific for a foreign pathogen. The cell-mediated 
immunity is characterized by the generation of various effector immune cells: CD4+ and CD8+ T 
lymphocytes (antigen-specific), macrophages, neutrophils, eosinophils and natural killer cells 
(antigen-non-specific). Unlike the humoral branch of the immune system, which serves mainly to 
eliminate extracellular bacteria and their products, the cell-mediated immunity is responsible for 
the clearance of intracellular pathogens, virus-infected cells, tumor cells and foreign grafts 
(Kuby, 1994). 
The large number of distinct cell types which are involved in the immune responses and their 
functions must be coordinated to insure a response that is appropriate in quality and in magnitude 
to the eliciting antigenic stimulus. A central role in this regulation and co-ordination of functions 
has the action of T lymphocytes, whose receptors are specific for peptides derived from the 
eliciting antigen, bound to a groove in a class I or a class II MHC molecules. Much of their 
function is mediated by a set of small proteins whose expression, secretion, or both is induced as 
a result of antigen-stimulated cellular activation. These proteins, designated cytokines, act by 
binding to high-affinity receptors expressed on target cells and by inducing biochemical signals 
within those cells that profoundly affect their behavior. 
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Cytokines are a diverse group of proteins, which can be subdivided into several families, 
including the haematopoietins, the interferons, tumor necrosis factor (TNF)-related molecules, 
immunoglobulin super-family members, and the chemokines (Paul & Seder, 1994). Among these 
molecules substantial overlap in functions is observed. These pleiotropic mediators act 
synergistically or antagonistically to orchestrate the behavior, proliferation and death of cells, 
acting directly or by regulating the expression of other cytokines. A paradigm of cytokine biology 
arises from the regulation of the differentiation of naive T cells. Among cloned lines of CD4+ T 
cells, two major subsets (TH1 and TH2) have been identified, which have shown a great degree of 
polarization in their cytokine-producing phenotype (Romagnani, 1991). TH1 clones tend to 
produce IL-2, IFNγ and TNFβ as their unique products, while TH2 clones express IL-4, IL-5, IL-6, 
IL-10 and IL-13. TH1 and TH2 cells develop from precursors of T helper cells (pTH), which are bi-
potent and their differentiation is determined by the present cytokines (Figure 1.1). IL-4 appears 
to be essential for priming the differentiation of pTH cells into TH2 cells, while IFNγ inhibits it 
(Seder et al., 1992). The differentiation into TH1 cells is enhanced by IL-12 and diminished by IL-
4 (Hsieh et al., 1993; Seder et al., 1993). 
 
              
+IL-2 and IL-4
+IL-2 and IL-12
IFN , IL-2, TNFγ β
IL-4, IL-5, IL-6
IL-10, IL-13
Cellular
immunity
Help for 
antibody
production
IL-4 inhibits
IFN  inhibitsγ
TH2 cell
TH1 cell
pTH cell 
 
 
Figure 1.1: Differentiation of pTH cells into TH1 and TH2 subtypes is determined by cytokines. A system through, 
which the polarization of CD4+ T cell response toward the production of IFNγ and the expression of cellular 
immunity or toward the production of IL-4 and expression of help for antibody production is mediated (Paul & 
Seder, 1994). 
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Interleukin-4 (IL-4) belongs to the haematopoietin family of cytokines. It was initially described 
in 1982 and first designated B-cell growth factor (Howard et al., 1982). IL-4 is produced by TH2 
cells (Figure 1.1), basophils and mast cells in response to receptor-mediated activation events 
(Seder & Paul, 1994). A specialized subset of T cells, some of which express NK1.1 and appear 
to be specific for CD-1 (NK T cells), has been also shown to produce IL-4 (Yoshimoto & Paul, 
1994; Chen & Paul, 1997). Eosinophils have also been reported to be capable of producing IL-4 
(Dubucquoi et al., 1994). 
Among the cytokine family, IL-4 is one that displays a wide range of biological effects on 
numerous cell types. These effects are either direct or indirect through the modulation of 
secretion of other cytokines. As mentioned above, IL-4 plays a central role in regulating the 
differentiation of antigen stimulated naive T cells into TH1 or TH2 subtypes and determines the 
kind of the following immune response (McKenzie, 2000). 
A second function of major physiologic importance is IL-4´s control of specificity of 
immunoglobulin class switching. IL-4 determines that human B cells switch to the expression of 
IgE and IgG4 and mouse B cells to IgE and IgG1 (Gascan et al., 1991; Coffman et al., 1986). 
This switching function is antagonized by IFNγ. Similarly, IL-4 inhibits the production of IgG2a 
in B cells treated with IFNγ (Pene et al, 1988). Thus, the control of production of this two 
cytokines is a key element in the qualitative nature of immune responses. Indeed, in IL-4 and IL-
4 receptor α (IL-4Rα) deficient mice the serum levels of IgE and IgG1 are strongly reduced 
(Kopf et al., 1993; Kuehn et al., 1991; Noben-Trauth et al., 1997). Taken together, these facts 
have established an important role of IL-4 in Ig isotype selection in vitro and in vivo. 
IL-4 has a variety of other effects in cells of the immune system. It is involved in activation and 
proliferation of T and B cells (Nicola, 1994; Rebollo et al, 1996; Friedrich & Wietek, 2001). In 
resting B cells IL-4 increases the expression of class II MHC molecules (Noelle et al., 1984), 
enhances expression of CD23 (Defrance et al., 1987), up-regulates the expression of the IL-4 
receptor (Ohara & Paul, 1988), and in association with lipopolysaccharide allows B cells to 
express Thy1 (Snapper et al., 1988). It also acts as a co-mitogen for B cell growth (Howard et al., 
1982). Although not a growth factor by itself for resting lymphocytes, it can substantially prolong 
the lives of T and B lymphocytes in culture (Hu-Li et al., 1987). IL-4 also has activity as a 
stimulant of IL-3-mediated mast cell growth. IL-4 acts on macrophages to inhibit the release of 
proinflammatory molecules such as TNF, IL-1, IL-8 and other cytokines (Nicola & Hilton, 1999). 
IL-4 also has an important role in tissue adhesion and inflammation. It acts with TNF to induce 
expression of vascular cell adhesion molecule-1 on vascular endothelial cells (Thornhill et al., 
1991) and it down-regulates the expression of E-selectin (Bennett et al., 1997). This shift in 
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balance of expression of adhesion molecules by IL-4 is thought to favor the recruitment of T cells 
and eosinophils, rather than granulocytes, to the side of inflammation. 
Many cell types respond to IL-4, including some without apparent connection to haematopoiesis 
or to the immune system, e.g. osteoblats, keratinocytes, or fibroblasts (Duschl & Sebald, 1996). 
IL-4 acts as a chemotactic factor for fibroblasts and induces dermal fibroblasts to secrete 
extracellular matrix proteins, such as type I and type III colagens and fibronectin (Chomarat & 
Banchereau, 1997). Although the mechanism remains unclear, IL-4 has been observed to enhance 
the killing of tumor cells in vivo (Tepper & Mule, 1994). 
Studies with transgenic mice have revealed that over-expression of IL-4 results not only in high 
serum IgE levels, but also in inflammatory lesions, which severity and frequency directly 
correlates with the level of transgenically expressed IL-4. These lesions histologically resemble 
those seen in human allergic disorders suggesting the importance of IL-4 in the pathogenesis of 
allergic diseases (Tepper et al., 1990). The pathophysiological features of allergic asthma are 
thought to result of aberrant expression of TH2 cells producing IL-4, IL-5 and IL-13. Such 
conclusion is supported by the fact that TH2 cells are necessary for induction of allergic asthma in 
murine models (Gavett et al., 1994). The type 2 cytokines undergo expansion in these models as 
well as in patients with allergic asthma (Walker et al., 1992). High amounts of these cytokines 
have been detected especially in the airway tissue of asthmatics and animal models (Gavett et al., 
1995; Tsicopoulos et al., 2000). Experiments using IL-4 deficient mice have shown significantly 
attenuated asthma phenotype after repeated allergen exposure, in contrast to wild-type control 
animals, where all asthmatic symptoms have developed (Brusselle et al., 1994; Brusselle et al., 
1995; Hamelmann et al., 1999). 
Recent studies have demonstrated the contribution of another type 2 cytokine, IL-13 for inducing 
allergic asthma in a IL-4-independant manner (Wills-Karp et al., 1998; Gruenig et al., 1998; 
Cohn et al., 1999, Izuhara et al., 2000). IL-13 is a cytokine closely related to IL-4 and both bind 
to IL-4Rα. Linkage analysis has mapped susceptibility to allergic asthma to a region on human 
chromosome 5q25-33, which includes the genes for both IL-4 and IL-13 (Marsh et al., 1996, 
Lonjou et al., 2000). A number of additional regions in the genome have been linked to asthma in 
human studies, suggesting a complex multifactorial phenotype (Nanavaty et al., 2001). However, 
diverse forms of asthma, implicating IL-4 and IL-13 might follow a final common effector 
pathway mediated through signals transduced by IL-4Rα. 
Allergy comprises a group of syndromes that includes asthma, atopic dermatitis and hay fever. 
These diseases have classically been described as caused by an allergic response characterized by 
immediate (type 1) hypersensitivity reactions, increased serum IgE, and increased bronchial 
reactivity to specific or non-specific inhaled allergens. Allergic asthma is a complex disorder 
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characterized by local and systemic allergic inflammation and reversible airway obstruction 
(Anderson & Morrison, 1998). Asthma develops because of both a genetic predisposition and the 
exposure to environmental factors, such as allergens, respiratory tract infections and atmospheric 
pollutants (Manian, 1997). Most major allergens are extremely well characterized. They are 
usually soluble proteins with dimensions that allow penetration into the airways of the nose or 
lung. Allergen sources include house dust mites, domestic and farm animals, and grass or tree 
pollen. 
Recent decades have brought dramatic increases in the prevalence and severity of allergic asthma. 
It is especially an important problem in developed societies, where 10% of the children are 
affected (Cookson & Moffatt, 1998). 
Although some details of the asthmatic pathogenesis remain unclear, the main mechanism and the 
role of IL-4 are well established (Figure 1.2). Processing of the allergen by antigen-presenting 
cells (APC) leads to the formation of an allergen peptide that is presented to the T-cell receptors 
(TCR) of CD4+ T cells in association with MHC class II molecules. IL-4 released by eosinophils, 
basophils and mast cells facilitates the differentiation of pTH cells into TH2 cells which secrete IL-
4, IL-5, IL-6, IL-10 and IL-13. Activated TH2 cells interact through the TCR with the peptide-
MHC complex on B cells. Adhesive interaction between TH2 and B cells are also mediated by the 
surface expression of CD40 ligand on TH2 cells and CD40 on B cells. IL-4 and IL-13, secreted to 
a varied extent by TH2 cells, basophils, mast cells and eosinophils, induce immunoglobulin class 
switching to IgE in B cells. Allergic disease is initiated when allergen comes into contact with 
IgE bound to the high affinity IgE receptor (FcεRI) on mast cells and basophils. Receptor cross-
linking releases a mixture of inflammatory mediators (histamine, peptide leukotrienes and 
platelet-activating factor) that are responsible for the symptoms of allergic asthma. Immediate 
inflammation and associated symptoms resolve and are followed by a second phase, which 
typically peaks 6 to 20 hours after antigen exposure (Marone, 1998). 
The conventional therapy of patients with allergic asthma includes symptomatic treatment with 
inhaled corticosteroids. The long term of steroid therapy has shown different side effects such as 
osteoporosis, skin thinning and hypertension. New, alternative strategies specifically target the 
TH1/TH2 balance of the immune response. Potent candidates for development of anti-allergic 
drugs are IL-4, IL-5 and IL-13. Possible therapies include the use of inhibitory antibodies, soluble 
cytokine receptors or antagonistic cytokine variants (Prasad et al., 2000; Ramshaw et al., 2001). 
An antibody-mediated blockade of IL-4 in a murine model has ablated the development  
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Figure 1.2: Mechanism of immediate (type I) hypersensitivity reactions. Allergens induce disease in sensitized 
individuals by the crosslinking of IgE bound to high-affinity receptors on mast cells. Mast cell degranulation initiates 
an inflammatory cascade and allergic symptoms. Th2 cells up-regulate IgE production, whereas Th1 cells down-
regulate it (Cookson & Moffatt, 1998). 
              
 
of allergic asthma only when the monoclonal antibody has been administered during the period of 
systemic immunization. No effect has been observed when anti-IL-4 has been administrated 
during the period of allergen challenge (Corry et al., 1996; Tanaka et al., 1998). Treatment of 
sensitized mice with soluble IL-4 receptor (sIL-4R) has demonstrated partial success, since the 
late phase pulmonary inflammation has been blocked to some degree (Henderson et al, 2000). 
Antagonistic IL-4 variants have been first described for human IL-4 (Kruse et al., 1992; Kruse et 
al., 1993). The most efficient human antagonist described so far is [R121D, Y124D]-IL-4 (Tony 
et al., 1994). A murine antagonistic variant, [Q116D, Y119D]-mIL-4, has shown inhibition of 
mIL-4 and has prevented completely the development of an allergy phenotype in treated animals 
(Grunewald et al., 1998). Another mutant variant of murine IL-4 (C118 deletion) was recently 
reported to prevent the development of allergic airway eosinophilia and airway 
hyperresponsiveness in mice (Tomkison et al, 2001). These examples demonstrated the 
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therapeutic potential of IL-4 mutant proteins as receptor antagonists that are able to inhibit both 
IL-4 and IL-13 in treatment of allergic asthma. 
Murine IL-4 is a glycoprotein with an approximate molecular weight of 19 kDa when purified 
from T-cell source (Ohara et al., 1985; Grabstein et al., 1986). Recombinant IL-4 produced in 
baculovirus expression system has an approximate molecular weight of 14 to 15 kDa, whereas 
recombinant IL-4 produced in yeast is quite heterogeneous in molecular weight with some forms 
having size of ∼50 kDa. These differences represent variable glycosylation. IL-4 that has been 
deglycozylated has full biologic activity (Le et al., 1988), as does recombinant IL-4 produced in 
E.coli. Human IL-4 has very similar characteristics (Table 1.1). It exists in molecular weight 
forms between 15 and 19 kDa. 
 
Table 1.1: Characteristics of murine and human IL-4 (Beckmann, 1992) 
 
Characteristic Murine IL-4 Human IL-4 
Amino acids   
    Precursor 140 153 
    Mature 120 129 
Molecular weight, kDa   
    Predicted 14 14 
    Expressed 15-19 15-19 
N-linked glycosylation sites 3 2 
Disulphide bonds  Yes (6 Cys) Yes (6 Cys) 
Gene size, Kbp ∼ 6 ∼ 10 
    Number of exons 4 4 
    Chromosomal location 11 5q23.3-31.2 
 
cDNA for both mouse and human IL-4 have been cloned (Lee et al., 1986; Yokota et al., 1986), 
and the proteins encoded by the murine and human cDNAs contain 140 and 153 amino acids, 
respectively. Both murine and human IL-4 contain putative signal sequences at their N-termini 
which following cleavage, result in mature proteins of 120 and 129 amino acids, respectively. 
There is approximately 50% overall identity between human and murine IL-4. 
The gene for human IL-4 has been mapped to the long arm of chromosome 5 at 5q23-31 (Le 
Beau et al., 1988). The IL-4 gene is linked to the genes of a few other cytokines: IL-13, IL-5, 
granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3. Due to their close 
localization, the similar exon structure of the genes and their primary sequence homology, this 
cytokines have been termed the IL-4 family (Paul & Seder, 1994). A homologous region has been 
found at mouse chromosome 11 (D´Eustachio et al, 1988). 
The secondary structure of IL-4 has been described in crystals and in solution (Powers et al., 
1992; Smith et al., 1992; Walter et al., 1992; Wlodawer et al., 1992). IL-4 displays the four α-
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helix bundle structure, which is a characteristic of the ligands from class 1 of the cytokine super-
family. The four-helix bundles of haematopoietic ligands have an “up-up-down-down” 
orientation in which the first two helices are parallel to each other and anti-parallel to the last two. 
This is achieved by cross-over connections linking helix A to B and helix C to D. Based on the 
overall length of the polypeptide chain, the length of the main helices, and the inter-helix angles, 
class 1of cytokine superfamily is further classified into two groups: a “long chain” and a “short 
chain” group (Sprang & Bazan, 1993). As seen from the structures of GH, G-CSF, LIF, EPO, IL-
6, and leptin, members of the long-chain group have about 160 to 200 amino acids, long helices 
(about 25 residues), and an angle between the AD and BC helix pairs of about 160°. Based on 
sequence comparisons, it is expected that PRL, ONC, CNTR, IL-11, and IL-12 belong to this 
group as well. In contrast, the ligands of the short-chain group are 105 to 145 amino acids long, 
have shorter helices (about 15 residues), and a large AD/BC packing angle (about 35°), as seen 
from the structure of GM- and M-CSF, IL-2, IL-4, and IL-5. Also IL-3, IL-7, IL-9, IL-13, and 
CSF are expected to show similar structural topology. Most of the ligands are monomeric, with 
the exceptions of the disulfide-linked dimers of M-CSF and IL-5 (for a review see Kossiskoff & 
de Vos, 1998; Nicola & Hilton, 1998). 
The overall structure of IL-4 is highly compact and globular with a predominantly hydrophobic 
core. The helices range in length from 14 to 25 residues. They are connected by one short and 
two long segments to form a left handed bundle topology (Figure 1.3). These connecting 
segments include residues 19-40 (loop AB), 59-69 (loop BC), and 95-108 (loop CD). Residues 
27-31 and 105-108 within the two long connections form a two-stranded anti-parallel β-sheet 
(Walter, et al., 1992).  
Human recombinant IL-4 contains three disulfide bonds and no free cysteine residues. Cys3 and 
Cys127 form a disulfide bond that links the N- and C-termini of the molecule. Cys24 is located at 
the C terminal end of helix A and forms a disulfide bond with Cys65, which is in the BC loop. 
Cys46 is in the middle of helix B and forms a disulfide bond with Cys99 located in the CD loop. 
The three disulfide bonds link the polypeptide chain at the three most spatially parts of the 
molecule (Walter et al., 1992). Exchange of the cysteine residues in human IL-4 with threonine 
residues has revealed that the disulfide bridge formed by Cys46–Cys99 is structural and functional 
essential, whereas the other two disulfide bridges (Cys3–Cys127 and Cys24–Cys65) are less 
important (Kruse et al., 1991). Human IL-4 contains two potential sites for N-linked 
glycosylation at positions 38-40 and 105-107. 
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Figure 1.3: Ribbon model of the IL-4 molecule. 
              
 
The ability of cytokines to influence the course of cell growth and differentiation uniquely 
depends on their recognition and binding by specific receptors. These are cell surface molecules 
that transduce the binding of messenger cytokines into cytoplasmatic signals and trigger 
developmental processes within the cell (Nicola & Hilton, 1998).  
IL-4 receptors (IL-4R) are present in haematopoietic, endothelial, epithelial, muscle, fibroblast, 
hepatocyte and brain tissues. Two types of IL-4R have been established, so far (Table 1.2). The 
type I IL-4R is constituted by the association of a high-affinity (Kd ~ 100 pM) IL-4R α-chain, 
(IL-4Rα) and the IL-2R γ-chain, known as IL-2Rγ or γc (Russell et al., 1993). This kind of 
receptor is especially found on T and B lymphocytes, and monocytes. The type II IL-4R, which is 
expressed on non-haematopoietic cells, is composed of the IL-4Rα and the low-affinity binding 
chain for IL-13 termed IL-13Rα1 (Obiri et al., 1995). The type II receptor is used by both IL-4 
and IL-13, whereas the type I is used only by IL-4 (Murata et al., 1998; Jensen, 2000). 
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Table 1.2: Comparison of IL-4R type I and II. Data from Jensen, 2000 is used. 
 
 Chain composition Type of cells Binding to IL-4 Binding to IL-13
IL-4R type I IL-4Rα, γc T and B lympho-
cytes, monocytes
high affinity no binding 
IL-4R type II IL-4Rα, IL-13Rα1 Cos-7, A431, 
Colo201 cells 
competition 
with IL-13 
high affinity; 
competition 
with IL-4 
 
Cytokine receptors are type I membrane proteins, where extracellular and intracellular domains 
may operate rather independent from each other. Transmembrane signaling is achieved by 
dimerization or oligomerization of receptor subunits. For IL-4, binding is a strictly sequential 
process (Figure 1.4). The ligand is first bound with high affinity by the ectodomain of IL-4Rα, 
and then this 1:1 complex can associate the γc creating in this way an active dimer. A cellular 
signal is generated because the joined intracellular domains can recruit signaling molecules from 
the cytoplasm (Duschl & Sebald, 1996). 
 
              
 Step 2: receptor dimerization Step 1: liga inding 
 
 
IL
 
IL-4Rα 
 
 
Figure 1.4: A two step 
   
 
Based on in vitro a
molecule. Site 1 bi
which is important
end of helix D, in
 nd b-4 
active dimer 1:1 complex γc 
mechanism of receptor activation by IL-4 (Duschl & Sebald, 1996). 
           
nd in vivo binding studies, two binding sites have been described in the IL-4 
nds to IL-4Rα and is marked by Glu9 in helix A and Arg88 in helix C. Site 2, 
 for the IL-4-dependent association between IL-4Rα and γc, is located at the 
cluding particularly Arg121, Tyr124, and Ser125. (Kruse et al., 1993). The 
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mechanism of sequential receptor dimerization and the established two binding sites have been 
exploited for design of antagonistic variants of IL-4. Such mutants cannot recruit the γc into the 
receptor complex, since the site 2 has been destroyed, but they bind to IL-4Rα with high affinity 
and in this way block the signaling pathways (Kruse et al., 1992). 
Ligand induced dimerization of cytokine receptors results in the activation of tyrosine kinases 
that phosphorylate cellular substrates and initiate signaling cascades (Miyajima et al., 1992). 
Neither the IL-4Rα nor the γc has endogenous kinase activity and therefore the IL-4R requires 
receptor-associated kinases for the initiation of signal transduction. The Janus-family (Jak) 
tyrosine kinases are critical in the initiation of signaling through the IL-4R system. Jak1 has been 
proposed to associate with IL-4Rα, while Jak3 associates with γc (Miyazaki et al., 1994). IL-4 
stimulation results in tyrosine phosphorylation of Jak1 and Jak3 (Figure 1.5). Activation of IL-
4R-associated kinases leads to tyrosine phosphorylation of the IL-4Rα chain itself, a process that 
occurs rapidly after IL-4R engagement (Smerz-Bertling & Duschl, 1995). The cytoplasmic 
domain of human IL-4Rα contains six conserved tyrosine residues, which are potential sites of 
phosphorylation and subsequent interaction with downstream signaling proteins through Src-
homology 2 (SH2) or phosphotyrosine-binding (PTB) domains within these molecules. The 
cytoplasmic region of IL-4Rα chain appears to have three functionally distinct domains, one that 
acts as an interaction site for Jaks, one required for activation of proliferative pathways 
(containing Tyr497), and a third involved in the activation of pathways leading to induction of 
gene expression (Tyr575, Tyr603, Tyr631). 
Analysis of IL-4Rα deletion mutants have indicated that the region between residues 557 and 657 
of the human IL-4Rα is critical for the induction of signaling pathways leading to expression of 
IL-4-responsive genes (Wang et al., 1996). The three conserved tyrosine residues within this 
region (Tyr575, Tyr603, Tyr631) are potential sites of phosphorylation and subsequent 
association of SH2-containing proteins. As a direct connection between the cytokine receptor and 
the transcription apparatus act molecules termed signal transducers and activators of 
transcription, or STATs. Experimentally it has been shown that Jak activation is required for 
STAT activation (Velazquez et al., 1992). Thus, the STAT activation pathway is often referred to 
as the Jak-STAT pathway. STAT6 is the primary STAT activated in response to IL-4 stimulation. 
IL-4 engagement results in the activation of Jak1 and Jak3, and phosphorylation of specific 
tyrosine residues in the receptor cytoplasmic region. STAT6 then binds to the phosphorylated 
receptor through a highly conserved SH2 domain, enabling the activated kinases to phosphorylate 
STAT6 at a C-terminal tyrosine residue. The conserved Tyr575, Tyr603, Tyr631 have been 
proposed to be docking sites for the SH2 domains of STAT6 (Figure 1.5).  
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Figure 1.5: Signal transduction through the IL-4R complex. A, B, C, and D, IL-4 helixes; IL-4RE, IL-4 responsive 
element; IL-1RA, IL-1R antagonist; GAS, IFNγ activated sequence. 
              
 
Once phosphorylated, the STAT6 molecule disengages from the receptor and forms homodimers 
through interaction of its SH2 domain with the C-terminal phosphotyrosine residue of a second 
STAT6 molecule. The dimerized STAT6 complexes translocate to the nucleus where they bind to 
specific DNA motifs in the promoter of responsive genes. The DNA motifs bound by different 
STATs bear remarkable similarity to each other and reflect a dyad symmetry. STAT6 appears to 
bind in particular to the sequence TTC-N4-GAA (Leonard & O´Shea, 1998). The exact 
mechanism by which STATs activate transcription is still being determined. Activation of gene 
transcription by STAT6 may require co-operative interaction with additional transcription factors 
(Schaefer et al., 1995; Look et al., 1995), or phosphorylation by kinases activated in the 
Ras/MAP kinase cascade (David et al., 1995). Alternatively spliced forms of STAT6 have 
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deletions in the N-terminal (STAT6b) or SH2 (STAT6c) regions (Patel et al., 1998) and may play 
a role in STAT6 regulation. 
Stimulation with IL-4 or IL-13 induces tyrosine phosphorylation of a 170 kDa protein designated 
insulin receptor substrate-2 (IRS-2), due to its high similarity to IRS-1 (Turner et al., 1991; 
Miossec, 1993). The IRS-1/2 molecules link IL-4R to signaling pathways involved in cellular 
proliferation (Sun et al., 1995). It has been shown that IRS-2 becomes phosphorylated as a result 
of interaction with a phosporylated motif of the IL-4Rα including Tyr497, presumably through 
the action of receptor-associated kinases (Wang et al., 1996). Among the molecules that interact 
with the phosphorylated IRS-1/2 are the regulatory subunit of phosphoinositide-3-kinase (PI-3-K) 
and the adapter molecule, Grb-2 (Figure 1.5). These interactions lead to the activation of the PI-3-
K and Ras/MAPK signaling pathways, respectively. The interaction between the regulatory 
subunit of PI-3-K and IRS-1/2 is followed by activation of the catalytic subunit of PI-3-K. Once 
activated, the catalytic subunit is capable of phosphorylating membrane lipids as well as Ser/Thr 
residues of proteins (Dh et al., 1994). The lipid kinase activity mediates phosphorylation of 
inositol in the cellular membrane (Toker et al., 1997). Since phosphoinositides have been 
implicated in the activation of a number of downstream kinases that play a key role in cell 
survival (Franke et al., 1997), it is hypothesized that activation of the PI-3-K pathway by IL-4 
may prevent apoptosis in haematopoietic cells. Although the importance of the Ser/Thr kinase 
activity has not yet been fully defined, it has been suggested that this pathway may result in a 
negative feedback loop, which contributes to the regulation of the IRS-1/2 signaling pathway. IL-
4 activation of Ras/MAPK is not consistently observed. In particular, this activation critically 
depends on cell type and more specifically on the variety of signaling molecules expressed in 
these cells. (Welham et al., 1995; Zamorano et al., 1998) 
The signaling pathways that are activated by IL-4R engagement, such as the Jak-STAT and 
IRS1/2 pathways, mirror those activated by a number of other cytokines. Nevertheless, the 
activation of these pathways results in a unique pattern of cellular responses to IL-4. In the case 
of IL-4, specificity is in part achieved through the activation of STAT6, an event that, among 
class I cytokine receptors, has been demonstrated to occur only through engagement of IL-4Rα. 
Specific cellular responses to IL-4 may also result from the unique character of the IL-4R (for a 
review, see Nelms et al., 1999). 
cDNA encoding the human high-affinity IL-4Rα have been obtained (Idzerda et al., 1990). The 
full-length cDNA contains an open reading frame encoding a 825 amino acids protein, which 
includes a signal sequence of 25 amino acids. The mature receptor chain is a glycoprotein with 
molecular weight of 140 kDa, which displays a 207-amino-acid extracellular domain, a 
transmembrane domain of 24 amino acids, and a 569-amino-acid cytoplasic domain. It contains 
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six potential N-glycosylation sites. Furthermore, an alternatively spliced form of IL-4Rα has 
been identified in mouse serum. It encodes a soluble product (sIL-4R) which binds IL-4 with an 
affinity comparable with that determined for the cell surface receptor chain (Fernandez-Botran & 
Vitetta, 1990). A role of a transport protein that prevents enzymatic degradation of IL-4, has been 
suggested for sIL-4R (Fernandez-Botran & Vitetta, 1991). 
The γc, first identified as a component of IL-2R, has been found to be shared as a common 
subunit among receptors for IL-2, IL-4, IL-7, IL-9 and IL-15. Therefore, it is now called the 
common γc. Neither IL-4 nor any other cytokine up to now could be demonstrated to bind directly 
to a solitary γc in whole cells (Sugamura et al., 1995). Molecular binding studies have indicated 
that the γc recognizes a complex of IL-4 and IL-4Rα and binds to it exhibiting a high dissociation 
constant Kd = 3 µM (Letzelter et al., 1998). Although γc does not contribute to the affinity of the 
IL-4R complex for IL-4, it is essential for formation of the functional IL-4R and activation of 
signaling pathways by IL-4 (Russel et al., 1993). Human cDNA clones encoding the 64 kDa-
protein of the common γc have been isolated (Takeshita et al., 1992). The mature form of γc 
consists of 347 amino acids, including an extracellular domain of 232 amino acids, a 
transmembrane domain of 29 amino acids, and an 86-amino-acid cytoplasmic domain that 
contains two SH2 regions. The human γc gene has been mapped on the same chromosomal locus 
(Xq13) as the putative gene responsible for the human X-linked severe combined 
immunodeficiency (XSCID) characterized by a complete or profound T cell defect. XSCID is 
now understood to be caused by mutations of γc (Sugamura et al., 1996). 
The human IL-13Rα1 cDNA encodes for an open reading frame of 427 amino acids. The signal 
sequence is represented by 20 amino acids and the mature receptor chain is constituted by an 
extracellular domain of 322 amino acids, a transmembrane domain of 24 amino acids, and a 60-
amino acid cytoplasmic domain. The IL-13Rα1 binds IL-13 with a weak affinity (Kd = 2-10 nM), 
but its co-expression with the IL-4Rα markedly increases the affinity of the interaction (Kd = 400 
pM) (Aman et al., 1996). However, in the interaction between IL-13 and IL-4R type II, IL-13Rα1 
is the specificity chain and such an interaction occurs only when this chain is present. Thus, IL-
4Rα has a high-affinity epitope for IL-4 and a low-affinity epitope for IL-13. The epitopes for the 
two ligands overlap, since both IL-4- and IL-13-dependent responses can be inhibited by 
antagonistic IL-4 variants blocking the IL-4Rα chain (Tony et al., 1994; Tomkinson et al, 2001). 
All three chains, which are components of the IL-4R/IL-13R system, belong to the class 1 of the 
cytokine receptor superfamily. The structural basis for the classification of the cytokine receptors 
in one superfamily is a conserved cytokine receptor homology (CRH) region within their 
extracellular portion. This CRH contains the ligand-binding determinants of the receptor. As first 
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proposed by Bazan (1990), the 200 to 250-amino acids long CRH region consists of two domains 
connected by a short linker. Both domains can be classified as fibronectin type III (FNIII) 
modules based on their overall fold and topology. Each domain consists of a β sandwich 
containing seven β strands, sequentially labeled A, B, C, C´, E, F and G following the accepted 
FNIII convention (Leahy et al., 1992). The CHR regions of receptors of class 1 of the super-
family have four strictly conserved cysteine residues in their N-terminal domain and a strongly 
conserved Trp-Ser-X-Trp-Ser sequence, the so-called “WSXWS motif”, near the C-terminus of 
the second domain (X being any residue).  
The crystal structure of the 1:1 complex between human IL-4 and IL-4BP revealed that IL-4BP 
exhibits all features characterizing the class I of the cytokine receptor superfamily (Hage et al., 
1999). It has an overall L shape (Figure 1.6) and is organized in two covalently linked domains, 
D1 (residues 1-91) and D2 (residues 97-197). The antiparallel β sheets are arranged in three-
strand (A, B, E) and four-strand (G, F, C, C´) β-pleated sheets that are twisted against each other 
by ~ 40°. Domain D1 belongs to the h-type topological subclass of the immunoglobulin fold 
where strand C´ interacts first with strand C, and then its direct continuation (designated D) 
switches to interact with strand E. It contains an additional single helical turn in BC loop and six 
cysteine residues that are engaged in three disulfide bridges as follows: Cys9-Cys19, Cys49-Cys61, 
and Cys29-Cys59. The first two are conserved among class I CHR´s (Bazan, 1990), while the third 
is unique to IL-4BP. D2 domain also shows FN III topology with two additional short helices and 
no disulfide bridges. 
The quaternary structure of the complex is assembled by IL-4BP binding to the helix AC face of 
IL-4 and is characterized by an almost perpendicular orientation of the L-shaped IL-4BP to the 
helical axes of αC and αA of IL-4 (Figure 1.7). Loops of IL-4BP that interact with IL-4 are 
almost co-linear with the axes of the IL-4 helices and are oriented in a stack-like fashion. They 
comprise four different levels, namely loop L2 from IL-4BP interacting with helix B of IL-4, 
loops L3 and L1 interacting with αC, and loops L5 and L6 interacting with αA. Loop L4 
connects domains D1 and D2 and has no interaction with IL-4. 
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Figure 1.6: A ribbon model of IL-4BP. Loops which make contacts to IL-4 are showed in blue. In the dark gray is 
loop L2 connecting D1 and D2.  
              
 
An important feature revealed by the complex is the polar character of the interacting epitopes, 
which are highly discontinuous and comprise multiple sequence segments. Contact residues on 
IL-4 are distributed over three helices and comprise mainly polar and charged residues. The 
complementary receptor epitope is assembled from residues of five loops and has a midline of 
hydrophobic side chains. The binding epitope reveals a mosaic-like assembly consisting of three 
discrete clusters of trans-interacting residues. Two of them exhibit conspicuous amphipathic 
structure with an outer mantle of hydrophobic side chain moieties and an inner core of polar 
groups. The third cluster has a completely different design and is dominated by electrostatic 
interactions. 
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Figure 1.7: A ribbon view of the structure of the IL-4/IL-4BP complex (IL-4BP, blue/yellow; IL-4, red). The five IL-
4BP loops that interact with IL-4 are highlighted in yellow. The loop depicted in blue connects D1-D2 and has no 
interactions with IL-4 (Hage et al., 1999). 
              
 
A mosaic-binding pattern has been independently confirmed by a systematic mutational and 
kinetic analysis of IL-4 contacting residues (Wang et al., 1997). This study has shown that 
charged and polar determinants located on helices A and C predominate in the high-affinity 
binding epitope of human IL-4. The binding epitope has been established as a set of side chains 
determining the dissociation rate constant (koff) and a partially overlapping set determining the 
association rate constant (kon) of IL-4/IL-4BP complex. Based on these results, the koff epitope is 
represented by two juxtaposed main determinants (Glu9 and Arg88) surrounded by a few side 
chains of lower importance (Ile5, Thr13, Arg53, Asn89, and Trp91). The kon epitope has been 
postulated as formed by five positively charged residues on helix C (Lys77, Arg81, Lys84, 
Arg85, and Arg88) and two neighboring residues on helix A (Glu9 and Thr13). Thus, both the 
data from the crystal structure and from the mutation analysis have revealed novel features, 
which are different from these known for the hGH, and are unique for the IL-4 functional epitope. 
The formation of complexes between proteins and the specific interactions between a ligand and 
its receptor in particular, are critical events in many biological processes. Structural analysis can 
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reveal the interactions that contribute to protein-protein recognition in atomic details (Jones & 
Thornton, 1996). However, it alone cannot show how these interactions contribute to the overall 
affinity and specificity. Ideally, the high-resolution structure of a complex would be used to guide 
a comprehensive functional survey of residues presented at the interface using site-directed 
mutagenesis, to allow their individual contribution to be assessed. Since the effects of alanine and 
glutamine substitution in IL-4 variants have been examined (Wang et al., 1997), the present study 
concentrates on functional mapping of IL-4BP binding surface. To analyze the contribution of 
individual side chains to overall binding energy in the interaction between IL-4 and IL-4BP, 
residues of the receptor interface implicated in ligand binding were subjected to systematic 
alanine substitution (alanine scanning). The IL-4BP variants were expressed in a eukaryotic 
expression system that allowed their glycosylation. The binding kinetics was measured by the 
means of the BIAcore technology. For this, the IL-4BP variants were immobilized at the 
biosensor matrix. Variants, which demonstrated large changes of the kinetic constants comparing 
to the wild-type interaction, were additionally mutated to a more conservative residue. That gave 
the possibility to assess weather the loss of binding affinity was due to grate conformational 
changes caused during the alanine substitution. In addition, energetic coupling between two 
residues was analyzed using variants in which two different mutations were introduced 
simultaneously. The effects on binding that was produced by the double mutants were compared 
to those observed when the corresponding residues were mutated singly. 
The nature of the interactions between cytokines and their receptors is of fundamental importance 
for detailed understanding of the immune response. While these receptors are clearly specific to 
their ligands, some of them share receptor functions between more than one different ligand. 
Understanding of the similarities and differences between these related proteins, and the 
molecular mechanisms involved in their binding, will provide insights into more general protein-
protein interactions. Moreover, knowledge about the structural and functional binding epitope of 
both IL-4 and IL-4BP, provides the basis for developing molecules with antagonistic properties 
to IL-4 and design of highly effective anti-allergic drugs. 
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2. Materials and Methods 
 
2.1 Abbreviations 
 
γc “common γ chain” 
Ab antibody 
AcNPV Autographa californica nuclear polyhedrosis virus 
Amp ampicillin 
APC antigen presenting cell 
APS ammonium persulfate 
BEVS Baculovirus expression vector system 
bp base pair 
BPB bromphenol blue 
BSA bovine serum albumin 
CD cluster of differentiation 
cDNA complementary deoxyribonucleic acid 
CNTF ciliary neurotrophic factor 
CRH cytokine receptor homology 
Da Dalton 
∆∆G change of binding free energy 
∆∆Gadd the ∆∆G value for a double mutant predicted by adding the ∆∆G values for the 
 corresponding individual mutants 
ddNTPs 2’,3’-dideoxyribonucleoside triphosphates 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
dNTPs deoxyribonucleoside triphosphates 
dsDNA double-stranded deoxyribonucleic acid 
DTT dithiothreitol 
E.coli Escherichia coli 
EBP erythropoietin binding protein 
EDTA ethylendiamintetraacetic acid 
EPO/EPOR erythropoietin/ erythropoietin receptor 
eq., equilib. equilibrium 
EtBr ethidium bromide 
EtOH ethanol 
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FCS fetal calf serum 
FNIII fibronectin type III 
GCSF granulocyte colony-stimulating factor 
GCSF-R granulocyte colony-stimulating factor receptor 
GH growth hormone 
GM-CSF granulocyte-macrophage colony-stimulating factor 
GuHCl guanidine hydrochloride 
hGH human growth hormone 
hGHbp human growth hormone-binding protein 
HMS high molecular standard 
HPLC high pressure liquid chromatography 
Ig immunoglobulin 
IL-13Rα1 interleukin-13 receptor α1 
IL-4Rα interleukin-4 receptor α chain 
IL-x interleukin-x 
IL-xBP interleukin-x binding protein 
IL-xR interleukin-x receptor 
INF interferon 
IRS-1/2 insulin receptor substrate-1/2 
Jak Janus kinase 
kbp kilo base pair 
Kd dissociation equilibrium constant 
kin. kinetic data 
koff dissociation rate constant 
kon association rate constant 
LB Luria Broth 
LIF leukaemia inhibitory factor 
LMS low molecular standard 
ln logarithm to the basis of “e” 
m mouse 
max. maximal 
MCS multiple cloning site 
M-CSF macrophage colony-stimulating factor 
MHC major histocomatibility complex 
min minute(s) 
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MOI multiplicity of infection (plaque-forming units/cell number) 
mRNA messenger ribonucleic acid 
MS molecular standard 
n number of measurements 
NK natural killer (cell) 
NMR nuclear magnetic resonance 
ORF Open Reading Frame 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PEG polyethylene glycol 
pfu plaque forming unit(s) = virus 
pg130 glycoprotein 130 (kDa) 
PI-3-K phosphoinositide-3-kinase 
PTB phosphotyrosine-binding 
rel. relative value 
RNA ribonucleic acid 
RP-HPLC reverse phase high pressure liquid chromatography 
RT room temperature 
RU resonance units 
s soluble 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SE standard error 
sec second(s) 
Sf Spodoptera frugiperda 
SH src homology (domain) 
SPR surface plasmon resonance 
ssDNA single-stranded deoxyribonucleic acid 
STAT signal transducer and activator of transcription 
TB Terrific Broth 
TCA trichloracetic acid 
TCR T cell receptor 
TEMED N,N,N’,N’-tetramethylethylenediamine 
TGR transforming growth factor 
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TH T helper (cell) 
TNF tumor necrosis factor 
TRIS tris(-hydroxylmethyl)-aminomethane 
U unit 
UV ultraviolet 
v/v volume: volume ratio 
Vol volume 
wt wildtype 
XSCID x-linked severe combined immunodeficiendcy 
 
 
2.2 Chemicals and Enzymes 
 
All chemicals and enzymes were purchased from the following companies: Amersham, Biorad, 
Boehringer Mannheim, Fermentas, Fluka, Gibco-BRL, Merck, Pharmacia, Roth, Serva, Sigma. 
All solutions used in the experiments were made with deionized water (Millipore-Q-System).  
 
 
2.3 Bacterial Strains 
 
The following genotypes E. coli were used: 
 
E. coli JM103 recA-  (McCarthy et al., 1985) 
Genotype:   endA, D (lac-pro), thi-1, strA, sbcB15, hsdR4, supE, F´traD36,  
proAB+, lacIq, zDM15, lambda-/F-  
 
E. coli JM109   (Yanisch-Perron et al., 1985) 
Genotype:   recA1, endA1, thi, gyrA96, hsdR17, supE44, relA1, D (lac- 
proAB), F´traD36, proAB+, lacIq 
 
 
2.4 Cell Lines 
 
Sf9 cell line - a cell line, which was originally established from ovarian tissues of Spodoptera 
frugiperda larvae (Vaughn et al., 1977). Sf9 cells may be grown in a monolayer or in a 
suspension. 
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2.5 Antibodies 
 
For detection of Western Blot the following antibodies were used: 
 
X14/38:  mAb from mouse against the extracellular domain of IL-4Rα (Reusch et  
al., 1994) 
anti-mouse IgG-POD: pAb from goat, POD-coupled (Sigma) 
 
 
2.6 Vectors and Oligonucleotides 
 
2.6.1 Expression Vector for E.coli 
(McCarthy et al., 1985) 
 
The bacterial vector RTSpRC109 (3988 bp) was used for expression of recombinant protein under 
the control of the right λ-phage promoter. It contains the CI857 repressor gene coding 
temperature-induced protein translation. 
 
 
2.6.2 Baculovirus Transfer Vector pAcGP67-B 
(Baixeras, E. et al., 1990) 
 
The Baculovirus transfer vector pAcGP67-B (Pharmingen) contains pg67 signal sequence 
upstream of a multiple cloning site. After co-transfection with Baculovirus DNA into Sf9 cells, 
the cloned gene is expressed as a gp67 signal peptide fusion protein under the control of the 
strong Baculovirus polyhedrin promoter. 
 
 
2.6.3 Oligonucleotides 
 
The oligonucleotides, which were used for cloning and sequencing in the work presented here, 
are presented in Table 2.1. 
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Table 2.1: Sequence and function of the used oligonucleotides. The mutated codons are underlined. 
 
 
Name Sequence Function 
5´Y13A 5´CGTCTCCGACGCCATGAGCATC 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 13  
3´Y13A 5´GATGCTCATGGCGTCGGAGACG 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 13 
5´Y13F 5´CGTCTCCGACTTCATGAGCATC 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 13 
3´Y13F 5´GATGCTCATGAAGTCGGAGACG 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 13 
5´L39A 5´CCTGTTGTACCAGGCGGTTTTTCTGC 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 39 
3´L39A 5´GCAGAAAAACCGCCTGGTACAACAGG 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 39 
5´F41A 5´CCAGCTGGTTGCTCGTCTCTCC 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 41 
3´F41A 5´GGAGAGCAGAGCAACCAGCTGG 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 41 
5´L42A 5´GCTGGTTTTTGCGCTCTCCGAAGC 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 42 
3´L42A 5´GCTTCGGAGAGCGCAAAAACCAGC 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position42 
5´L43A 5´CTGGTTTTTCTGGCCTCCGAAGCC 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 43 
3´L43A 5´GGCTTCGGAGGCCAGAAAAACCAG 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 43 
WYH46 5´GCTCATGGATGCCGTGGTCAGTGC 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 67 
WYH47 5´GCACTGACCACGGCATCCATGAGC 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 67 
5´V69A 5´GCTCATGGATGACGTGGCCAGTGC 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 69 
3´V69A 5´GCACTGGCCACGTCATCCATGAGC 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 69 
C4D72A 5 5´GTCAGTGCGGCTAACTATACA 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 72 
C4D72A 3 5´TGTATAGTTAGCCGCACTGAC 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 72 
5´D72N 5´CGTGGTCAGTGCGAATAACTATACACTGG 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 72 
3´D72N 5´CCAGTGTATAGTTATTCGCACTGACCACG 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 72 
C4K91A 5 5´GGCTCCTTCGCGCCCAGCGAG 3` PCR induced mutagenesis/ 
IL-4Rα in AA at position 91 
C4K91A 3 5´CTCGCTGGGCGCGAAGGAGCC 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 91 
5´K91D 5´CTCCTTCGATCCCAGCGAG 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at posotion 91 
3´K91D 5´CTCGCTGGGATCGAAGGAG 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 91 
WYH60 5´CTTCAAGCCCGCCGAGGCATGTG 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 93 
WYH61 5´CACATGCTCGGCGGGCTTGAAG 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 93 
WYH31 5´CCTGACAATGCCCTGTATAATCATC 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 127 
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Name Sequence Function 
WYH32 5´GATGATTATACAGGGCATTGTCAGG 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 127 
5´Y127F 5´CCCCCTGACAATTTCCTGTATAATC 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 127 
3´Y127F 5´GATTATACAGGAAATTGTCAGGGGG 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 127 
5´Y183A 5´GCTCAGGCCGCTTAACACCACCTG 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 183 
3´Y183A 5´CAGGTGGTGTTAGCGGCCTGAGC 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 183 
5´Y183F 5´GCTCAGGCCTTTAACACCACCTGG 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 183 
3´Y183F 5´CCAGGTGGTGTTAAAGCCTGAGC 3´ PCR induced mutagenesis/ 
IL-4Rα in AA at position 183 
WYH37 5´CGCGGATCCATGAAGGTCTTGCAGGAGC 3´ an external primer, a BamHI 
restriction site, IL-4Rα 
mutagenesis 
WYH38 5´GCATAACCGATATATTCGGTCGCTGA 3´ an external wild tipe primer for 
amlifing IL-4Rα 
MF37 5´GGCGCATTCTGCCTTTGCG 3´ a sequencing primer- 
pAcGP67B 
WYH39 5´CAGGAAAGGATCAGATCTGCAG 3´ a sequencing primer- 
pAcGP67B 
5´R53A/IL4 5´CGACTGTCTTAGCGCAGTTCTACAGC 3´ PCR induced mutagenesis/ IL-
4 in AA at position 53 
3´R53A/IL4 5´GCTGTAGAACTGCGCTAAGACAGTCG 3´ PCR induced mutagenesis/ 
IL-4 in AA at position 53 
5´Y56A/IL4 5´TTAAGGCAGTTCGCGAGCCACCATGAGAAG
GACA 3´ 
a cassette for mutagenesis in 
IL4 - AA at position 56 
3´Y56A/IL4 5´CGCGTGTCCTTCTCATGGTGGCTCGCGAACT
GCC 3´ 
a cassette for mutagenesis in 
IL4 - AA at position 56 
MF8 5´CGTTAAATCTATCACCGCAAG 3´ an external wild-type primer 
for amplifing IL-4 
MF14 5´GTCATCACCGAAACGCGCGAG 3´ an external wild-type primer 
for amplifing IL-4 
PWU22-5´ 5´CAGGACTACTACGTTTTAACTGA 3´ a sequencing primer- 
RTSpRC109 
PWU22-3´ 5´CAGGATCGGTCGCTGAGGCTTGCA 3´ a sequencing primer- 
RTSpRC109 
 
 
2.7 Microbiological Methods 
 
2.7.1 Sterilization 
 
Experiments dealing with bacteria were performed at sterilized conditions. Glassware and other 
experimental materials were sterilized at 180oC for 6 hours in a hot-air-cabinet (Heraeus, ST 
5060). Buffers, media and plastic containers were autoclaved (Sterico Vapoclav 
Dampfsterilisator) at 121oC and 1.1 bar for 20 min. Solutions of temperature-unstable substances 
were sterilized by filtering through Millipore-Filter (DynaGard 0.22µm). 
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2.7.2 Culture Media 
 
LB-medium:   10g/l Bacto-Trypton, 5g/l Bacto-Yeast Extract, 10g/l NaCl pH7.5  
(Sambrook et al., 1989) with 0.1N NaOH adjusted  
TB-medium:   13.3g/l Bacto-Trypton, 26.6g/l Bacto-Yeast Extract, 4.4ml/l  
(Sambrook et al., 1989) glycerin 
    before use 10% sterilized 10x Phosphate buffer was added  
10 x Phosphate buffer: 0.17M KH2PO4, 0.72M K2HPO4 
(Sambrook et al., 1989) 
5 x ENB-medium:  40g/l Nutrient Broth, 25g/l Bacto-Pepton, 7.5g/l KH2PO4, 17.5g/l 
(Sambrook et al., 1985) NaH2PO4, 25g/l NaCl 
ENB-amp-plates  15 g agarose in 800 ml H2O was autoclaved. When the agarose  
    solution was cooled to 50oC, 200 ml 5 x ENB-medium, 2.5 ml 2M  
    glucose, 0.5 ml thiamin solution in H2O (10mg/ml) and 50 mg  
    ampicilin in 2ml 1M TrisHCl buffer (pH 8.0) were added. After  
    mixing, the agarose solution was filled into plates, cooled at RT  
    and kept at 4oC 
 
Ampicillin solution, 50 mg/ml in 1M TrisHCl pH 8.0, must be freshly prepared and added to final 
concentration of 50 µg/ml for all kinds of media. 
 
 
2.7.3 Culturing of Bacteria 
 
Glycerin stock-culture was spread over an agar plate and incubated at 30oC or 37oC overnight. A 
colony was picked up and incubated in 2 ml of medium at 30oC or 37oC for a day. This culture 
was further used for making larger culture. 
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2.7.4 Electrocompetent E.coli 
 
2.7.4.1 Preparation of electrocompetent bacterial cells 
 
E.coli from an agar plate or frozen stock were cultivated in 2 ml of TB-medium with ampicillin at 
37oC for 8 h. From this culture was started 200 ml of a new culture, which was incubated and 
shook (200 rpm, Cetromat-R) overnight under the same conditions.  
The overnight culture was centrifuged at 3500 rpm (Beckmann J2-21, JA-10 rotor), 4oC for 10 
min. and then washed with 200 ml cold solution of 10% glycerin/H2O (v/v). The suspension was 
consecutively centrifuged in the same way and resuspended in 100 ml, 50 ml, 20 ml and 2 ml of 
cold 10% glycerol solution. The final suspension was aliquoted in chilled Eppendorf tubes (40µl) 
and frozen in liquid Nitrogen. The competent cells were stored at -70oC. 
 
 
2.7.4.2 Electrotransformation of competent E.coli  
 
The electrocompetent E.coli were placed on ice and thawed out. 10-20 ng of DNA (in TE-buffer) 
were added and the suspension was mixed and transferred to a chilled 0.2 cm electroporation 
cuvette. Immediately after the pulse was applied (Biorad Gene PulserTM: 250 V, 25 mF and 200 
W), 500 µl of LB-medium were added and the cuvette was vigorously shaken. The suspension 
was incubated at 30oC or 37oC for 30 min. For selection the bacterial material was placed in 2 
ENB-amp-plates, which were kept at 30oC or 37oC overnight. 
 
 
2.7.5 Storage of Bacterial Cultures 
 
10 µl bacterial suspension was spread over an agar plate and incubated at 30oC or 37oC overnight 
until colonies appeared. Such a plate can be kept 4 to 6 weeks at 4oC. 
For long-term bacterial storage, a single bacterial colony was cultivated in 50 ml of LB-medium 
with ampicillin at 30oC or 37oC until the suspension reached OD550 of 1.5 - 1.7 (LKB Novaspec). 
The following centrifugation was carried out at 3000 rpm for 10 min. The pellet was resuspended 
in 2 ml of LB-medium/amp and mixed with 2ml of sterilized glycerol (87%). This culture can be 
kept at -20oC several years. 
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2.8 Molecular Biological Methods 
 
2.8.1 Determination of the Concentration of Nucleic Acids 
 
The concentration of nucleic acids was measured by spectrophotometry in the absorption 
spectrum range 240-320 nm. (Kontron Uvikon 930 Spectrophotometer). Considering an 
extinction value of 1, the relation between A260 and the concentration is as follows: 
 
Nucleic acids Concentration 
dsDNA 50 µg/ml 
ssDNA 33 µg/ml 
Oligonucleotide 20 µg/ml 
 
The concentration of DNA can be roughly estimated by using an agarose gel electrophoresis. For 
amounts less than 200 ng, the flourescence of the ethidium bromide, incorporated in the DNA 
fragments is proportional to the concentration of DNA. The intensity of the examined bands was 
compared to this of DNA standards with known concentrations. 
 
 
2.8.2 Phenol Extraction of DNA 
 
phenol solution: saturated phenol, neutralized with 1/50 Vol. 2.5M Tris-HCl pH8.0 
 
To the DNA containing fraction was added the phenol solution (1:1 Vol). After 5 min of shaking, 
the sample was treated with (1/2 Vol.) chloroform/isoamyl alcohol solution (24:1), again shaken 
for 2 min and finally centrifuged for 2 min at 14000 rpm. The aqueous phase was transferred to a 
new tube. 
 
 
2.8.3 Ethanol Precipitation of DNA 
 
DNA solutions were precipitated by adding 1/10 Vol. 3M NaOAc pH 8.0 and 2.5 Vol. EtOH. The 
sample was thoroughly vortexed, incubated for 30 min at -20oC and centrifuged (15 min, 14000 
rpm). The pellet was washed with 70% EtOH and dried under vacuum. The pellet was dissolved 
in desired volume sterile dH2O or TE buffer. 
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2.8.4 DNA Molecular Standards 
 
The following DNA molecular standards were used: 
HMS:  phage λ DNA, digested by HindIII 
LMS:  pBr322 plasmid DNA, digested by AluI 
 
Table 2.2: DNA molecular standards  
 
HMS LMS 
bp % bp % 
23130 47.7 1608 21.2 
9416 19.4 1201 15.9 
6682 13.4 999 13.2 
4361 9.0 711 9.4 
2322 4.8 567 7.5 
2027 4.2 517 6.8 
564 1.2 396 5.2 
125 0.3 360 4.8 
  1222/219/214 9.6 
  132/120/112 4.8 
  76/65/30/27 2.6 
 
 
2.8.5 DNA Agarose Gel Electrophoresis 
(Hermann et al., 1980) 
 
running buffer: 40mM Tris-acetate pH 8.2, 20mM NaOAc, 1M EDTA pH 5.0 
EtBr:   5 mg/ml 
5 x stop buffer: 15% Ficoll, 50mM EDTA, 0.5%SDS, 0.05% XC, 0.05% BPB in running  
   buffer 
 
DNA fragments with different length require different concentrations of the agarose for 
separation by gel electrophoresis (Table 2.3). 
 
Table 2.3: DNA agarose gel electrophoresis 
 
Length of DNA fragments [kbp] Agarose concentration in % 
5 – 60 0.3 
1 – 20 0.6 
0.8 – 10 0.7 
0.4 – 7 1.0 
0.2 – 4 1.5 
0.1 – 3 2.0 
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The agarose was dissolved in running buffer by heating in a microwave oven and kept at 65oC. 
After adding of 1/1000 Vol. EtBr (final concentration 5 µg/ml), the agarose was poured into a 
horizontal gel-plate. A comb was put in the agarose and it was cooled down until the gel was 
formed.  
The examined DNA was mixed with ¼ Vol. of 5 x stop buffer and heated at 65oC for 5 min. The 
DNA samples and 100 ng DNA molecular standard were loaded in parallel starts of the gel. The 
electrophoresis was performed in the electric field of 3 V/cm. The sample was visualized under 
UV light due to the incorporation of EtBr in DNA. The length of the DNA fragments was 
estimated by comparison with the bands of the standard. 
 
 
2.8.6 Purification of DNA by Agarose Gel Electrophoresis 
 
DNA fragments were purified from agarose gels using NukleotrapTM kit (Macherey-Nagel).  
A preparative agarose gel was run and the DNA fragment of interest was cut under a UV light 
panel. 330-350 mg of agarose gel containing DNA were transferred in an Eppendorf tube, where 
300 µl of buffer T1 were added for each 100 mg from agarose material. This suspension together 
with 20µl of the glass beads “Nucleotrap” was incubated at 55oC for 10 min and meanwhile 
vortexed a few times. The sample was centrifuged for 30 sec at 13000 rpm and the supernatant 
was removed. This step was followed by consecutively washing the pellet twice with 500 µl of 
T2 buffer and twice with T3 buffer. After the pellet dried on air, it was resuspended in 50 µl of 
TE buffer pH 8.0 and incubated for 10 min at RT. The suspension solution was centrifuged 1min. 
at 13000 rpm and the DNA containing supernatant was then transferred to a clean Eppendorf 
tube. 2 µl of the DNA solution were analyzed on an agrose gel. 
 
 
2.8.7 Site-directed Mutagenesis by PCR 
(Higuchi et al., 1990) 
 
apparatus:   DNA Termal Cycler 480, Perkin Elmer 
10 mM dNTPs 
Pfu polymerase 
10 x Cloned Pfu buffer: 200mM Tris-HCl pH 8.0, 20mM MgSO4, 100mM KCl,  
    100mM (NH)4SO4, 1% Triton X-100, 1mg/ml nuclease-free BSA 
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Most of the mutations were generated by using a two-step polymerase chain reaction. The first 
step was performed in two different reactions - reaction 1a and reaction 1b. In reaction 1a (Table 
2.4) the 5´-primer carries the mutation of interest and the 3´-primer is external (Table 2.1). The 
3´-primer, which was used in reaction 1b, was mutated and complementary to the 5´-primer in 
reaction 1a. The 5´-primer in reaction 1b was external. 
 
Table 2.4: PCR - reaction 1a and reaction 1b 
 
 Reaction 1a Reaction 1b 
template 50 ng 50 ng 
mutant primer 50 pmol (5´-primer) 50 pmol (3´-primer) 
external primer 50 pmol (3´-primer) 50 pmol (5´-primer) 
dNTPs 10 nmol 10 nmol 
10 x Pfu polymerase buffer 5 µl 5 µl 
Pfu polymerase 2.5 U 2.5 U 
H2O to 50 µl to 50 µl 
 
The synthesized products from reaction 1a and 1b were analyzed by an agarose gel and directly 
used as a template during the second step of the PCR generated mutagenesis. This recombinant 
PCR was performed with the two external primers, used in the first step: the 3´-primer from 
reaction 1a and the 5´-primer from reaction 1b (Table 2.5). 
 
Table 2.5: Second step of the PCR generated mutagenesis 
 
 Reaction 2 
reaction product 1a 2 µl 
reaction product 1b 2 µl 
5´-primer (from reaction 1b)  50 pmol 
3´-primer (from reaction 1a) 50 pmol 
dNTPs 10 nmol 
10 x Pfu polymerase buffer 5 µl 
Pfu polymerase 2.5 U 
H2O to 50 µl 
 
All reactions were performed in safe-lock Eppendorf tubes with the following program: 
 
  denaturation:  95oC  5 min. 
  25 cycles:  95oC  1 min. 
     55oC  1 min. 
     72oC  2 min. 
  extension:  72oC  7 min. 
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The product, synthesized during the second step of the PCR, contains the mutation of choice. 
After visualization on a agarose gel, it was precipitated with EtOH and dissolved in 20 µl of H2O. 
 
 
2.8.8 Site-directed Mutagenesis Using DNA Cassettes 
 
This method was used for generation of mutations in the cDNA of IL-4. The cassette is synthetic 
double-stranded DNA, which contains a mutation of interest. Its ends are designed as restriction 
endonuclease cutting sites. In this way, it is possible using a ligation reaction to insert the cassette 
between the same cutting sites represented in the cDNA of IL-4. 
 
 
2.8.9 Digestion of DNA 
 
All restriction reactions were performed in the presence of recommended 10 x reaction buffer. 
For analytical purposes were digested 100-500 ng DNA in reaction volume of 10 µl, using 1-10 
U restriction endonuclease. The reaction mix was incubated for 1 h at 37oC and then 2-4 µl were 
examined by agarose gel electrophoresis. 
The reaction volume of a preparative digestion is dependent on the amount of the used DNA, 
which should not exceed 1 µg/ml. It is necessary to consider that the standard enzyme solutions 
normally contain 50% glycerol. Some restriction endonucleases work non-specifically in the 
presence of too high glycerol concentrations (“star activity”). Because of this, the glycerol 
content in the reaction volume should not be more than 10%. Every kind of DNA, independent 
on the number of restriction sites, was digested with 1-5 U of restriction endonuclease per µg 
DNA. (1 enzyme unit (U) is defined as the amount of the restriction endonuclease, which is able 
to digest 1 µg of DNA for 1 h.) The incubation was done - if it is not mentioned otherwise - for 2 
h at 37°C. The restriction reaction was stopped by adding ¼ volume 5 x stop buffer (15% ficoll, 
0.5 % SDS, 50mM EDTA, 0.5 % BPB, 0.5% XB in 5 x tris-acetate buffer). A small aliquot was 
examined on an agarose gel. The rest of the DNA was purified by agarose gel electrophoresis, 
before it was used for ligation reaction. 
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2.8.10 Ligation of DNA 
 
T4 DNA ligase 
10 x T4 DNA ligase buffer:  500mM Tris-HCl pH 7.6, 100mM MgCl2, 10mM ATP,  
     10mM DTT 
 
A vector : insert molar ration of 1:3 was determined to be optimal. The total amount of DNA for 
cloning per 10 µl reaction volume was 200 ng. The reaction mix, containing 1-5 U of T4 DNA 
ligase was incubated for 3 h at RT or for 12-16 h at 15oC. The reaction was stopped by heating at 
65oC for 10 min. 25% from the ligation mix were loaded on an agarose gel to examine the 
reaction efficiency. The recombinant plasmid DNA (1 µl of the ligation mixture) was directly 
used to transform electrocompetent E.coli. To monitor the efficiency of the ligation and 
transformation steps, cut vector DNA was ligated in the absence of an insert and competent cells 
were transformed with it as well as with uncut non-recombinant vector. 
 
 
2.8.11 Preparation of Plasmid DNA 
 
2.8.11.1 Lysozyme-alkaline-lysis procedure 
(Birnboim and Doley, 1979) 
 
solution 1:  50mM glucose, 10mM EDTA, 25mM Tris-HCl pH 8.0, 2mg/ml  
lysozyme, 100 µg/ml RNase A (DNase free) 
solution 2:  1% SDS, 0.2M NaOH 
solution 3:  3M KOAc pH4.8 
   (60 ml 5M KOAc with 11.5 ml acetic acid and 28.5 ml H2O) 
 
The described procedure is a simple and fast method for preparation of plasmid DNA and gives 
material with quality sufficient for restriction analysis. DNA for analyses, which require better 
quality (e.g. sequencing), was isolated by other procedures. 
Bacterial cultures were started from single colonies and incubated in 2 ml of TB-medium/amp 
overnight at 30oC or 37oC. 1.4 ml of the bacterial suspensions were transferred into Eppendorf 
tubes and centrifuged (Eppendorf Centrifuge 5415C) for 2 min at 14000 rpm. The supernatant 
was removed by aspiration with a water beam pump. The cell pellet was resuspended in 200 µl of 
solution 1 and then 200 µl of solution 2 were added. The samples were thoroughly mixed by 
inverting the tubes and incubated for 5 min on ice. After 200 µl of solution 3 were added and the 
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tubes were inverted again, the samples were incubated for 15 min on ice. This turbid solution was 
centrifuged for 15 min at 14000 rpm. The clear supernatant was transferred to a fresh Eppendorf 
tube, avoiding floating precipitate. After precipitation with an equal volume of isopropanol, the 
DNA containing pellet was washed with 70% EtOH and dried under vacuum. The pellet was 
dissolved in 20 µl of dH2O. An aliquot of 2-5 µl was used for restriction analysis. 
 
 
2.8.11.2 PEG precipitation procedure 
(Tartof and Hobbs, 1987) 
 
solution 1 (GTE buffer):  50mM glucose, 10mM EDTA, 25mM Tris-HCl pH 8.0 
solution 2:    1% SDS, 0.2M NaOH 
solution 3:    3M KOAc pH4.8 
     (60 ml 5M KOAc with 11.5 ml acetic acid and 28.5 ml  
     H2O) 
RNase solution:  10 mg/ml RNase A (DNase free) 
PEG solution:    13% PEG8000 autoclaved 
 
The following procedure was used for preparation of plasmid DNA for sequencing. 
Aliqouts (1.4 ml) of overnight cultures were transferred to Eppendorf tubes and centrifuged at 
14000 rpm in a microcentrifuge (Eppendorf Centrifuge 5415C). The supernatant was removed by 
aspiration and the bacterial pellet was resuspended in 200 µl of solution 1. Then 300 µl of 
solution 2 were added. The content of the tube was mixed by inversion and incubated for 5 min 
on ice. After this, 300 µl of solution 3 were added, the content was mixed by inversion of the 
tubes and the sample was incubated again for 5 min on ice. Centrifugation at 14000 rpm for 15 
min followed. The supernatant was carefully transferred in a fresh tube, avoiding floating 
precipitates. Solution of RNase A was added to a final concentration of 25 µg/ml and the tubes 
were incubated for 30 min at 37oC. DNA was extracted using 400 µl phenol/Tris and 400 µl 
chloroform/isoamylalcohol (24:1). After centrifugation for 1 min at 14000 rpm, the aqueous 
phase was transferred to a fresh Eppendorf tube. DNA was precipitated with equal volume of 
isopropanol and washed with 70% EtOH. The dried pellet was dissolved in 32 µl of H2O and 
after 8 µl of 4M NaCl and 40 µl of autoclaved PEG8000 solution were added, the sample was 
thoroughly vortexed and placed on ice for 20 min. The following centrifugation was performed at 
4oC, 14000 rpm, for 15 min in a fixed-angle rotor centrifuge (Biofuge A, Heraeus). The 
supernatant was carefully removed and the pellet was rinsed with 70% EtOH and dried under 
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vacuum. The DNA containing pellet was dissolved in 20 µl of dH2O. The so prepared DNA can 
be used for restriction analysis as well as for sequencing. The plasmid DNA was stored at -20oC. 
 
 
2.8.11.3 Preparation of plasmid DNA with LiCl 
 
solution 1:  50mM glucose, 10mM EDTA, 25mM Tris-HCl pH 8.0, 5mg/ml lysozyme 
solution 2:  1% SDS, 0.2M NaOH 
solution 3:  3M KOAc pH4.8 
   (60 ml 5M KOAc with 11.5 ml acetic acid and 28.5 ml H2O) 
solution 4:  5M LiCl 
RNase solution: 10 mg/ml RNase A (DNase free) 
 
The underwritten method is a simple way to prepare more plasmid DNA comparing to the 
described already PEG precipitation. The purity and the amount of the prepared DNA is 
sufficient for co-transfection in Sf9 cells. 
Bacterial culture was started from a single colony in 2 ml of TB-medium/amp and incubated 8 h 
at 37oC. 10-20 µl were transferred in 30-40 ml of fresh medium and cultivated at 37oC overnight. 
The bacterial suspension was transferred in a Falcon tissue culture tube and was spun down by 
centrifugation at 3000 rpm for 5 min (Megafuge1.0, Heraeus). The pellet was resuspended in 2 
ml of solution 1 and after 50 µl of RNase solution were added, the sample was mixed and placed 
on ice for 5-10 min. 3 ml of solution 2 were added, the content was thoroughly but gently mixed 
by inverting the tube and incubated for 5-10 min on ice. After this step, 2 ml of solution 3 were 
added and the tube was thoroughly but gently inverted until a homogeneous suspension was 
formed. The sample was incubated 5-10 min on ice, 6 ml of solution 4 (5M LiCl) were added and 
the content was mixed. After 5-10 min of incubation on ice, the sample was centrifuged for 15 
min at 5500 rpm (Megafuge 1.0, Heraeus). The supernatant was further filtered through 2 layers 
of precision wiper paper and transferred to a new Falcon tissue culture tube. DNA was 
precipitated with an equal volume of isopropanol and after the pellet was rinsed with 70% EtOH, 
it was dried under vacuum. Then the pellet was resuspended in 500 µl of dH2O, transferred to a 
fresh Eppendorf tube and 50 µl of RNase solution were added to the DNA solution. The sample 
was incubated for 30-60 min at 37oC. DNA was extracted with 400 µl saturated phenol/tris and 
400 µl of chloroform/isoamylalcohol (24:1) solution. The aqueous phase was transferred to a new 
Eppendorf tube and 1/10 Vol. of 3M NaOAc and an equal volume of isopropanol were added to 
it. The sample was thoroughly vortexed, incubated at RT for 5 min and centrifuged at high speed 
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(14000 rpm) for 10 min. The pellet was briefly dried under vacuum and redissolved in 40 µl of 
dH2O. When the plasmid DNA was isolated to be used for co-transfection in Sf9 cells, the pellet 
from the last step was dried under sterile conditions and was dissolved in sterile dH2O. 
The concentration of the plasmid DNA was determined by spectrophotometry and the quality was 
examined by agarose gel electrophoresis. 
 
 
2.8.12 DNA Sequencing 
 
The DNA sequencing was performed by Wolgang Haedelt, using an automatic DNA Seguencer 
(Applied Biosystems, Model 373A) and according to manufacturer’s instructions. 
The used method, according to Sanger, relies on the base-specific termination of the DNA chain 
elongation by random integration of labeled ddNTPs at the end of the chain. Four independent 
sequencing reactions were carried out for each analyzed DNA sample. Each reaction contained 
different chain-terminating ddNTP coupled to a corresponding fluorescent day. After the end of 
PCR, the products of the four reactions were mixed together and analyzed on a 7 % 
polyacrylamide gel. Due to the different fluorescence, the single DNA fragments could be 
detected by an argon laser beam. 
 
 
2.9 Protein Chemical Methods 
 
2.9.1 Determination of the Protein Concentration 
 
The concentration of a protein solution, when it is diluted to 0.1-0.5 mg/ml, can be measured by 
spectrophotometry at the absorption spectrum range 250-320 nm (Kontron Uvikon 930 
Spectrophotometer). For calculation was used the absorbency value A at 280 nm. The 
concentration of IL-4 and IL-4BP per absorbency unit (A280 = 1) and the path length equal to 1 
cm are shown in the Table 2.6. 
 
Table 2.6: Molar absorbency factor and concentration of IL-4 and IL-4BP 
 
Protein Molar absorbency factor 
[mol-1*cm-1] 
Concentration per 
absorbency unit 1  [mg/ml] 
IL-4 8610 1.7 
IL-4BP 66930 0.357 
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2.9.2 Lyophilization of Proteins 
 
The purified protein was divided into aliquots of 100 µl each and then placed in an aluminum 
block and frozen at -70oC overnight. The frozen protein aliquots were then transferred to a 
Lyophilizator (Christ Lac-1), which was pre-cooled to -55oC and vacuum pumped to 0.02 bar 
overnight. KOH was kept in the lyophilization chamber as a dry reagent. 
 
 
2.9.3 Molecular Weight Standard for Protein Samples 
 
The molecular weight of the proteins was estimated by comparison with a protein standard 
marker, which was loaded parallel to the samples on a PAGE. This was used to identify the size 
of proteins, loaded on the gel. The characteristic bands of the protein standard and their molecular 
weights are presented in Table 2.7. 
 
Table 2.7: Protein standard used for PAGE 
 
Protein Molecular weight 
[Da] 
phosphorylase b 94000 
albumin 67000 
ovalbumin 43000 
carboanhydrase 30000 
trypsin-inhibitor 20100 
lacalbumin 14400 
 
 
2.9.4 SDS - Polyacrylamide Gel Electrophoresis 
(Laemmli, U.K., 1970) 
 
acrylamide solution:  30% acrylamide, 0.8% N,N´methylenbisacrylamide 
4 x lower Tris:  1.5M Tris-HCl, 0.4% SDS, pH 8.8 
4 x upper Tris   0.5M Tris-HCl, 0.4% SDS, pH 6.8 
glycerol:   87% glycerol 
TEMED 
APS solution:   40% APS 
SDS running buffer:  25mM Tris-HCl pH 8.6, 190mM glycin, 0.15% SDS 
SDS sample buffer:  62.5mM Tris-HCl pH 6.8, 2% SDS, 20% glycerol,  
    2% BPB, 2% β-mercaptoethanol 
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staining solutuion:  0.25% Coomassie Brilliant Blue R250 in destaining solution 
destaining solution:  1 Vol. acetic acid, 1 Vol. isopropanol, 8 Vol. H20 
 
In denaturating SDS-polyacrylamide gels the proteins were separated by their molecular weight. 
The electrophoresis was performed in a vertical gel electrophoresis system Mini-V 8.10 (Gibco 
BRL). Different acrylamide concentrations can be used for different gel preparations (Table 2.8) 
depending on the size of the separated proteins. 
 
Table 2.8: Amount of the different components used for SDS-polyacrylamide gel electrophoresis 
 
Solution Stacking gel Separating gel 
  7.5% 10% 12% 
acrylamide solution 0.25 ml 1.25 ml 1.67 ml 2 ml 
4 x lower Tris - 1.25 ml 1.25 ml 1.25 ml 
4 x upper Tris 0.62 ml - - - 
H2O 1.6 ml 1.5 ml 1.1 ml 0.75 ml 
87% glycerol - 1 ml 1 ml 1 ml 
TEMED 6 µl 5 µl 7 µl 7 µl 
40% APS 6 µl 5 µl 7 µl 7 µl 
 
The separating gel solution was decanted between two vertical glass-slabs (layer thickness 0.75 
mm) with a Pasteur pipette to 2/3 of the glasses upper edge and then covered with a water layer. 
After polymerization, the water was poured out, the stacking gel solution was filled on the top 
and a comb was immediately inserted. 
The protein samples and SDS sample buffer (1:1) were mixed and boiled at 100oC for 5 min. A 
microlitre syringe was used to place the protein solutions in the wells of the slab. For each well 
0.5-2 µg of protein was loaded. In the first lane, parallel to the samples, was loaded the protein 
standard. Until the samples were concentrating, the gel was running at 100 V and for the 
separating part 150 V were used. 
After the end of the electrophoresis, the gel was placed for 30 min in a coomassie solution for 
staining. The destaining was done overnight. The ready gel was kept 1 h in 20 % methanol and 
dried between two pieces of cellophane. 
 
 
2.9.5 Concentration of Protein Samples by TCA 
 
When the protein concentration was low, concentration by TCA was done before the sample was 
loaded on PAGE. To the protein sample, which had to be concentrated was added 1/9 Vol. of 5% 
TCA. After mixing, the protein solution was incubated for 20 min on ice and then centrifuged for 
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20 min at 14000 rpm (Eppendorf Centrifuge). The pellet was dissolved in desired volume of SDS 
sample buffer. When the solution had a yellow color, 1 µl of 2.5M Tris-HCl pH 8.0 was added 
until the color got blue. 
 
 
2.9.6 Biotinylation of Proteins 
 
For biotinylation were used protein solutions of purified IL-4BP in PBS. To 300 µl of such a 
solution 50 µl of 0.5M NaHCO3, pH 8.5 were added. A solution of 1 µg EZ-LinkTM Sulfo-NHS-
LC-Biotin (Pierce) in 300 µl DMSO was prepared. Biotin solution was added to the protein 
sample in such an amount that the protein and the biotin were in a molar ratio of 1:5. The sample 
was shortly vortexed and then incubated on ice for 3 h. 
The biotinylated protein sample was separated from the free biotin by gel filtration through a 
column filled with Biogel P6DG. The column volume was about 14 ml and for elution was used 
PBS. The biotinylated protein was eluted after 4-5 ml flow through. The sample was divided into 
aliquots, which were kept at -20oC.  
 
 
2.10 Immunological methods - Western Blot 
 
2.10.1 Transfer of Proteins to a Nitrocellulose Membrane 
(Gershoni and Palade, 1983) 
 
Transfer buffer:  25mM Tris-HCl, 192 mM glycin, 20% methanol 
Amidoschwarz:  0.1% (w/v) amidoschwarz 10-B, 45% methanol, 10% acetic acid 
destaining solution:  1 Vol. acetic acid, 1 Vol. propanol, 8 Vol. H20 
nitrocellulose membrane (Schleicher and Schmuell BA85) 
Whatman paper 
 
Western blotting was used to verify the expression of IL-4BP by Sf9 cells, after the second step 
of virus amplification. 
First, the proteins were electrophoretically separated on a SDS polyacrylamide gel. 10 µl of virus 
supernatant were mixed with equal volume of protein sample buffer and after 5 min of boiling, 
the sample was loaded on a gel, parallel to a protein standard. As a negative control was used a 
sample of equal volume, which contained only the medium for Sf9 cells. The positive control was 
a sample of wild-type IL-4BP with known concentration. After the end of the electrophoresis, the 
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gel was rinsed shortly in transfer buffer. Then a paper-thin nitrocellulose membrane, which 
tenaciously binds most proteins, was carefully applied on the face of the gel, preventing the 
formation of air bubbles. The gel and its attached membrane were sandwiched between two 
pieces of Whatman paper, two porous pads and the plastic support was tightly fixed. The blotting 
apparatus (Blot Module Mini-V8.10), containing the gel and the membrane, was placed in an 
electrophoresis chamber in a way that the nitrocellulose membrane was toward the anode. The 
chamber was filled with transfer buffer and an electric field was applied (150 V) for 1 h. At this 
step, the proteins were driven out of the gel and transferred to the membrane.  
After the blotting, the membrane was separated from the gel and the first lane, containing the 
protein standard was cut out and stained for 5 min in amidoschwarz solution. Then this part of the 
membrane was placed in destaining solution, washed in H2O and dried. 
All manipulations were carried out with gloves to prevent the transfer of foreign proteins to the 
membrane. 
 
 
2.10.2 Detection of Western Blots by a Peroxidase Coupled Antibody  
 
washing buffer:  10mM Tris-HCl pH 8.0, 150mM NaCl, 0.5% tween 
blocking buffer:  3% BSA in washing buffer 
luminol solution:  2.5 mM luminol (3-aminophthalhydrasid), 100mM Tris-HCl pH  
    8.5, 1% DMSO 
enhancing solution:  90mM p-cumar acid in DMSO 
primary antibody:  3 µg/ml X-14-38 (anti-IL-4BP monoclonal antibody) in blocking  
    buffer 
secondary antibody:  anti-mouse polyclonal antibody from goat, peroxidase coupled 
 
In the next step, the membrane was soaked in a solution of the primary antibody, specific for IL-
4BP. Only the band, which contained this protein, bound the antibody. To identify the band 
containing the protein of interest, the membrane was developed by a secondary antibody, coupled 
with POD. 
After the blotting, the membrane was rinsed once for 5 min in washing buffer. Then it was 
incubated in blocking buffer for 30 min on a platform shaker to reduce the background of non-
specific binding by blocking potential binding sites with irrelevant proteins. The blocking buffer 
was replaced by 5 ml solution of the primary antibody and the membrane was incubated at RT for 
at least 2 h with gentle agitation on a platform shaker. When the antibody solution was removed, 
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the membrane was rinsed 4 times in washing buffer (5 min between each change) at RT. From 
the final wash, the nitrocellulose membrane was transferred in 5 ml solution of the secondary 
antibody (0.5-5.0 µg/ml antibody in blocking buffer) and incubated for 1-3 h at RT with gentle 
agitation on a platform shaker. The reaction with the secondary antibody was stopped by rinsing 
the membrane 4 times in washing buffer (5 min between each change) at RT. For the developing 
solution in two separated tubes were added 2.5 ml of luminol solution and 11 µl of enhancing 
solution or 2.5 ml of 0.1M Tris pH 8.5 and 1 µl of 30% H2O2, respectively. Right before the 
development, the content of the two tubes was mixed. The development was completely carried 
out in a dark room. There the membrane was transferred into the developing solution and was 
incubated until luminescence was seen (usually not more than 30 sec). The nitrocellulose 
membrane was shortly dried, exposed to a X-ray film (Kodak X-100) for 30 sec to 1 min and then 
the film was developed. 
 
 
2.11 Expression of Recombinant Proteins in E.coli 
(Kato et al., 1985; Weigel et al., 1989) 
 
2.11.1 Temperature Induced Protein Expression 
 
medium:  TB medium, 10 x phosphate buffer 
antibiotic:  ampicillin 
TE buffer  10mM Tris-HCl, 1M EDTA pH 8.0 
expression vector: RTSpRC109, containing the insert of interest 
 
Bacterial culture was started in 2 ml of TB-medium from a single colony and incubated for 8 h at 
30oC. 20 µl of this suspension were used to start culture in 50 ml of fresh medium, which was 
incubated overnight at 30oC. In a flask (2 l) was prepared 800 ml TE-medium, containing 
ampicillin (50 µg/ml) and 1.6 ml from the overnight bacterial culture were added. This bacterial 
culture was grown at 30oC on a shaker (Braun Ceromat, 200 rpm) to early logarithmic phase with 
OD550 of 0.5 (LKB Novaspec). The flask was then immediately moved to a rotatory water bath, 
where it was incubated for another 3 h at 42oC and shaken at 200 rpm. After this time, usually 
OD550 of 1.2-1.5 was reached. 
The bacterial cells were harvested by centrifugation for 10 min at 6000 rpm (Beckmann J2-21, 
JA-10 rotor). The pellet was resuspended and washed in 30 ml of TE buffer, pH 8.0. After the 
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bacterial suspension was centrifugated under the same conditions, the pellet was resuspended in 
10 volumes of TE buffer (vol/wet mass) and frozen at -20oC. 
 
 
2.11.2 Preparation of Inclusion Bodies 
 
TE buffer was added to the thawed out cell suspension to about 50 volumes of wet mass. The 
bacterial cells were sonicated eight times (each time 30 sec sonication followed by 30 sec break) 
at 300 W by a sonicator (KLN System 585). During the sonication, the solution was kept in an 
ice bath. The suspension was centrifuged at 11000 rpm (Beckmann J2-21, JA-14 rotor) for 30 
min at 4oC. The tight sediment was resuspended and washed once in 100 ml of TE buffer and 
then centrifuged under the same conditions for 20 min. The final pellet was resuspended in 10 
volumes of TE buffer (vol/wet mass). 
 
 
2.11.3 Denaturation and Renaturation of Proteins 
 
GuHCl solution:  6M guanidine hydrochloride, 100mM Tris-HCl pH 8.0 
PBS:    120mM NaCl, 2mM KCl, 3 mM NaH2PO4 pH 4.8, 7mM  
    Na2HPO4 pH 8.0 
TE buffer:   10mM Tris-HCl, 1mM EDTA, pH 8.0 
acetic acid:   4M acetic acid pH 5.0 
 
To the suspension, containing inclusion bodies slowly were added 3 volumes of 6 M guanidine 
hydrochloride solution and 0.1% (by volume) 2-mercaptoethanol. The mixture was stirred for 30 
min at RT and then centrifuged at 11000 rpm (Beckmann J2, JA-10 rotor) for 15 min at 4oC. 4 
volumes H2O were added drop by drop to the supernatant. The sample was centrifugated at 11000 
rpm for 20 min at 4oC. The supernatant was dialysed against 20 volumes of PBS pH 7.4 for 16-20 
h at 4oC. The cloudy suspension first was adjusted to pH 5.0, using 4 M acetic acid and then was 
centrifuged at 11000 rpm (Beckmann JA-14 rotor) for 20 min at 4oC. The protein containing 
supernatant was further purified by ion exchange chromatography. 
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2.12 Expression of Recombinant Proteins in SF9 cells 
 
2.12.1 General Handling Techniques 
 
2.12.1.1 Insect cell culture media 
 
Insect - Express medium (BioWhittaker) 
SF - 1 medium (BioConcept) 
Sf - 900 II Serum-Free Medium (Gibco BRL) 
Pluronic F68 for ICM - 10% (BioConcept) 
Lipid Ethanol solution for ICM (BioConcept) 
L - Glutamine (Seromed) 
FCS (Gibco BRL) 
 
All of these media provide basic nutrients for Sf9 cells and have a pH of approximately 6.2. 
Insect-Express medium does not require additional supplements and was completed only with 5% 
of FCS. The rest of the mentioned mediums were supplemented as shown in Table 2.9. 
 
Table 2.9: Insect cell culture media and required supplements 
 
Medium Lipid mix Pluronic L-glutamine FCS 
Insect-Express 
1000 ml 
- 
 
- - 50 ml 
SF-1 
950 ml 
1 ml 10 ml 25 ml 50 ml 
SF-900 SFM II 
980 ml 
1 ml 10 ml 10 ml 50 ml 
 
 
2.12.1.2 Cultivation of Sf9 cells 
 
To prevent bacterial or yeast contamination, all experiments dealing with Sf9 cells were 
performed at sterile conditions. Glass pipettes, plastic materials and solutions were sterilized. 
Flasks and tubes, containing cells were opened only in a laminar flow hood (LaminAir HB 
2448S, Heraeus).  
Old medium was exchanged with fresh every second day, since the healthy Sf9 cells double every 
18-24 h. The culture was incubated at 27oC in incubators (Heraeus, Memmert). 
 46
________________________________________________________2. Materials and Methods 
2.12.1.3 Staining and counting of Sf9 cells 
 
trypan blue  0.4% (w/v) solution in PBS 
 
The trypan blue exclusion method was used to count the proportion of viable cells and their 
concentration in the suspension. Since the exclusion of the stain is a selectively working 
definition for viability, the dead cells appear as blue spots, when observed with an inverse 
microscope.  
A small aliquot of cells was mixed with trypan blue solution at a ratio of 1:1 and kept at RT for 1 
min. Apart of this, the suspension was placed in a Neubauer’s chamber and observed with an 
inverse microscope. The viable cells in 16 different squares were counted. To calculate the cell 
density (cells/ml), the sum of cells counted within those squares has to be multiplied by 104. 
 
 
2.12.1.4 Long-term cell storage 
 
freezing medium:  90% culture medium and 10% DMSO, freshly filtered through  
    22 µm filter 
cryovials:   2.0 ml, sterile (Nalgene) 
 
Sf9 cells can be stored for long periods of time by freezing in liquid nitrogen. Sf9 cells from a 
healthy, log-phase culture were spun down at 2500 rpm (Megafuge 1.0, Heraeus) for 10 min. 
After the supernatant was decanted, the cell pellet was kept on ice and resuspended in such a 
volume of freezing medium, that the final cell density was 4 x 106. The cell suspension was 
aliquoted (1 ml) into freezing vials. To freeze the cells slowly, the vials were placed at -20oC for 
1 h and then kept at -80oC overnight. The next day the cells were transferred to liquid nitrogen. A 
week or two after the cells were frozen, one vial was thawed to check for cell viability and 
contamination. 
The frozen cells were quickly thawed by gentle agitation in a 37oC water bath. Then, they were 
transferred to a centrifuge tube (Falcon) and 25 ml of fresh medium were added. The cells were 
spun down by centrifugation at 1000 rpm (Megafuge 1.0, Heraeus) for 5 min. The pellet was 
resuspended in 40 ml of fresh medium and centrifuged again at the same conditions. After the 
supernatant was removed, the cells were resuspended in 10 ml of medium and the suspension was 
seeded in a 25 cm2 culture flask, which was incubated at 27oC. After 12-24 h the old medium was 
replaced with fresh and the culture was incubated at 27oC as long as the cells needed to get 
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confluent. Then they were transferred to a bigger flask (75 cm2) and the medium was exchanged 
with fresh. 
 
 
2.12.1.5 Monolayer culture 
 
tissue culture flasks:  25 cm2 (Falcon) 
    75 cm2 (Falcon) 
    175 cm2 (Falcon) 
 
Insect cells grow well both in suspension and as monolayer cultures and can be transferred from 
one to the other with minimal adaptation. 
Sf9 cells from a monolayer culture were subcultured when they were 80-90% confluent. After the 
culture was examined for contaminations and cells floating in the medium, the old medium was 
discarded and the cells were washed from the surface of the flask by gentle pipetting using 10 ml 
of fresh medium. A small aliquot of this suspension was stained with trypan blue. The cells were 
examined and counted with an inverse microscope. The suspension was diluted and the cells were 
seeded in a new flask with a density of 7.0 x 104 - 1.0 x 105 cells/cm2 in a final volume of 5 ml 
(for 25 cm2 flask), 15 ml (for 75 cm2 flask) or 35 ml (for 175 cm2 flask). A culture prepared with 
such cell density was ready for next passage in 2-3 days. The flasks were incubated in a 
humidified incubator at 27oC. 
 
 
2.12.1.6 Suspension culture 
 
plastic roller bottles:  2 l (Greiner) 
 
Continuous propagation of Sf9 cells in suspension for more than a few passages resulted in 
decreased cell viability and growth rate. That was the reason, that the stock cultures were 
passaged as monolayer and used then to seed suspension cultures when it was required. 
Usually, 2-3 confluent 175 cm2 flasks were used to start one bottle of a suspension culture. After 
the cells were counted, they were inoculated in a plastic roller bottle with a density of 0.8 x 105 - 
1.0x 106 cells/ml in a total volume of 80-100 ml. The bottle was incubated at 27oC in an 
incubator, where it was slowly rolled (5 rpm). When cells from the suspension attached to the 
wall of the bottle and the cell density reached 3-4 x 106 cells/ml, fresh medium was added to the 
 48
________________________________________________________2. Materials and Methods 
culture. In a roller bottle were incubated maximum 200 ml of cell suspension and the cell density 
was controlled to be not more than 4.5 x 106 cells/ml. 
 
 
2.12.2 Generation of Recombinant Baculoviruses 
 
2.12.2.1 The Baculovirus expression system 
 
Baculoviruses belong to a diverse group of large double-stranded DNA viruses that infect 
different insects as their natural hosts (Matthews, R.E.F., 1982). The Baculovirus genome is 
replicated and transcribed in the nuclei of infected host cells where the large Baculovirus DNA 
(between 80 and 120 kbp) is packaged into rod-shaped nucleocapsids. Since the size of this 
nucleocapsids is flexible, recombinant Baculovirus particles can accumulate large amounts of 
foreign DNA. 
One of the most commonly used Baculoviruses for expression vector work is Autographa 
californica nuclear polyhedrosis virus (AcNPV). Infectious AcNPV particles enter susceptible 
insect cells by endocytosis or fusion and viral DNA is uncoated in the nucleus. DNA replication 
starts 6 h post-infection. The virus infection cycle can be divided into two different phases: early 
and late. During the early phase, the infected insect cell releases extracellular virus particles by 
budding off from the cell membrane of infected cells. During the late phase of the infection cycle, 
occluded virus particles are assembled inside the nucleus. The occluded viruses are embedded in 
a homogenous matrix made predominantly of a single protein, the polyhedrin protein. That is 
why, during the late phase of infection, the polyhedrin protein accumulates to very high levels. 
Although the polyhedrin protein seems to be one of the most abundant proteins in infected insect 
cells, it is not essential for the Baculovirus life cycle in tissue culture. Cloning of a gene of 
interest under the control of the polyhedrin promoter, leads to high expression levels of the 
recombinant protein. This fact defines the Baculovirus expression vector system as one of the 
most powerful available systems for eukaryotic expression of recombinant proteins. 
 
 
2.12.2.2 Co-transfection of BaculoGold DNA and a transfer vector into insect cells 
 
The Baculovirus genome is too large to directly insert foreign genes easily. Hence the foreign 
gene has to be cloned first in a transfer vector, which later is co-transfected with AcNPV DNA 
into Sf9 cells. 
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For co-transfection was used BaculoGold DNA (Pharmingen), which is a modified AcNPV 
Baculovirus DNA, containing a lethal deletion and does not code for viable virus. Co-transfection 
of BaculoGold DNA with a complementing Baculovirus Transfer Vector rescues the lethal 
deletion. The foreign gene has to be cloned into a transfer vector that contains flanking 
sequences, which are homologous to the Baculovirus genome. After co-transfection, 
recombination takes place within the insect cells between the homologous regions in the transfer 
vector and the BaculoGold DNA. Recombinant virus produces recombinant protein and also 
infects additional insect cells, thereby resulting in additional recombinant virus. 
As a transfer vector was used pAcGP67B, where the gene of interest was cloned under the 
control of the strong Baculovirus polyhedrin promoter. It also contains gp67 signal sequence 
upstream of a multiple cloning site, which is one of the most effective Baculovirus-encoded 
signal sequences for protein secretion. The signal peptide mediates the forced secretion of the 
recombinant protein, even if it is normally not secreted. During transport across the cell 
membrane, the signal peptide is cleaved and the native protein can be purified from the infection 
supernatant. The vector has an E.coli origin of replication, which allows to be amplified in 
bacteria. It was prepared for co-transfection by LiCl purification method (see 2.7.11.3). 
 
Co-transfection was performed using BaculoGold transfection kit (Pharmingen). The following 
materials were required: 
confluent monolayer culture of Sf9 cells 
BaculoGold transfection kit:  linearized BaculoGold Baculovirus DNA 
     transfection buffer A 
     transfection buffer B 
     AcNPV wild-type high titer stock solution 
purified recombinant Baculovirus transfer vector (pAcGP67B) 
FCS 
6-well tissue-culture plate 
 
Confluent Sf9 cells were counted and diluted with medium containing 5% FCS to a cell density 
of 7 x 105 cells/ml. In each well of a 6-well tissue culture plate, 1 ml of this cell suspension was 
seeded and 1 ml of fresh medium was added. The plate was incubated shortly at 27oC until the 
cells attached firmly to the bottom. 
In a sterile Eppendorf tube in a laminar hood, 1 µg of the pure recombinant transfer vector was 
mixed with 0.25 µg (2.5 µl) of BaculoGold DNA. After 5 min of incubation at RT, 500 µl of 
transfection buffer B were added to the co-transfection mixture. To prepare the positive control, 
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25 µl of AcPNV wild-type high titer stock solution were added to 1.5 ml of medium. The old 
medium from the cells in the experimental co-transfection well was aspirated and replaced with 
500 µl of transfection buffer A. The medium in the positive control well was replaced with the 
mixture containing wild-type AcNPV. In the negative control well the medium was aspirated and 
1.5 ml of fresh medium were added. Nothing else was added to this well. Drop-by-drop, in the 
experimental co-transfection well was added the earlier prepared solution containing BaculoGold 
DNA and Baculovirus transfer vector. After every 3-5 drops, the plate was gently rocked back 
and forth to mix the drops with the medium. During this procedure, a fine calcium 
phosphate/DNA precipitate with white color was formed. The plate was incubated for 4 h at 27oC 
and then the medium from the experimental and the positive control wells was aspirated. The 
cells there were washed with 1.5 ml of fresh medium, which then was removed. Again 1.5 ml of 
fresh medium was added to each of these wells. The plate was placed in a incubator and kept at 
27oC for 5 days.  
After 5 days the cells in the three wells were examined for signs of infection. The supernatant 
from the experimental co-transfection well was collected and centrifuged at 2500 rpm (Biofuge 
A, Heraeus) for 5 min. The supernatant was stored at 4oC in the dark and later was used for 
plaque purification. 
 
 
2.12.2.3 Generating pure virus stocks by plaque purification 
 
The principle of the following method is to infect cells with extremely low numbers of infectious 
particles, so that only isolated cells become infected. An overlay of agarose keeps the cells stable 
and limits the spread of virus. When the originally infected cell produces virus and eventually 
lyses, only the immediate neighboring cells become infected. Each group of infected cells is 
referred to as a plaque. Uninfected cells are dispersed throughout the culture, surrounding the 
plaques. After several infection cycles, the infected cells in the center of the plaques begin to lyse 
and the peripheral infected cells remain surrounded by uninfected cells. All the virus particles in a 
plaque derive from a single infectious particle. Therefore, clonal virus populations may be 
purified by isolating individual plaques. 
 
confluent monolayer Sf9 culture 
FCS 
Insect Express Medium (2 x) (BioWhittaker) 
agarose solution: 1.8% SeaPlaque Agarose (BioZym) dissolved in H20, autoclaved  
and kept at 65oC 
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MTT solution:  1 mg/ml MTT dissolved in H2O, filtered through 22 µl filter 
6-well tissue culture plate 
 
The cells were counted and diluted to a cell density of 1.2 x 106 cells/ml. In each well was seeded 
1 ml of cell suspension and 1 ml of fresh medium was added. The plate was kept 10-15 min at 
27oC on a level surface to allow the cells to spread evenly over the bottom. Serial dilutions of the 
viral transfection supernatant in fresh medium were made, as it follows:  
   3 x 10-1, 1 x 10-1, 1 x 10-2, 1 x 10-3 and 1 x 10-4. 
All dilutions were performed in a total volume of 1 ml in sterile Eppendorf tubes. The medium 
was aspirated and replaced with the virus in oculum. One well was used for negative control and 
there only fresh medium was added. The plate was incubated at 27oC for 1 h. For each plate was 
prepared a solution containing 5 ml of agarose solution, 4.5 ml of Insect Express Medium (2x), 
and 500 µl of FCS, which was kept fluid at 40oC. The virus dilutions were aspirated and the cells 
were overlaid with an agarose containing solution (1 ml/well). The plate was kept on a leveled 
surface until agarose hardened (about 20 min). The plate was incubated in a humid atmosphere at 
27oC until visible plaques developed (usually 5-6 days). 
To better visualize the plaques, the cells were stained with solution of MTT. To each well was 
applied 1 ml of it and the plate was incubated for 1 h at RT. After this time, the plaques were seen 
as small white points on a violet background.  
 
 
2.12.3 Amplification of Virus Stocks 
 
The generation of a pure high titer virus stock involved the preparation of a stock starting from a 
single infectious unit. During the virus amplification, the following steps were performed to 
increase the volume and the titer of the virus stock. 
 
 
2.12.3.1 Virus amplification from a single virus plaque 
 
The plaques were picked from wells containing not more than 20 single plaques. To pick up the 
plaques, a sterile micropipette tip was used. Each single plaque was placed in a sterile Eppendorf 
tube containing 1 ml of medium and was incubated for 1 h at 27oC. In a 6-well tissue-culture 
plate was seeded 1 ml/well Sf9 cells from confluent culture with a cell density of 1.2-1.5 x 106 
cells/ml and 1 ml of fresh medium was added to each well. After the cells attached to the bottom, 
 52
________________________________________________________2. Materials and Methods 
the medium was replaced with plaque containing solutions. In the negative control well, 1 ml of 
fresh medium was added. The plate was incubated for 1 h at 27oC and then 1 ml of fresh medium 
was added to each well. 
After 3 days of incubation at 27oC, the supernatant from the different virus clones was collected 
and centrifuged at 2500 rpm (Biofuge A, Heraeus) for 5 min. This amplifying step was repeated 
once more using 500 µl of each virus stock mixed with 500 µl of fresh medium. After the second 
amplification, the virus clones were tested for protein expression by Western blotting (see 2.9). 
The virus clone, which showed the best expression level, was chosen for further amplification. 
 
 
2.12.3.2 Virus amplification in a small volume scale 
 
In a 175 cm2 tissue-culture flask were seeded Sf9 cells with a density of 1.6-2.0 x 105 cells/cm2 in 
a total volume of 35 ml. After the cells attached to the bottom, the medium was aspirated and 
cells were infected with 1 ml of the virus supernatant collected after the second amplification 
step. Additionally, 10 ml of fresh medium were added and the flask was incubated for 1 h at 
27oC. Then 24 ml of fresh medium were added to the flask. After 3 days of incubation at 27oC, 
the virus supernatant was collected and centrifuged (Megafuge 1.0, Heraeus) at 2500 rpm for 5 
min. 
 
 
2.12.3.3 Virus amplification in a large volume scale 
 
5 ml from the virus supernatant collected after the described amplification step were used to 
infect Sf9 cells in a roller bottle (Greiner). 95 ml of suspension culture from Sf9 cells with cell 
density 1.5 x 106 cells/ml were transferred to a fresh plastic roller bottle and then the virus stock 
was added. After 3 days of incubation at 27oC, the supernatant was centrifuged at 2500 rpm 
(Megafuge 1.0, Heraeus) for 5 min and was used for determination of virus titer. 
 
 
2.12.3.4 Determination of virus titer by plaque assay 
 
The titer of a virus stock is the concentration of infectious virus particles in that stock. It was 
determined by a plaque assay. Plaque assay of a virus stock involves essentially the same 
protocol as plaque purification. Because each plaque derives from a single infectious unit, 
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counting the number of plaques formed by different dilutions of a virus stock allows determining 
the concentration of infectious units in the stock. Viral titers determined in this manner are 
expressed in plaque-forming units/ml (pfu/ml). For practical purposes, the virus stock titered by 
plaque assay was diluted as it follows: 
   1 x 10-4, 1 x 10-5, 1 x 10-6, 1 x 10-7 and 1 x 10-8. 
 
 
2.12.3.5 Virus storage 
(Jarvis, D.L. et al., 1994) 
 
Working stocks of recombinant viruses were stored at 4oC in tissue-culture medium containing 
5% of FCS. Infected cells and cell debris were removed from the virus stock by centrifugation at 
1000 x g for 5 min. The stocks were stored in the dark, because the viruses are extremely light 
sensitive. 
For long-term storage, aliquots of the virus stock were frozen in polypropylene cryovials at          
-80oC without any cryoprotectant. Before freezing, FCS was added to 10%. Virus stocks were 
retitrated before use after prolonged storage. 
 
 
2.12.4 Protein Expression 
 
After the virus titer was determined, the high titer virus stock was used for protein expression. 
200 ml of suspension culture with cell density 1.5 x 106 cells/ml, were transferred to a fresh 
plastic roller bottle. The cells were infected with such an amount of high titer virus stock, that the 
multiplicity of the infection (infectious virus units/cell) was between 3 and 5. The bottle was 
rolled (5 rpm) at 27oC. Aliquots were examined under a microscope and depending on the 
number of infected cells, the expression was done for 4 or 5 days. The suspension was 
centrifuged at 3000 rpm for 10 min. The protein containing supernatant was frozen and stored at -
20oC. 
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2.13 Purification of Recombinant Proteins 
 
2.13.1 Purification of Proteins Expressed in E.coli 
 
2.13.1.1 Protein purification by ion exchange chromatography 
 
buffer A:  25mM NH4OAc, pH 5.0 
buffer B:  25mM NH4OAc, 1M NaCl, pH 5.0 
column:  3 x 10 cm (Biorad) 
ion exchanger: CM-Sepharose fast flow 
pump:   LKB 2232 Microperpex S Peristaltic Pump 
detector:  LKB 2238 Uvicord, LKB 2210 Recorder 
collector:  ISCO Retriever II 
 
CM-Sepharose fast flow (Pharmacia) was equilibrated with 4 M NH4OAc, pH 5.0 and washed 
several times with 25 mM NH4OAc, pH 5.0 by a funnel. The so prepared ion exchanger was 
packed in a column (5-10 ml) and washed with solution A, until the elute reached pH 5.0. The 
protein containing solution was slowly loaded (ca. 250 ml/h) into the column. This was followed 
by rinsing with five column volumes of solution A. The elution of proteins was performed by a 
60 ml linear salt gradient from 0 to 0.5 M NaCl/25 mM NH4OAc pH 5.0 with a flow rate ca.0.5 
ml/min. The elute peak was detected with an absorbance device at 280 nm and recorded. The 
described procedure was performed in a 4oC room. The collected fractions (2 ml each) were 
measured at 280 nm (Konto Uvikon 930 Spectrophotometer), using solution A as a blank. 
Further, the fractions (10 µl from each) were examined on a SDS-polyacrylamide gel. The 
fractions, which contained pure protein in a sufficient amount were combined and later purified 
additionally by the use of RP-HPLC. 
 
 
2.13.1.2 Protein purification by RP-HPLC 
 
controller:  LKB 2152 HPLC Controller 
pump:   LKB 2150 HPLC Pump 
detector:  Merk Hitachi 655A Variable Wavelength UV Monitor 
recorder:  LKB 2210 
superrac:  LKB 2210 
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acetonitrile:  acetonitrile (Roth, HPLC Grade), filtered through a 22 µm filter 
TFA:   0.1% TFA (Merck) in H2O, filtered through a 22 µm filter 
protein stock buffer: 12.5 ml of 4 x upper Tris-HCl, 20 ml of 10% SDS, 47.5 ml of H2O, 30 ml  
   of glycerol mix  
 
The protein containing fractions, collected during the ion exchange chromatography, were 
centrifuged at 3000 rpm for 15 min at 4oC. The supernatant was injected into a Vydac C4 HPLC 
column (250 x 4.6 mm or 250 x 8 mm), equilibrated with 0.1% TFA. The protein was eluted by 
acetonitrile gradient from 0 to 100%. The elution was controlled automatically by the presented 
programs (Table 2.10). 
 
Table 2.10: Acetonitrile gradient and retention time, used for analytical and preparative RP-HPLC 
 
 Acetonitrile [%] Retention time [min] 
Analytical RP-HPLC 0 – 35 15 
 35 – 45 40 
 45 – 100 15 
 100 – 100 10 
Preparative RP-HPLC 0 – 30 5 
 30 – 50 45 
 50 – 100 10 
 100 – 100 10 
 100 – 0 10 
 
The flow rate was 0.7 ml/min for the column (250 x 4.6 mm) and 2 ml/min for the column (250 x 
8 mm). The protein concentration of the collected fractions was measured at the absorption 
spectrum range 250-320 nm (Kontron Uvikon 930 Spectrophotometer). An aliquot (10 µl) from 
every fraction was mixed with 30 µl of protein buffer and 5 µl from this solution was analyzed by 
SDS-polyacrylamide gel electrophoresis. The fractions with the highest amount of pure protein 
were combined, aliquoted and lyophilized. 
In addition to the SDS-PAGE, the protein purity was also examined by analytical RP-HPLC, 
performed with the use of the small column (250 x 4.6 mm). The procedure followed the 
described details for preparative RP-HPLC, except that only 100 µg of protein were required for 
analysis and the detection sensitivity was set at 0.08. 
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2.13.2 Purification of Proteins Expressed in Sf9 Cells 
 
2.13.2.1 Affinity chromatography using IL-4 as a ligand 
 
PBS:    120mM NaCl, 2mM KCl, 3mM NaH2PO4, pH 7.4 
eluent:    4M MgCl2  
affinity adsorbent:  IL-4, immobilised to Sepharose gel 
pre-column:   1 x10 cm column (Biorad) 
filling for pre-column: CM Sepharose fast flow (Pharmacia) 
 
The affinity matrix (2 ml) was packed in a sterile Pasture pipette. The so prepared affinity column 
was washed with 10 volumes of PBS and stored at 4oC. The filling for the pre-column (CM 
Sepharose fast flow) was washed several times with 20 x PBS, using a funnel. The gel was stored 
under 20 x PBS at 4oC. Immediately before the purification step, 2-3 ml were used to fill the pre-
column, which was washed with 10 volumes of PBS. 
The protein containing supernatant was thawed out and centrifuged at 2500 rpm (Megafuge 1.0, 
Heraeus) for 10 min to eliminate the precipitate, resulting from freezing. After the affinity 
column and the pre-column were connected, the protein material was loaded in a way that it 
passed slowly (about 100 ml/h) first through the pre-column. The two columns were 
disconnected and the affinity column was washed with 10 column volumes (20 ml) of PBS. 
During the elution, which was performed with 4 M MgCl2, 5-6 protein fractions were collected 
(each 1.5 ml). The described procedure was carried out at 4oC. The protein concentration was 
measured at the absorption spectrum range 250-320 nm (Kontron Uvikon 930 
Spectrophotometer). The quality of the protein was analyzed by an SDS-PAGE, where 15 µl of 
every fraction were loaded. The fractions containing the highest amount of pure protein were 
combined. 
The pre-column could be used only once, and then had to be cleaned and refilled with fresh CM 
Sepharose. After elution, the affinity column was washed with 20 ml of PBS and recovered in 
this way for the next protein purification. It was stored at 4oC under PBS. 
 
 
2.13.2.2 Affinity chromatography using X14/38 as a ligand 
 
PBS:   120mM NaCl, 2mM KCl, 3mM NaH2PO4, pH 7.4 
eluent:   4M MgCl2  
affinity adsorbent: X-14-38, bond to Sepharose gel 
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pre-column:   1 x10 cm column (Biorad) 
filling for pre-column: CM Sepharose fast flow (Pharmacia) 
 
X14/38 is an anti-IL-4BP monoclonal antibody, which was used as a ligand for the purification of 
low-affinity IL-4BP variants that could not be purified by the method described in above.  
The procedure is essentially the same as described in 2.12.2.1. The main difference was, that the 
protein containing supernatant was loaded very slowly (usually overnight) onto the columns.  
 
 
2.13.2.3 Dialysis  
 
After the purification by an affinity column, the fractions containing the highest amount of pure 
IL-4BP, were combined and dialyzed in order to reduce the high salt concentration. The protein 
solution was placed in a semi-permeable dialysis tubing (type 20/32, Roth) made of cellulose 
acetate. The dialysis was performed in 2 l of PBS, which was stirred at 4oC overnight. At the next 
day, the buffer was exchanged with fresh and the dialysis repeated one more night. To prevent 
contamination with foreign proteins, the tubing was touched only through gloves. 
 
 
2.13.2.4 Concentration of proteins by ultrafiltration 
 
ultrafilter:  YM10 = 10000 MW (Amicon) 
apparatus:  stirred cell covering range 1-10 ml (Amicon 8010) 
 
During ultrafiltration, water and other small molecules were driven out of the protein solution 
through a semi-permeable membrane by a transmembrane force, such as high pressure.  
The new membrane was washed according to the manufacturer’s instructions and stored under 
30% ethanol at 4oC. Before use, the filter was washed with dH2O. The system was assembled and 
the membrane was placed with the glossy side toward the solution. It was rinsed by filtering a 
few ml of PBS at 3.5 atm. PBS was replaced by the dialyzed protein solution (10-15 ml) and 
pressure of 4 atm was applied until the protein sample reached a volume of 1-1.5 ml. The 
ultrafilter was rinsed in dH2O and stored under 30% ethanol solution at 4oC. The protein 
concentration was measured at the absorption spectrum range 250-320 nm. Aliquots of 350 µl 
were frozen at -20oC and further biotinylated. 
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2.14 Analysis of Protein-Protein Interactions by BIAcore Technology 
 
The analysis of kinetic and thermodynamic data of protein-protein interactions between the 
extracellular domain of IL-4 receptor (IL-4BP) and its mutated variants with the ligand (IL-4) 
was performed with a BIAcore 2000 (Pharmacia). BIAcore 2000 is an instrument, which 
measures bio-molecular interactions in real time without labeling of the interactants and allows 
detailed investigation of the reaction kinetics by analysis of the resultant signals (Karlsson, R. & 
Fealt, A., 1997). 
For this purpose, one interactant (here IL-4BP or its variants) is immobilized on the surface of a 
sensor chip and a solution containing the other binding partner (IL-4) flows continuously over the 
chip. The sensor chip consists of a glass slide coated with a thin gold film to which is attached, by 
an inert linker layer, a dextran matrix onto which the mentioned interactant can be immobilized 
using well-defined chemistry. The sensor chip forms one wall of a micro-flow cell where its 
matrix covered side comes into contact with the solution containing the second interactant. This 
system uses the detection principle of surface plasmon resonance. During the interaction, light 
passing a prism is focused onto the gold surface of the sensor chip through the glass, and 
reflected light is monitored. Evanescent wave photons produced by the incident polarized light 
interact with free oscillating electrons (plasmons) in the gold surface. Resonance occurs at a 
critical angle of the incident light, and light energy is transferred to electrons in the metal film 
surface, causing a minima in the reflected light. This angle depends on the refractive index at, or 
close to the metal surface opposite to where the light is focused. By measuring small changes in 
refractive index, the instrument monitors the change in mass as a ligand binds to, or dissociates 
from, its binding partner. Data are presented as sensograms that show the change in resonance 
units (RU) versus time. For proteins, which have a refractive index increment of approximately 
0.18, a signal of 1000 RU is equivalent to a surface concentration of 1 ng/mm2 (Stenberg, E. et 
al., 1990). 
Association is monitored when a sample is injected and binding occurs to the immobilized 
interactant. After sample injection, buffer alone flows over the sensor surface and dissociation 
parameters can be recorded. At the end of the experiment, the surface can be regenerated using 
suitable reagents to remove remaining bound analyte without denaturing the immobilized 
reaction partner and the chip can be used for a new cycle of measurements (Nice, E.C. & 
Catimel, B., 1999) 
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2.14.1 Immobilization of Proteins by Streptavidin-Biotin Coupling 
 
After streptavidin was covalently immobilized onto the surface of a sensor chip, the biotinylated 
protein was bound to the prepared matrix. 
 
sensor chip:  CM5 
EDC:   50mM N-Ethyl-N´-(dimethylaminopropyl) carbodiimide 
NHS:   200mM N-Hydroxysuccinimide 
HBS buffer:  10mM HEPES pH 7.4, 150mM NaCl, 3.4 mM EDTA,  
   0.005% Surfactant P20 
streptavidin solution: 100µg/ml streptavidin in 10mM NaOAc, pH 4.5 
regeneration buffer: 100mM HOAc, 1M NaCl, pH 3.0 
 
The immobilization and preparation of a sensor chip was carried out according to the 
manufacturer’s instructions (BIAcore Handbook, 1995). The immobilization of streptavidin was 
run automatically following the program shown in Table 2.11. 
 
Table 2.11: Immobilization of streptavidin by amine coupling 
 
Immobilization procedure 
continuously flow buffer HBS flow rate 5 µl/min 
EDC/NHS (50 mM/200 mM) 35 µl (7 min) 
streptavidin (100 µg/ml) 35 µl (7 min) 
1 M ethanolamine-HCl 35 µl (7 min) 
 
The concentration of biotinylated proteins used for immobilization was usually 0.1 µg/ml. 
 
 
2.14.2 Measuring and Evaluation of Protein-Protein Interactions 
 
A typical sensogram recorded with BIAcore 2000 is characterized by the following three phases: 
1) Association phase - when the sample is injected; increases in the signal correspond to binding 
to the immobilized interactant. 
2) The signal reaches a constant plateau when equilibrium between association and dissociation is 
reached. 
3) Dissociation phase - occurs when buffer alone flows over the sensor surface. The decrease in 
signal reflects dissociation of analyte from the surface-bound complex. 
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Kinetic rate constants can be derived from the association and dissociation phases of the 
sensogram. The height of the plateau represents the thermodynamic affinity of binding.  
The program BIAevaluation 2.0 was used to calculate the kinetic and thermodynamic constants. 
The theoretical equations, which describe the kinetics and equilibrium of interactions in real-time 
BIA, are listed in Appendix 1. 
 
 
2.14.3 Assessment of the Energetic Effects of Introduced Mutations 
 
Substitution of a residue, which is direct or indirect involved in binding is followed by a change 
in the binding energy of the protein-protein complex. The equilibrium dissociation constants 
determined by experiments performed with the BIAcore 2000 analytical system were used to 
calculate the loss of binding free energy (∆∆G) characterizing the mutated variants: 
 
   ∆∆G = R*T*ln (Kd mut/Kd wt) 
 
where R is the gas constant, T is the absolute temperature, Kd mut is the equilibrium dissociation 
constant for the mutant variant, Kd wt is the equilibrium dissociation constant for the wild-type 
interaction. 
The total change in binding free energy (∆G) for the interaction of IL-4 and IL-4BP was 
calculated according to the formula:  
 
   ∆G = -R*T*ln (1/Kd) 
 
where R is the gas constant, T is the absolute temperature, Kd is the equilibrium dissociation 
constant for the IL4/IL-4BP interaction.  
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3. Results 
 
 
3.1 Preparation of Recombinant IL-4BP and Its Variants 
 
In the framework of the present project was analyzed the effect of amino acid substitutions within 
the α-chain of the human IL-4 receptor on the kinetics of the interaction with IL-4. Earlier, it was 
shown that the separately expressed 207-residue ectodomain of the α-chain (IL-4BP) forms a 1:1 
complex with IL-4 and exhibits the same binding affinity as the entire receptor α-chain (Hoffman 
et al., 1995; Shen et al., 1996). Based on these results, the selection of the amino acids subjected 
to mutagenesis was restricted to the mentioned domain.  
 
Table 3.1: IL-4BP variants designed by site-specific mutagenesis.  
IL-4BP Variant IL-4BP Loops 
Y13A A-B L1 
Y13F A-B L1 
L39A C-C´ L2 
F41A C-C´ L2 
L42A C-C´ L2 
L43A C-C´ L2 
D66A E-F L3 
D67A E-F L3 
V69A E-F L3 
D72A E-F L3 
D72N E-F L3 
K91A G-A L4 
K91D G-A L4 
S93A G-A L4 
D125A B-C L5 
N126A B-C L5 
Y127A B-C L5 
Y127F B-C L5 
L128A B-C L5 
Y183A F-G L6 
Y183F F-G L6 
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All variants of IL-4BP, which were constructed by specific substitutions of a single amino acid, 
are shown in Table 3.1. Variants D66A, D67A, V69A, D125A, N126A, Y127A and Y128A were 
expressed and purified by Dr. Yonghong Wang and further examined by the author. The study 
was accomplished by analyses of variants containing two independent mutations (Table 3.2).  
 
Table 3.2: A list of the IL-4BP double mutants. The contact clusters are defined according Hage et al., 1999. 
 
Contact cluster Variant 
I II III 
Y13F/L39A Y13 L39  
Y13F/F41A Y13 F41  
Y13F/D67A Y13  D67 
Y13F/V69A Y13 V69  
Y13F/D72N Y13 D72  
Y13F/Y127A Y13               Y127   
Y13F/Y183F Y13               Y183   
D72N/L39A  D72                   L39  
D72N/F41A  D72                   F41  
D72N/D67A  D72 D67 
D72N/V69A  D72                   V69  
D72N/Y127A Y127 D72  
D72N/Y183F Y183 D72  
 
The proteins representing IL-4BP and its variants, without any exceptions, were recombinantly 
expressed in an eukaryotic expression system (Baculovirus expression system). Since in the 
human IL-4BP six sites of potential N-linked glycosylation are present, the expression of 
functionally active recombinant proteins requires eukaryotic conditions. Therefore, was chosen 
the Baculovirus expression system that offers the advantage to express high levels of soluble 
proteins in which post-translational modifications are performed. 
The kinetics of the binding of IL-4 to the IL-4BP variants was measured by means of the 
BIAcore system after the receptor variants were immobilized on the biosensor matrix. This 
method requires high purity and homogeneity of the examined samples because this is the only 
way to determine the exact concentration of the recombinant IL-4BP variants. The variants that 
had relatively higher affinity to IL-4 were purified by affinity chromatography exploring IL-4 as 
a ligand. For the rest of the proteins a chromatographic step using anti-IL-4BP antibody was 
performed. Both procedures resulted in highly pure protein fractions, which could be used for 
BIAcore measurements without any necessity of further purification.  
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3.1.1 Cloning of IL-4BP and Its Variants in the Baculovirus Transfer Vector pAcGP67B 
 
The cDNA representing the first 207 residues of mature human IL-4 receptor α chain, 
extracellular domain was mutated by recombinant PCR. As a template was used the vector 
pRPR9IL4FD (C. Söder, based on vector RTSpRC109, McCarthy et al., 1985, Appendix 2). It 
contains an IL-4BP cDNA modified at position C182A, in which the free cysteine is substituted 
in order to prevent the formation of disulfide bridges. The complete nucleotide and amino acid 
sequence of hIL-4BP is shown in Figure 3.1. 
 
              
    Y  A  F  K  V  L  Q  E  P  T  C  V  S  D  Y  M  S  I  S  T 
5´CTATGCATTTAAGGTCTTGCAGGAGCCCACCTGCGTCTCCGACTACATGAGCATCTCTAC 3´ 
                10             20             30             40             50             60 
3´GATACGTAAATTCCAGAACGTCCTCGGGTGGACGCAGAGGCTGATGTACTCGTAGAGATG 5´ 
 
    C  E  W  K  M  N  G  P  T  N  C  S  T  E  L  R  L  L  Y  Q 
5´TTGCGAGTGGAAGATGAATGGTCCCACCAATTGCAGCACCGAGCTCCGCCTGTTGTACCA 3´ 
                70             80             90             100            110            120 
3´AACGCTCACCTTCTACTTACCAGGGTGGTTAACGTCGTGGCTCGAGGCGGACAACATGGT 5´ 
 
    L  V  F  L  L  S  E  A  H  T  C  I  P  E  N  N  G  G  A  G 
5´GCTGGTTTTTCTGCTCTCCGAAGCCCACACGTGTATCCCTGAGAACAACGGAGGCGCGGG 3´ 
                130            140            150            160            170            180 
3´CGACCAAAAAGACGAGAGGCTTCGGGTGTGCACATAGGGACTCTTGTTGCCTCCGCGCCC 5´ 
 
    C  V  C  H  L  L  M  D  D  V  V  S  A  D  N  Y  T  L  D  L 
5´GTGCGTGTGCCACCTGCTCATGGATGACGTGGTCAGTGCGGATAACTATACACTGGACCT 3´ 
                190            200            210            220            230            240 
3´CACGCACACGGTGGACGAGTACCTACTGCACCAGTCACGCCTATTGATATGTGACCTGGA 5´ 
 
    W  A  G  Q  Q  L  L  W  K  G  S  F  K  P  S  E  H  V  K  P 
5´GTGGGCTGGGCAGCAGCTGCTGTGGAAGGGCTCCTTCAAGCCCAGCGAGCATGTGAAACC 3´ 
                250            260            270            280            290            300 
3´CACCCGACCCGTCGTCGACGACACCTTCCCGAGGAAGTTCGGGTCGCTCGTACACTTTGG 5´ 
 
    R  A  P  G  N  L  T  V  H  T  N  V  S  D  T  L  L  L  T  W 
5´CAGGGCCCCAGGAAACCTGACAGTTCACACCAATGTCTCCGACACTCTGCTGCTGACCTG 3´ 
                310            320            330            340            350            360 
3´GTCCCGGGGTCCTTTGGACTGTCAAGTGTGGTTACAGAGGCTGTGAGACGACGACTGGAC 5´ 
 
    S  N  P  Y  P  P  D  N  Y  L  Y  N  H  L  T  Y  A  V  N  I 
5´GAGCAACCCGTATCCCCCTGACAATTACCTGTATAATCATCTCACCTATGCAGTCAACAT 3´ 
                370            380            390            400            410            420 
3´CTCGTTGGGCATAGGGGGACTGTTAATGGACATATTAGTAGAGTGGATACGTCAGTTGTA 5´ 
 
    W  S  E  N  D  P  A  D  F  R  I  Y  N  V  T  Y  L  E  P  S 
5´TTGGAGTGAAAACGACCCGGCAGATTTCAGAATCTATAACGTGACCTACCTAGAACCCTC 3´ 
                430            440            450            460            470            480 
3´AACCTCACTTTTGCTGGGCCGTCTAAAGTCTTAGATATTGCACTGGATGGATCTTGGGAG 5´ 
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    L  R  I  A  A  S  T  L  K  S  G  I  S  Y  R  A  R  V  R  A 
5´CCTCCGCATCGCAGCCAGCACCCTGAAGTCTGGGATTTCCTACAGGGCACGGGTGAGGGC 3´ 
                490            500            510            520            530            540 
3´GGAGGCGTAGCGTCGGTCGTGGGACTTCAGACCCTAAAGGATGTCCCGTGCCCACTCCCG 5´ 
    W  A  Q  A  Y  N  T  T  W  S  E  W  S  P  S  T  K  W  H  N 
5´CTGGGCTCAGGCCTATAACACCACCTGGAGTGAGTGGAGCCCCAGCACCAAGTGGCACAA 3´ 
                550            560            570            580            590            600 
3´GACCCGAGTCCGGATATTGTGGTGGACCTCACTCACCTCGGGGTCGTGGTTCACCGTGTT 5´ 
 
    S  Y  R  E  P  F  E  Q  H  ∗ 
5´CTCCTACAGGGAGCCCTTCGAGCAGCACTAG 3´ 
                610            620            630 
3´GAGGATGTCCCTCGGGAAGCTCGTCGTGATC 5´ 
 
 
Figure 3.1: Nucleotide and amino acid sequence of hIL-4BP cDNA. 
              
 
The PCR reactions were divided into two steps. During the first step (PCR 1) two fragments 
(PCR1a and PCR1b) were separately synthesized and a mutation of interest was introduced with 
the help of mutant primers containing one mismatch codon. For variants which were constracted 
by a substitution of a single amino acid, as a template in this reaction was used the wild-type 
cDNA. To produce variants in which two different amino acids were mutated, as a template was 
used a plasmid of hIL-4BP containing already one modified site and applying the described PCR 
techniques a second mutation was created. The length of the fragments differed for the particular 
variants depending on the exact location of the introduced mutation (Figure 3.2). 
 
              
 
 
    LMS    PCR1a       PCR1b PCR2 
 
 
Figure 3.2: Reaction products from PCR 1 and PCR 2 of IL-4BP. 
              
 
The fragments from PCR 1 (20-30 ng) were used as a template in PCR 2. Since the external 
primers specific for PCR 2 were in large excess compared to the amount of primers left from 
PCR 1a and PCR 1b, the purity of the reaction product was ensured. One of the external primers 
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in this step introduces a BamHI restriction site (WYH37) and the other (WYH38) contains a 
wild-type sequence. The product of PCR 2 has the length of 682 bp for all mutants in this method 
and yielded 1-3 µg DNA. 
After the reaction mixture from PCR 2 was precipitated in a volume of 30 µl, and than digested 
by BamHI. The restriction product containing the mutated IL-4BP cDNA has a length of 635 bp. 
This fragment was isolated and purified exploring an agrose gel electrophoresis and glass milk 
elusion. It was inserted into the baculovirus transfer vector pAcGP67B cut by BamHI (Appendix 
3). The plasmid caring the mutated IL-4BP (Figure 3.3) was then used for electrotransformation 
of competent E.coli (JM 103 recA- or JM 109). 
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Figure 3.3: Baculovirus transfer vector pAcGP67B with cloned IL-4BP. 
              
 
The first selection of plasmid–containing E.coli was performed by plating the transformation cell 
suspension on ampicillin agar plates. Since the plasmid contains an ampicillin resistance gene, 
only bacterial cells, which carry the plasmid pAcGP67B/IL-4BP, would be able to form colonies. 
The selection procedure was completed by analytical restriction endonuclease digestion. For this 
were prepared plasmid DNAs from several individual clones at analytical scale. The intact 
circular plasmids were digested first with BamHI to confirm the presence of IL-4BP in the 
plasmid. The positive clones showed a band of 635 bp after the restriction reaction, which was 
visualized on a 1 % agarose gel (Figure 3.4a). Only in few plasmid samples an IL-4BP insert was 
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not found. Most likely the reason that bacterial clones, which do not carry IL-4BP, grew up over 
agar plates, is not completed dephosporylation of vector ends. Since only one cutting enzyme was 
used during cloning, the positive plasmid samples were analyzed by a second restriction reaction 
with EcoRV and SacI. The products from this reaction give information about the orientation of 
the inserted IL-4BP fragment within the plasmid pAcGP67B. The cutting site of SacI is unique 
and located asymmetrically within the cDNA sequence of IL-4BP. Therefore plasmids which 
inserted the IL-4BP cDNA parallel to the direction of transcription, showed after such restriction 
reaction a shorter fragment of 320 bp, and those of them which inserted it in the opposite 
direction were characterized by a fragment of 800 bp (Figure 3.4b). Usually, equal number of 
bacterial colonies representing both kinds of plasmids was detected, as it was theoretically 
expected. 
 
              
 
 
 
 
      LMS     1      2       3       4       5       6      7       8        9   MHS                      LMS      1        2        3       4       5        6        7        8       9 
       
 
a) Analytical restriction with BamHI. Lines 1 to 9 
represent positive clones. 
 
 
 
 
 
b) Analytical restriction with EcoRV and SacI. Lines 
1,2,4,6 and 9 represent positive clones. Lines 3, 5, 7 
and 8 represent clones which inserted .the modified 
cDNA but in the “wrong” direction.  
Figure 3.4: Analytical restriction of pAcGP67B containing the modified IL-4BP cDNA. 
              
 
Plasmid DNA was isolated from clones, which were positive after all selection steps. Such 
preparations were used for sequence analyses and therefore another purification procedure was 
used which increased the amount and the quality of purified DNA (see 2.7.11.2). Sequencing was 
performed with 5´- and 3´- external primers (MF37 and WYH39). The sequence analysis 
confirmed the presence of the introduced mutation in all samples. No other mutations in the DNA 
sequence were detected. After the mutation was verified by sequencing, the mutant plasmid DNA 
was prepared at large scale for storage and following co-transfection (see 2.7.11.3). With the used 
method usually 20 to 30 mg of plasmid DNA were obtained from 40 ml of bacterial culture. 
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3.1.2 Co-transfection into SF9 Insect Cells and Amplification of the Recombinant Virus 
 
The first step necessary to construct recombinant Baculoviruses was co-transfection of the 
transfer vector pAcGP67B containing mutated IL-4BP cDNA and BaculoGold DNA into SF9 
insect cells. BaculoGold DNA is a modified AcNPV Baculovirus DNA, which contains a lethal 
deletion and does not code for viable virus. Co-transfection of the BaculoGold DNA with a 
complementing Baculovirus Transfer Vector, such as pAcGP67B, rescues the lethal deletion by 
homologous recombination. Since only the recombinant BaculoGold produces viable virus, a 
recombination frequency of 99 % is expected. To purify the stock of generated recombinant 
viruses during co-transfection, plaque purification was performed. The virus stock after co-
transfection showed titer between 5 x 107 and 5 x 108 pfu/ml. Since each plaque represents a 
single virus, several individual plaques were randomly picked up and used to generate clonal 
virus populations. Usually, the plaques were picked up from plates corresponding to a viral 
dilution of 1:10-7 or 1:10-6. All clonal virus populations were separately amplified in two steps. A 
Western blot was performed with the virus supernatants to verify the protein production (Figure 
3.5). The examined clones were compared to a sample of purified IL-4BP with known 
concentration. As expected, 100 % recombination efficiency was achieved during co-transfection 
and in all tested supernatants expression of IL-4BP was detected. The virus clone, which showed 
the largest amount of recombinant IL-4BP (clone 7), was selected for further amplification. 
 
              
 
    MS 
K+       1              2           3            4            5             6          7 
 
 
Figure 3.5: Western blot analysis of virus supernatants after the second virus amplification. MS, molecular standard; 
K+, positive control (40 ng); lines 1 to 7, examined recombinant virus clones. Clone 7 was chosen for further 
amplification. 
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Two additional steps of virus amplification were performed to produce a larger stock of 
recombinant virus with a high titer. Using a plaque assay the viral titer was determined to vary 
between 3 x 107 to 2 x 108 pfu/ml (Table 3.3). An aliquot was frozen for long-term storage and 
the rest was used to infect SF9 cells for expression of recombinant protein. 
 
 
3.1.3 Expression and Purification of Recombinant IL-4BP and Its Variants 
 
Recombinant proteins were expressed into SF9 insect cells after infection with high titer virus 
stock. For optimal protein production the MOI was estimated to be 5. The infected cells were 
incubated at 27°C for 3, 4, and 5 days and the protein content in the supernatant was examined. 
After the fourth day the level of expressed proteins did not increase and therefore 4 days were 
established as the optimal incubation time. Protein expression was performed in serum-free and 
serum-containing insect culture medium. The presence of serum increased the cell viability and 
respectively the amount of expressed protein. Since it did not interfere with the purification 
procedure, serum was kept in the expression medium. Under these conditions, the expression of 
recombinant IL-4BP and its variants from SF9 cells yielded 2-7 mg protein per liter of insect cell 
suspension (Table 3.3). 
The modified cDNAs were cloned downstream of the gp67 signal sequence in the transfer vector, 
which ensured that the recombinant proteins were expressed as gp67 signal peptide fusion 
proteins. The signal peptide mediates the forced secretion of recombinant proteins. During the 
transport across the cell membrane, the signal peptide is cleaved. Therefore the mature 
recombinant proteins could be purified from the infection supernatant, which was collected at the 
end of the incubation period. 
 
 
3.1.3.1 Purification of IL-4BP and its variants by IL-4 affinity column 
 
The purification of IL-4BP and most of its mutated variants explored the high-affinity binding 
(Kd ≈ 100 pM) of IL-4 to its receptor (Shen, 1996). A column, containing IL-4–Sepharose 6B gel 
was prepared and used for affinity chromatography. After the expression step, the clarified 
culture supernatant was passed over the affinity matrix and washed with PBS to clean the column 
from non-specifically bound proteins. The specifically bound IL-4BP and variants were eluted 
with 4 M MgCl2. The protein amount and purity of the collected fractions were analyzed on a 
SDS-PAGE (Figure 3.6). 
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Table 3.3: Virus titer and protein expression of IL-4BP and its variants 
Virus titer 
[pfu/ml] 
Expressed protein  Column used for 
purification Variant [mg/l cell suspension] 
IL-4BP 1.8 x 10  8 7.0 IL-4 
Y13A 5.6 x 10  7 4.0 Ab 
Y13F 7.0 x 10  7 5.5 IL-4 
L39A 1.0 x 10  8 4.0 IL-4 
F41A 1.1 x 10  8 4.5 IL-4 
L42A 2.2 x 10  8 7.5 IL-4 
L43A 2.3 x 10  8 6.5 IL-4 
D66A 1.5 x 10  8 3.0 IL-4 
D67A 2.0 x 10  8 3.0 IL-4 
V69A 1.5 x 10  8 3.0 IL-4 
D72A 1.4 x 10  8 3.5 Ab 
D72N 1.5 x 10  8 3.5 Ab 
K91A 2.3 x 10  7 4.5 IL-4 
K91D 1.5 x 10  8 4.0 IL-4 
S93A 2.5 x 10  7 4.5 IL-4 
D125A 4.0 x 10  7 3.5 IL-4 
N126A 2.3 x 108 3.5 IL-4 
Y127A 6.0 x 107 2.0 IL-4 
Y127F 8.0 x 107 6.0 IL-4 
L128A 2.3 x 108 2.0 IL-4 
Y183A 1.3 x 108 3.5 Ab 
Y183F 7 4.5 IL-4 
Y13F/L39A 4.0 x 107 2.5 Ab 
Y13F/F41A 2.2 x 108 3.5 Ab 
Y13F/D67A 5.5 x 107 3.0 Ab 
Y13F/V69A 3.8 x 107 2.5 Ab 
Y13F/D72N 8.0 x 107 3.5 Ab 
Y13F/Y127A 2.2 x 107 3.5 Ab 
Y13F/Y183F 5.2 x 107 3.5 Ab 
D72N/L39A 7.9 x 107 2.5 Ab 
D72N/F41A 8.0 x 107 3.5 Ab 
D72N/D67A 6.0 x 107 3.0 Ab 
D72N/V69A 4.3 x 107 3.5 Ab 
D72N/Y127A 6.7 x 107 2.5 Ab 
D72N/Y183F 9.0 x 107 3.0 Ab 
7.0 x 10  
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Usually, the first 3 to 4 fractions showed concentrations of pure protein in the range of 100 – 400 
µg/ml and in the rest of the fractions the protein was either of an inadequate quality either of an 
insignificant quantity. The best fractions were collected together, dialyzed against PBS and 
concentrated by ultrafiltration to a total volume of 1.5 ml. The amount of protein in the 
concentrated samples was determined by spectrophotometry and the purity was examined on a 
SDS-PAGE. No difference was found between the quality of protein samples expressed in the 
presence of FCS or in FCS-free culture medium. 
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Figure 3.6: Fractions after purification via IL-4 affinity column (variant F41A). MS, molecular standard; St, standard 
of IL-4BP (1 µg); lines 1, 2, 3, 4, fractions 1 to 4, respectively. 
              
 
IL-4BP and its variants produced in SF9 insect cells are extensively glycosylated. Accordingly, 
on SDS gels they migrate as two bands with apparent molecular masses of 35 kDa and 32.5 kDa. 
Respectively, variant N73A where a potential N-glycosylation site was modified exhibited only 
one band, corresponding to 32.5 kDa (Figure 3.7). 
Using the IL-4 affinity column successfully were purified IL-4BP, most variants included in the 
alanine screening (L39A, F41A, L42A, L43A, D66A, D67A, V69A, N73A, K91A, S93A, 
D125A, N126A, Y127A, and L128A), variants in which the original tyrosine amino acid was 
exchanged by phenylalanine (Y13F, Y127F, and Y183F) and variant K91D (Table 3.3, Figure 
3.7). The total amount of pure protein varied between 200 µg and 1 mg. A correlation between 
the protein amount and purity on the one side, and the subsequently determined binding affinity 
on the other, was observed for the variants purified by an IL-4 affinity column. Mutated variants 
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that later showed a similar Kd to this which characterizes the interaction between IL-4 and IL-
4BP in BIAcore measurements, were yielded in larger amount and with better quality than the 
variants which exhibited grater values of Kd. 
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Figure 3.7: Variants purified by an IL-4 containing affinity column. 
              
 
Figure 3.8 shows the result of the purification of variant D72A via IL-4 affinity column in 
comparison to IL-4BP, which was prepared in parallel. Since it was the first variant for which the 
purification step did not give a useful protein and the Western blot showed lower levels of 
expression, contamination in the virus clone was considered and a new viral stock was prepared. 
A Western blot after subcloning revealed that the newly generated viral clones expressed the 
recombinant protein in amounts comparable to all other variants, which were already successfully 
purified. Despite the convincing expression demonstrated by Western blot, the second attempt for 
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purification through an IL-4 affinity column failed again. Significant amount of recombinant 
protein was found in the flow-through fraction, which indicated that the column failed to bind 
specifically variant D72A. 
 
              
 
 
 
        MS  1  2 
 
 
Figure 3.8: Purification of variant D72A via IL-4 affinity column. Line 1 represents IL-4BP and line 2, variant 
D72A. Both samples were loaded after dialysis and concentration. 
              
 
Those experiments led to the conclusion that the purification problems did not concern 
expression levels, rather the affinity of variant D72A to IL-4 and respectively to the affinity 
column. Since D72 was suggested to be one of the most prominent amino acids implicated in the 
interaction with IL-4, the alanine substitution at this position was considered to affect the 
functional epitope to such an extent that the binding properties of variant D72A were altered 
completely. Therefore to exam the contribution of D72 in the receptor ligand interaction, an 
alternative variant was designed. In the additional variant the aspartic acid at position 72 was 
replaced by aspargine, which is a more conservative substitution and was expected to influence 
the binding affinity to IL-4 to a minor degree. Surprisingly, variant D72N was not able to bind to 
the IL-4 affinity column and demonstrated already during the purification procedure lower 
binding affinity to IL-4 than anticipated. At a later stage of the study, similar purification 
problems occurred also with variant Y13A and all double mutants included in the study. This was 
the first indication that the variants mentioned above would demonstrate extremely low binding 
affinity to IL-4 during BIAcore measurements. 
The purification of variant Y183A through IL-4 affinity column resulted in larger amount of 
protein compared to D72A and D72N. Although the sample was determined to contain a fraction 
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that migrated on a SDS-PAGE as IL-4BP, generally the purity was of inadequate quality. Since 
the interaction between variant Y183A and IL-4 was characterized by Kd ≈ 60 nM, such a 
constant value seems to settle the affinity limits for purification of IL-4BP variants by the IL-4 
affinity column. 
 
3.1.3.2 Purification of IL-4BP variants through Antibody column 
 
All IL-4BP variants, which could not be purified through the IL-4 affinity column, in spite of 
these negative results, demonstrated an intensive signal when they were examined by Western 
blot. As an example, Figure 3.9 represents the protein expression of variants Y13A, D72A, 
D72N, and Y183A, in SF9 insect cells. For detection was used the monoclonal Ab X14/38, 
against the extracellular domain of IL-4R. Those results suggested that despite the introduced 
mutation, the mAb X14/38 still recognizes the modified proteins. Obviously, two different and 
independent epitopes within the IL-4BP molecule are responsible for the high-affinity interaction 
with IL-4 and the recognition events with the used mAb. Therefore, even when the affinity to IL-
4 was affected due to a mutation introduced in the IL-4-binding epitope, the anti-IL-4BP mAb 
X14/38 was still able to recognize specifically the IL-4BP modified forms. 
  
              
 
         MS     D72A      D72N        Y13A      Y183A        K+ 
 
 
 
Figure 3.9: A Western blot of some IL-4BP variants, which could not be purified using the IL-4 affinity column, 
demonstrated intensive signals after detection with the mAb X14/38. 
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Based on these conclusions, the mAb was used to prepare a column for purification of those IL-
4BP variants, which failed to be purified by the use of the IL-4 affinity column. To examine the 
qualities of the new column and to find a suitable purification procedure, it was tested by 
purification of IL-4BP. At first, conditions similar to these already established for the IL-4 
affinity column were tested. After expression in SF9 cells, the clarified supernatant was applied 
to the column. A washing step with 10 column volumes of PBS was performed. The protein was 
eluted with 4 M MgCl2 and the first 10 collected fractions were examined on a SDS-PAGE. 
Fractions 1 to 4 showed IL-4BP which purity was comparable to the IL-4BP sample purified by 
the IL-4 affinity column. These fractions were combined and the procedure was completed by 
dialysis against PBS and concentration by ultrafiltration. In the analyzed fractions no traces of the 
mAb X-14-38 released from the column were found. The Ab containing column was washed with 
20 volumes of PBS and a following purification of IL-4BP was performed to verify whether the 
column was able to regenerate or not. The collected fractions from the second purification were 
examined specrophotometrically and on a SDS-PAGE. Both analyses confirmed that the column 
recovered fully and could be successfully used more than once. Experiments with different 
column flow rates indicated that the sample had to be applied slower than to the IL-4 column. A 
flow rate of 0.5 ml/min was established as optimal.  
Purification following the described procedure was performed with the variants that failed to be 
purified via IL-4 affinity column. In all experiments the first 3 to 4 eluted fractions contained a 
pure protein, which on a SDS-PAGE migrated in parallel to IL-4BP (Figure 3.10).  
 
              
 
 
                MS      1           2            3            4            5 
 
 
Figure 3.10: Purification of variant D72A through an Ab column. Line 1 represents a control of IL-4BP, lines 2 to 5 
correspond to fractions 1, 2, 3, and 4 of D72A, collected during the purification. 
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Generally, the protein concentration was lower than in the corresponding fractions for variants 
purified by the IL-4 column and varied between 50 and 200 µg/ml. The flow-through was 
examined and residual protein was found there. This suggested that the lower protein 
concentration resulted from a low capacity of the Ab column, rather than from low expression 
levels. However, the column capacity was not optimized, since the amount of pure proteins was 
sufficient for the following experiments.  
The Ab containing column was used to purify variants Y13A, D72A, D72N, Y183A, 
Y13F/L39A, Y13F/F41A, Y13F/D67A, Y13F/V69A, Y13F/Y127A, Y13F/Y183F, D72N/L39A, 
D72N/F41A, D72N/D67A, D72N/V69A, D72N/Y127A, D72N/Y183F, and Y13F/D72N (Table 
3.3, Figure 3.11). 
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Figure 3.11: A full collection of proteins purified by a column containing a mAb against IL-4BP (X14/38). 
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None of them failed to be purified, confirming that the substituted amino acids are located out of 
the epitope recognized by X14/38. Accordingly, independent on the kind of introduced mutation 
and its modifying effect on the measured binding affinity, all analyzed protein samples showed 
similar purity. There was no correlation between the protein quantity and the extent to which a 
mutation affected the binding properties. 
In summary, an alternative procedure for purification of IL-4BP and its variants through an Ab 
containing column was established. The new purification method is simple for accomplishment 
and very similar to the methods for purification required by the IL-4 column. That makes possible 
the simultaneous and reversal use of both columns for more effective purification. 
 
 
3.1.4 Biotinylation of IL-4BP Recombinant Variants 
 
The IL-4BP recombinant variants purified by affinity chromatography or antibody column were 
biotinylated following the procedure described in 2.9.6. The biotinylated protein samples were 
further purified using gel filtration. During the purification step around 50-60 % of the protein 
was lost. Therefore the biotinylated proteins were in a final concentration range between 20 and 
70 µg/ml and the total protein amount varied between 30 and 80 µg. For each variant was 
prepared a dilution with protein concentration of 1 µg/ml, which was further used in biosensor 
experiments. 
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3.2 Preparation of Recombinant IL-4 Variants 
 
Although a collection of different IL-4 variants was previously analyzed, within the framework of 
the presented project two more amino acids of IL-4 were substituted by alanine. The crystal 
structure of the complex between the human IL-4 and IL-4BP suggested a contribution of R53 
and Y56 to possible contacts with the receptor part. Both amino acids are located on helix B of 
IL-4 and are part of the second discrete cluster of trans-interacting residues within the binding 
epitope (Hage et al., 1999). 
 
 
3.2.1 Cloning of IL-4 Mutant Variants 
 
The cDNA of IL-4 was inserted into the expression vector RTSpRC109 under the control of the 
right λ-phage promoter (Figure 3.12; Appendix 4). The regulation of the transcription was 
performed through the temperature sensitive repressor cI185, which is also encoded by this 
expression plasmid. 
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Figure 3.12: Schematic diagram of expression vector RTSpRC109/IL-4. 
              
 
The variant Y56A was generated by cassette mutagenesis. A synthetic doublestranded DNA 
cassette which carried the mutation of interest was inserted between engineered restriction 
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endonuclease cutting sites of AflII and MluI. The complete nucleotide and amino acid sequence 
of hIL-4 cDNA with the restriction sites of both endonucleases is shown in Figure 3.13.  
 
              
 
                                                           M 
5´CCTCGAGTAATTTACCAACACTACTACGTTTTAACTGAAACAAACTGGAGACTGCCATGC 3´ 
                10             20             30             40             50             60 
3´GGAGCTCATTAAATGGTTGTGATGATGCAAAATTGTCTTTGTTTGACCTCTGACGGTACG 5´ 
 
  H  K  C  D  I  T  L  Q  E  I  I  K  T  L  N  S  L  T  E  Q 
5´ACAAGTGCGATATCACCTTACAGGAGATCATCAAAACTTTGAACAGCCTCACAGAGCAGA 3´ 
                70             80             90             100            110            120 
3´TGTTCACGCTATAGTGGAATGTCCTCTAGTAGTTTTGAAACTTGTCGGAGTGTCTCGTCT 5´ 
 
  K  T  L  C  T  E  L  T  V  T  D  I  F  A  A  S  K  N  T  T 
5´AGACTCTGTGCACCGAGTTGACGGTAACCGACATCTTTGCTGCCTCCAAGAACACAACTG 3´ 
                130            140            150            160            170            180 
3´TCTGAGACACGTGGCTCAACTGCCATTGGCTGTAGAAACGACGGAGGTTCTTGTGTTGAC 5´ 
 
  E  K  E  T  F  C  R  A  A  T  V  L  R  Q  F  Y  S  H  H  E 
5´AGAAGGAAACCTTCTGCAGGGCTGCGACTGTCTTAAGGCAGTTCTACAGCCACCATGAGA 3´ 
                190            200            210            220            230            240 
3´TCTTCCTTTGGAAGACGTCCCGACGCTGACAGAATTCCGTCAAGATGTCGGTGGTACTCT 5´ 
           Afl II 
 
  K  D  T  R  C  L  G  A  T  A  Q  Q  F  H  R  H  K  Q  L  I 
5´AGGACACGCGTTGCCTGGGTGCGACTGCACAGCAGTTCCACAGGCACAAGCAGCTGATCC 3´ 
                250            260            270            280            290            300 
3´TCCTGTGCGCAACGGACCCACGCTGACGTGTCGTAAAGGTGTCCGTGTTCGTCGACTAGG 5´ 
     Mho I 
 
  R  F  L  K  R  L  D  R  N  L  W  G  L  A  G  L  N  S  C  P 
5´GATTCCTGAAACGGCTCGACAGGAACCTCTGGGGCCTGGCCGGCTTGAATTCCTGTCCTG 3´ 
                310            320            330            340            350            360 
3´CTAAGGACTTTGCCGAGCTGTCCTTGGAGACCCCGGACCGGCCGAACTTAAGGACAGGAC 5´ 
 
  V  K  E  A  N  Q  S  T  L  E  N  F  L  E  R  L  K  T  I  M 
5´TGAAGGAAGCCAACCAGAGTACGTTGGAAAACTTTCTAGAAAGGCTAAAGACGATCATGA 3´ 
                370            380            390            400            410            420 
3´ACTTCCTTCGGTTGGTCTCATGCAACCTTTTGAAAGATCTTTCCGATTTCTGCTAGTACT 5´ 
 
  R  E  K  Y  S  K  C  S  S  ∗  ∗ 
5´GAGAGAAATATTCAAAGTGTTCGAGCTGAAAGGATCC 3´ 
                430            440            450 
3´CTCTCTTTATAAGTTTCACAAGCTCGACTTTCCTAGG 5´ 
 
Figure 3.13: Nucleotide and amino acid sequence of the hIL-4 cDNA. The modified residues are encircled. The 
endonuclease restriction sites of Afl II and Mlu I were used for cassette mutagenesis.  
              
 79
______________________________________________________________________3. Results 
Both complementary oligonucleotides were first phosphorylated, hybridized and then ligated into 
the vector, which was cut, by AflII and MluI. E.coli cells (JM109) were transformed with the 
plasmid RTSpRC109IL-4Y56A by electroporation. 
Since there were not available any suitable endonuclease restriction sites which could be used to 
mutate R53, the site-directed mutagenesis of the variant R53A was accomplished by means of 
PCR technology. Similarly to the approach used to mutate IL-4BP, a two-step PCR was 
performed. The products resulting from the first step (PCR 1a and PCR 1b), when the mutation 
was introduced by internal primers, had lengths of 455 bp and 629 bp, respectively. They were 
used as a template for PCR 2. During this reaction, with the help of two external primers, a 
product of 1057 bp was synthesized (Figure 3.14).  
 
              
 
 
        LMS     PCR 1a    PCR 1b   PCR 2 
 
Figure 3.14: Amplification products from the PCR induced mutagenesis of variant R53A. 
              
 
The PCR 2 reaction product was precipitated and then cut with restriction enzymes XhoI and 
BamHI to produce 3 fragments with the length of 230 bp, 450 bp, and 380 bp. The digestion 
mixture was separated by an agarose electrophoresis and the 450 bp fragment containing the 
mutated IL-4 cDNA was isolated and purified from the gel. The pure fragment was used in a 
ligation reaction with the XhoI/BamHI digested expression vector RTSpRC109. Electrocompetent 
E.Coli (JM 109) were transformed with the recombinant plasmid. 
The transformed E.Coli were plated on selective ampicillin containing medium. Plasmid DNAs 
from a few bacterial colonies representing both variants were isolated for analytical application. 
The intact circular plasmids were digested with restriction enzymes XhoI and BamHI to confirm 
the presence of the insert. All analyzed plasmid samples after separation on an agarose gel, 
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showed the 450 bp fragment representing the hIL-4 cDNA. In addition, the exact DNA sequence 
and the presence of the mutation were verified by DNA sequencing with 5´- and 3´- external 
primer. 
 
 
3.2.2 Expression and Purification of IL-4 Variants 
 
For expression of IL-4 variants, E.coli was cultivated until reaching early logarithm phase with 
OD550 of 0.5-0.6 and then induced by heating at 42°C and incubated for 3 h. Under these 
conditions, the recombinant IL-4 variants were expressed as insoluble aggregate form (inclusion 
bodies) in the cell cytoplasm. The amounts of bacterial cells and inclusion bodies for both 
variants, which were obtained from 1 liter of E.coli culture, are compared in Table 3.4. 
 
Table 3.4: The yields at different steps of preparation of recombinant proteins for the IL-4 variants. 
 
 Cells Inclusion bodies Protein [mg] 
Variant [g] [g] (after CM-Sepharose) (after HPLC) 
 (per 1 liter of E.Coli culture) 
R53A 3.1 1.3 1.6 0.6 
Y56A 3.8 1.7 1.7 0.9 
 
The inclusion bodies were completely dissolved in 6 M guanidine hydrochloride (GuHCl), pH 
8.0. To reduce the disulfide bonds between cysteine residues and to accomplish the protein 
denaturation, 0.1% of β-mercaptoethanol was added. The renaturation of the protein to its native 
form was achieved by slow dialysis in PBS. 
Since the pI of hIL-4 is 10.5 (Callard, R. & Gearing A, 1994) the refolded proteins were applied 
to a CM-Sepharose matrix at pH 5.0. During this cation-exchange chromatography, the acidic and 
neutral contaminating proteins, which comprised most of the impurities, could not bind to the 
column and therefore the IL-4 variants were effectively separated. The bound proteins were 
eluted using a linear salt gradient from 0 M NaCl to 0.5 M NaCl. Only a limited amount of basic 
contaminating proteins overlapped with the IL-4 pick (Figure 3.15). After this step, the purity of 
the IL-4 variants reached over 90%. 
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Figure 3.15: Purification of the IL-4 variants through CM-Sepharose column. (A) The elution chart of variant Y56A. 
(B) SDS-PAGE analysis of collected fractions for variant R53A. The fractions represented here by lines 3, 4, 5, 6, 7, 
and 8 were selected for following purification. (C) SDS-PAGE of the fractions collected during the purification of 
the variant Y56A. The fractions represented by lines 4 and 5 were further purified. MS, molecular standard. 
              
 
Further, the protein purification was accomplished by reversed phase HPLC. Based on 
hydrophobic interactions, the protein bound to the chromatography matrix and then elution with 
increasing concentration of acetonitrile was performed (Figure 3.16 A). The IL-4 variants were 
eluted at around 40% of acetonitrile. Both variants were successfully purified, suggesting that 
neither the protein refolding neither the protein stability were disrupted by the individual 
mutations. The collected fractions during HPLC were monitored by SDS-PAGE, which revealed 
high purity of the obtained protein (Figure 3.16 C, D). In addition, the purity and the refolding 
quality of the proteins were examined by analytical RP-HPLC performed in a small column with 
detective sensitivity of 0.08. Both variants showed only a single sharp peak confirming the high 
homogeneity of the analyzed samples (Figure 3.16 B). The highly purified proteins were divided 
into aliquots lyophilized and in this way stored for following experiments. 
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Figure 3.16: HPLC purification step of the IL-4 variants. (A) The elution chart of the variant Y56A.  
(B) Analytical HPLC of variant Y56A. (C) SDS-PAGE of variant R53A. The fraction represented by line 3 was 
chosen for further applications. (D) SDS-PAGE of the fractions collected for variant Y56A. The fractions 
represented by lines 4 and 5 were combined (line 9) and used in following experiments. MS, molecular standard. 
              
 
 
 
 83
______________________________________________________________________3. Results 
3.3 Kinetic Analysis of the Interaction of IL-4 with the IL-4BP Variants Using 
BIAcore Technology 
 
The purified IL-4BP and its variants were used in a biomolecular examination to determine both, 
the kinetic and equilibrium binding constants characterizing the interaction with the ligand. This 
comprehensive analysis was carried out to assess the roles of the mutated side chains in 
modulating the affinity and kinetics of binding. 
A biosensor technology that relies upon surface plasmon resonance to measure changes in 
refractive index upon ligand binding to an immobilized receptor was explored to record binding 
curves and to evaluate the kinetic parameters of the interaction. The evaluation methods are 
described in 2.13.2. 
 
 
3.3.1 Immobilization of the Biotinylated IL-4BP and its Variants on the Sensor Chips 
 
Among the several available immobilization techniques, the amine coupling and streptavidin-
biotin coupling had been chosen to immobilize IL-4BP and its mutated variants on sensor chips. 
Earlier experiments have proven that this method offered a higher ligand binding capacity of the 
chip, considering the certain amount of immobilized receptors (Shen et al., 1996). The reason for 
this seems to be the nonspecific nature of the amine coupling technique and stereo obstacle, 
which gives rise to association perturbation of IL-4 to IL-4BP. Therefore the streptavidin-biotin 
coupling was used as a standard immobilization method in this study. 
First, the four cells of a sensor chip CM5 were coated with streptavidin employing the amine 
coupling procedure as described in 2.13.1 (Figure 3.17). Thereafter, the matrix of flow cells 2, 3 
and 4 was loaded separately with different IL-4BP variants, which earlier were randomly 
biotinylated (Figure 3.18). No receptor was loaded onto flow cell 1. It was used to record a 
background sensogram that was subtracted during the evaluation from the sample sensograms in 
flow cells 2, 3 and 4. 
Experimental conditions connected with different density of the immobilized receptor were 
tested. Usually, in the beginning the variants were loaded on the chip with a density of 
approximately 150 RU. Since the streptavidin-biotin interaction has an extremely high affinity 
(~1015 M-1) (BIAcore Handbook, 1995) the chips could be repeatedly regenerated and the amount 
of the immobilized receptor could be increased. For low affinity variants more receptor was 
added to the chip until a density of 200, 400 or 500 RU was reached (Table 3.5). 
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Figure 3.17: Sensogram showing the immobilization of streptavidin on a sensor chip CM5 by using standard amine 
coupling. (1) Baseline signal for the unmodified sensor chip treated with continuous flow buffer HBS (5 µl/min). (2) 
Injection of 35 µl of NHS/EDC for 7 min. to activate the dextran matrix. (3) 7 min. injection of 35 µl of streptavidin 
(50 µg/ml). (4) Injection of 35 µl of ethanolamine hydrochloride (1 M) to deactivate the matrix and remove non-
covalently bound streptavidin. 
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Figure 3.18: Immobilization of an IL-4BP variant on a streptavidin chip. The protein was manually injected into the 
chip and the injection was stopped at 200 RU. 
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Table 3.5: Amount of the immobilized receptor at the biosensor matrix for IL-4BP and the different variants 
 
Receptor variant Immobilized protein 
 [g] [M] Rel. Resp. [RU]
IL-4BP 4.0 x 10-10 6.6 x 10-11 79 
Y13A 5.4 x 10-9 3.3 x 10-10 243 
Y13F 2.8 x 10-10 6.7 x 10-11 89 
L39A 2.8 x 10-10 6.7 x 10-11 103 
F41A 6.4 x 10-10 6.7 x 10-11 151 
L42A 5.6 x 10-10 6.7 x 10-11 151 
L43A 7.4 x 10-10 6.7 x 10-11 148 
D66A 7.0 x 10-10 1.6 x 10-10 163 
D67A 6.7 x 10-10 1.1 x 10-10 157 
V69A 3.4 x 10-9 3.3 x 10-10 503 
D72A 6.4 x 10-10 1.8 x 10-10 225 
D72N 6.1 x 10-10 1.7 x 10-10 223 
K91A 5.6 x 10-10 6.6 x 10-11 154 
K91D 1.6 x 10-9 6.6 x 10-11 145 
S93A 8.4 x 10-10 6.6 x 10-11 152 
D125A 5.6 x 10-10 6.6 x 10-11 152 
N126A 7.0 x 10-10 1.7 x 10-10 156 
Y127A 2.3 x 10-9 2.9 x 10-10 505 
Y127F 2.4 x 10-10 6.6 x 10-11 102 
L128A 4.0 x 10-10 1.7 x 10-10 154 
Y183A 9.4 x 10-10 6.7 x 10-11 152 
Y183F 3.6 x 10-10 6.6 x 10-11 94 
Y13F/L39A 2.0 x 10-10 3.3 x 10-10 128 
Y13F/F41A 7.0 x 10-10 2.6 x 10-10 97 
Y13F/D67A 4.0 x 10-10 3.3 x 10-10 136 
Y13F/V69A 7.0 x 10-10 1.7 x 10-10 216 
Y13F/D72N 8.0 x 10-9 1.3 x 10-10 423 
Y13F/Y127A 6.0 x 10-10 1.8 x 10-10 225 
Y13F/Y183F 7.0 x 10-10 1.9 x 10-10 248 
D72N/L39A 1.0 x 10-9 1.7 x 10-10 417 
D72N/F41A 1.1 x 10-9 1.7 x 10-10 400 
D72N/D67A 1.3 x 10-9 1.7 x 10-10 394 
D72N/V69A 1.1 x 10-9 1.7 x 10-10 413 
D72N/Y127A 1.2 x 10-9 1.7 x 10-10 410 
D72N/Y183F 9.5 x 10-9 1.8 x 10-10 407 
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3.3.2 Kinetics of the Interaction of IL-4 and IL-4BP 
 
Although the kinetics of binding of IL-4 to IL-4BP was investigated in a earlier study (Shen et 
al., 1996), similar measurement was performed again as a control basis of estimation the changes 
in binding affinity of the mutated variants. Experiments were performed with IL-4 concentrations 
of 2.5, 5.0 and 7.5 nM (Figure 3.19). The sensograms, which recorded the interaction of IL-4 and 
IL-4BP at different IL-4 concentrations, showed the typical model of extremely fast association 
and slow dissociation, observed earlier.  
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Figure 3.19: Overlay of sensograms showing the binding of IL-4 to the immobilized IL-4BP. IL-4 at concentrations 
of 2.5, 5.0 and 7.5 nM was applied. 
              
 
Both, the association and dissociation phases were evaluated with BIAevaluation software to 
yield the association (kon) and dissociation (koff) rate constants, respectively (Figure 3.20). Due to 
the very fast association that in the beginning was diffusion controlled, only a small window (5 
RU) could be evaluated for calculation of the association rate constant before attaining 
equilibrium. Based on this, the association rate constant was determined to be kon =1.3x107 M-1s-1. 
The dissociation phase commenced when the perfusion with IL-4 was exchanged to a perfusion 
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with buffer alone. An exponential dissociation of the complex occurred only during a short initial 
period of 10 s. This part of the sensogram was used to evaluate the dissociation rate constant as 
koff = 1.0 x 10-3 s-1.  
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Figure 3.20: Association (A) and dissociation (B) plots of the recorded interaction of IL-4 and IL-4BP. 
              
 
The constant phase of the sensogram represents the equilibrium level between the IL-4 
dissociation and association reached at a defined IL-4 concentration. Usually, this part is 
evaluated for calculation of the equilibrium dissociation constant Kd. However, this was not 
possible during the present analysis because of technical reasons. The low Kd characterizing the 
IL-4/IL-4BP interaction would have required such low concentrations of IL-4 which could not be 
handled with the used technical device. Therefore, the equilibrium dissociation constant Kd was 
determined from the ratio of the association and dissociation constants (koff/kon) to be 77 pM. 
The results of the kinetic analysis were not only reproducible in the frame of the presented 
experiments, but they are also comparable with the findings of all previous studies dealing with 
this interaction. The association rate constant fits in completely with the earlier established range 
of 1.3-1.8 x 107 M-1s-1. Previously, the dissociation rate constant was evaluated as koff = 1.5-2.1 x 
10-3 s-1. The value of the equilibrium dissociation constant calculated here is as well comparable 
to the Kd of 58-160 pM, determined earlier (Shen et al., 1996; Wang et al., 1997). 
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3.3.3 Effects of Site-Specific Perturbations in IL-4BP on the Interaction with IL-4 
 
Initially, the amino acids from IL-4BP which were submitted to site-directed mutagenesis, were 
selected using the structural alignment between the receptor sequences including human and 
mouse IL-4BP, hGHbp (human growth hormone- binding protein), human and mouse IL-2β and 
γc  (Bamborough et al., 1994). Furthermore, the set of amino acids of interest was extended based 
on the results obtained from the crystal structure of the complex between IL-4 and IL-4BP (Hage 
et al., 1999). With the purpose of establishing the structure-function correlation, as targets for 
mutagenesis were identified residues involved in polar and hydrophobic interactions in the 
complex. Basically, all amino acids of interest were included in an alanine scanning mutational 
analysis. In order to define the results from the alanine scan more accurately, it was necessary to 
replace additionally a few tyrosine residues, involved in potentially important contacts with the 
ligand, by phenylalanine. 
 
 
3.3.3.1 Kinetics of the binding of IL-4 to the alanine variants of IL-4BP 
 
The rationale behind alanine scanning mutagenesis is that all interactions of a side chain except 
for the Cβ are eliminated (Lau & Fersht, 1987; Cunningham & Wells, 1989). This strategy 
assumes that the alanine substitution eliminates interaction without introducing new properties. 
The contribution of the deleted groups relative to the alanine residue is assessed from the 
difference between the properties of the wild-type relative to the alanine mutant. Free energies of 
binding are used to quantify the effect of the alanine substitution at any given site (Di Cera, 
1998). 
To assess the effect of the introduced mutation on the binding of IL-4 to the IL-4BP, every single 
variant was immobilized to a sensor chip as mentioned above (Table 3.5). Sensograms recorded 
at different concentrations of IL-4 were evaluated for the kinetic constants (Table 3.6). Based on 
the results from the BIAcore measurements the alanine variants assessed in the frame of this 
study could be classified into 3 main groups, according to the extent to which the mutation affects 
the functional properties of the IL-4BP molecule. 
1. Variants L42A, L43A, D66A, K91A, S93A, D125A, N126A, and L128A showed a pattern of 
binding very similar to this observed during the interaction of IL-4 and the wild-type IL-4BP. As 
the sensograms revealed (Figure 3.21 - A and B), these variants rapidly associate when perfusion 
with IL-4 is committed and slowly dissociate when it is changed to perfusion with buffer alone. 
IL-4 was applied in concentrations of 2.5, 5 and 7.5 nM. Under such conditions it was possible to 
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evaluate both the association and the dissociation phase for all variants from this group (Figure 
3.22). The alanine substitution in variant K91A merely did not have any effect on the association. 
Variants L42A, L43A, D66A, D125A, and L128A showed association rate constants which were 
only slightly altered due to the present mutation (Table 3.6). The on-rates of variants S93A and 
N126A were found to be negligible faster than that of IL-4BP. 
 
Table 3.6: Kinetic constants for binding of IL-4 to IL-4BP and its variants included in the alanine screening. 
 
Receptor 
variant 
 
n 
kon             (SE) koff            (SE) Kd [M] 
  [x 106M-1s-1] [x 10-3s-1] Kd (kin.) Kd (equilib.) 
IL-4BP 3 13             (0.8) 1.0            (0.3) 7.7 x 10-11   
Y13A 18 ND ND ND 7.9 x 10-7  
L39A 15 4.9            (0.7) 42             (7.8) 8.6 x 10-9  1.6 x 10-8 
F41A 9 5.6            (0.7) 29             (3.4) 5.2 x 10-9  8.8 x 10-9  
L42A 3 12             (0.8) 1.5            (0.4) 1.2 x 10-10   
L43A 3 12             (0.8) 3.1            (0.4) 2.6 x 10-10   
D66A 3 11             (0.6) 6.0            (0.4) 5.6 x 10-10   
D67A 9 3.1            (0.2) 32             (1.2) 1.0 x 10-8  9.3 x 10-9  
V69A 9 6.3            (0.8) 26             (0.9) 4.1 x 10-9  6.1 x 10-9  
D72A 18 ND ND ND 2.0 x 10-7  
D72N 18 ND ND ND 2.7 x 10-7  
K91A 3 13             (2.2) 4.3            (0.4) 3.2 x 10-10   
K91D 9 4.8            (0.6) 12             (0.3) 2.5 x 10-9  1.9 x 10-9  
S93A 3 17             (0.9) 2.6            (0.5) 1.5 x 10-10   
D125A 18 9.4            (0.5) 7.3            (0.6) 7.8 x 10-10   
N126A 9 14             (0.6) 6.8            (0.4) 4.7 x 10-10   
Y127A 18 4.5            (0.2) 19             (0.3) 4.3 x 10-9  6.2 x 10-9  
L128A 18 7.5            (0.4) 11             (1.3) 1.5 x 10-9   
Y183A 18 ND ND ND 6.2 x 10-8  
 n: number of measurements. 
 SE: Standard error. 
 Kd (kin.): Kd calculated from kinetic data. 
 Kd (equilib.): Kd calculated from steady state binding data. The mean standard error for this value over all 
 variants was 9 %. 
 ND: the values could not be accurately determined because they exceeded the limitations of the instrument. 
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No large changes in the dissociation rate constant were observed in the above-mentioned set of 
alanine variants. The off-rate constant increased in variant L128A 12-fold and this was the fastest 
recorded dissociation constant among all variants from this group. Variants D66A, D125A and 
N126A showed a 6-7-fold increase of the dissociation rate constant. A 3-4-fold higher off-rate 
was found in variants L43A and K91A. A marginal increase in koff occurred in IL-4BP variants 
L42A and S93A. 
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Figure 3.21: Overlay of sensograms of IL-4BP variants included in the alanine screening. (A) L42A, (B) K91A 
              
 
Unfortunately, it was not possible for any of those variants to evaluate the part of the sensograms 
representing the equilibrium level between ligand association and dissociation. Similar to the 
interaction of IL-4 and the wild-type IL-4BP, the binding of IL-4 to the variants is characterized 
by such low equilibrium dissociation constants that would require concentrations of the ligand 
under the limit, which the technical device is able to process. Therefore, the equilibrium 
dissociation constants for the variants included in the first group were calculated from the ratio of 
the on- and off-rates (Table 3.6). Regarding Kd, the most considerable difference showed variants 
L128A and D125A, whose binding affinity dropped down 20- and 10-fold, respectively 
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compared to the wild-type. The effect is due to the relatively high ratios of koff, which were 
recorded for both mutant forms. Marginal increases in Kd, 2 to 7-fold, were observed for variants 
L43A, D66A, K91A, and N126A. The equilibrium dissociation constant of variants L42A and 
S93A was almost not altered in comparison to the wild-type receptor (Table 3.7). 
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Figure 3.22: Plots representing the association (A, C) and the dissociation (B, D) phase of variants with high affinity 
to IL-4. (A) and (B), L42A; (C) and (D), K91A. 
              
 
Based on the models of the complex between IL-4 and IL-4BP, K91 was suggested to stabilize 
this complex by forming an ion pair with the IL-4 residue E9 (Bamborough et al., 1994). 
Therefore, K91 was a residue of particular interest, and additionally to the alanine substitution it 
was subjected to a charge conversion. The positive charge was exchanged with negative by 
replacing the original lysine residue with aspartic acid. Although a dramatic effect was expected, 
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the charge variant K91D exhibited simply 30-fold decrease in binding affinity. The kinetic 
constants were as well only slightly affected after the negative charge was introduced. Both the 
results from the analyses of the alanine and the charge variant did not support an important 
implication of K91 in contacts to amino acids from IL-4. 
The described features define the alanine variants included in the first group as not highly 
affected due to the introduced amino acid substitution. Alanine substitution at the particular 
positions neither caused large changes of the kinetic constants, nor brought the binding affinity 
drastically down. Generally, the mutated variants retained relatively high binding affinity to IL-4. 
Thus, even if the analyzed amino acids influence the interaction to some extent, they are not main 
binding determinants of the receptor part. 
2. The alanine variants L39A, F41A, D67A, V69A, and Y127A represent a different model of 
binding to IL-4. As the sensograms recorded (Figure 3.23), the association phase is still a rapid 
process. In contrast to the above-mentioned IL-4BP variants, the dissociation phase occurred to 
be much faster. Since lower binding affinity was expected after the preliminary analysis, the 
BIAcore measurements were performed a with wider concentration range of the ligand. The IL-4 
concentration was increased to over 100 nM in some cases. Within such a concentration range it 
was still possible to obtain plots from the association and dissociation phase and to evaluate the 
kinetic constants (Figure 3.24 A, B, D and E). 
The evaluated on-rates for all variants are merely slightly lower than the on-rate for IL-4BP 
(Table 3.6). Variant D67A exhibited a 4-fold decreased association rate constant. 2 to 3-fold 
lower kon compared to the wild-type interaction characterized the rest of the variants. In contrast, 
the complex dissociation was considerably accelerated in all examined receptor mutants. The 
largest effect in this respect was recorded for variant L39A, which off-rate constant increased 
over 40-fold compared to the wild-type receptor. In two further alanine mutants, F41A and 
D67A, koff was found to be 30-fold faster. The variant V69A showed a dissociation rate constant 
that was 25-fold faster. The alanine substitution in variant Y127A resulted in a relatively modest 
effect of 20-fold increase in the off-rate constant.  
The relatively low binding affinity of the alanine variants included in this group allowed an 
independent determination of the dissociation equilibrium constants by evaluating the receptors 
saturation levels obtained at different IL-4 concentrations (Figure 3.24 C and F). The Kd values 
derived from the equilibrium phase are in good agreement with the Kd values calculated from the 
kinetic constants (Table 3.6). A more than 210-fold reduced binding affinity characterizes the 
variant L39A. Over 100- fold decreased the binding affinity for variants F41A and D67A. Both, 
variants V69A and Y127A exhibited 80-fold faster Kd than the IL-4BP (Table 3.7). 
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Figure 3.23: Sensograms which recorded the binding of IL-4 to the IL-4BP mutants F41A (A), D67A (B), V69A (C), 
and Y127A (D). 
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Figure 3.24: Plots for variants L39A and Y127A representing association (A and D), dissociation (C and F), and 
equilibrium phases (C and F). 
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Generally, alanine substitution at the mentioned sites is followed by severely affected receptor 
binding properties, suggesting an important function of the replaced amino acids in forming 
contacts within the complex with IL-4. However, the effect is still limited and does not imply that 
the particular residues are the main contact determinants in the receptor molecule. 
3. Compared to the wild-type the alanine mutants D72A, Y13A, and Y183A revealed the most 
significant changes, as demonstrated by the overlay of the corresponding sensograms (Figure 
3.25 A, B, and D). The three variants still associated rapidly with IL-4, but they as well 
dissociated extremely fast when buffer alone was applied. Due to the low binding affinity, it was 
necessary to increase the amount of the immobilized receptor on the chip, which for the variants 
D72A and Y13A exceeded 200 RU (Table 3.5). In addition, the IL-4 concentration was also 
increased during the experiments until it reached 750 nM.  
The high ligand concentration caused such rapid association phase that could not be evaluated to 
calculate the association rate constant. The alanine substitution enhanced the dissociation phase 
to such an extent that it was impossible to estimate the dissociation rate constant. Therefore, as 
presented in table 3.6, the kinetic constants for those variants are not available.  
The presented data for the equilibrium dissociation constant Kd was obtained by the evaluation of 
the equilibrium phase (Figure 3.26). By far the most affected variant occurred to be Y13A. The 
interaction of IL-4 and Y13A was characterized by over 10000-fold decreased binding affinity. 
Sensitive to the alanine substitution was also variant D72A which binding affinity dropped down 
2600-fold. Although the variant Y183A showed a less remarkable effect, it still demonstrated 
large changes in Kd (Table 3.7). The variant decreased its binding affinity to IL-4 800-fold. The 
observed extreme changes in Kd give a reliable explanation to the fact that particularly these 
variants could not be successfully isolated and purified by an affinity column containing IL-4. 
The strong effect of the alanine substitution on the binding affinity indicates that the replaced 
amino acids provide the largest contribution from the receptor side to the stabilization of the 
complex. However, it has to be considered that if the introduced alanine residues would cause 
structural perturbation in the receptor molecule, the observed effect would rather be structural 
than functional. To assess the exact functional role of the examined residues in the interaction and 
the character of the contacts in which they are implicated, additional experiments were 
performed. 
Furthermore, a mutational variant D72N was analyzed. Originally, the variant was constructed as 
more conservative than D72A and was expected to retain the high binding affinity to IL-4. As 
already mentioned, D72N could not be purified using the IL-4 affinity column, and this was the 
first indication that it was strongly affected due to the amino acid substitution. The overlay of the  
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Figure 3.25: Overlay of sensograms representing the interaction of IL-4 and the low affinity variants of IL-4BP: 
Y13A (A), D72A (B), D72N (C), and Y183F (D). 
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sensograms which recorded the interaction supported this suggestion (Figure 3.25 C). The kinetic 
constants could not be calculated and the equilibrium phase was used to evaluate the equilibrium 
dissociation constant Kd (Figure 3.26 B). Similar to the corresponding D72A, the variant D72N 
revealed largely altered Kd (Table 3.6). Moreover, D72N was characterized by slightly lower 
binding affinity than D72A. 
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Figure 3.26: Equilibrium phase. Variants D72A (A), D72N (B), Y13A (C), Y183A (D). 
              
 
The analysis of variant D72N was of particular significance since the original amino acid and the 
replacing are structurally very similar, implying that the observed effects as to both D72A and 
D72N were caused by functional alterations, but not structural. In addition, the low binding 
affinity of D72N indicates that D72 takes part in the interaction due to the charge of its side 
chain. Thus, the obtained results confirm the functional importance of the aspartic acid at position 
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72 in forming ion pairs within the complex, and define it as one of the main binding determinants 
in the IL-4BP. 
The analyses of the alanine variants and one additional mutant (K91D) performed by BIAcore 
system demonstrate that the rate constant of association between IL-4 and IL-4BP is remarkably 
insensitive to amino acid substitutions. The examined residues did not apparently determine the 
velocity of the complex formation to an appreciable degree. Loss of charge generally did not 
affect the on-rates except in a case of variant D67A. Unfortunately, it was not possible to obtain 
neither association nor dissociation rate constants for the variants which exhibited the largest 
changes regarding binding affinity and therefore to figure out weather the charge of D72 
contributes to the rapid association phase. As far as off-rates could be calculated, they showed 
more significant changes, which were followed by a corresponding decrease in the binding 
affinity of the particular variants. Generally, no correlation was noticed between the side chains 
that had the most affected on- and off-rate. Among the amino acids that showed significant effect 
on the dissociation rate constant after alanine substitutions are some large hydrophobic side 
chains as well as charged residues. That suggests that electrostatic interactions in parallel with 
hydrophobic contacts stabilize the complex between IL-4 and IL-4BP.  
 
 
3.3.3.2 Thermodynamic aspects of the interaction between IL-4 and the IL-4BP variants 
included in the alanine scanning mutagenesis   
 
The introduction of a mutation in the system requires determining the energetic consequences of 
the substitution made. The information about the energetic alteration caused by an amino acid 
substitution indicates how exactly and to which extent the exchanged residue contributes to the 
binding properties of the receptor and its importance for the stability of the complex with the 
ligand. As an estimation of the effect of the site-directed mutation on the binding process often is 
used the change of binding energy relative to the wild-type protein (∆∆G), which in fact measures 
the linkage between the functional properties of the examined molecule and the mutation. 
Therefore, when the contact determinants are defined the data about ∆∆G is considered as 
follows. When ∆∆G >0, the mutation is assumed to reduce the complex stability, whereas 
enhanced stability are reflected by ∆∆G <0, and no effect is considered when ∆∆G = 0 (Di Cera, 
1998). 
The total change in binding free energy (∆G) for the interaction of IL-4 and IL-4BP is 13.8 
kcal/mol, as it was calculated from the corresponding equilibrium dissociation constant of 77 
pmol estimated within the present study. The loss of binding energy in the alanine variants (∆∆G) 
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was calculated according to the change in the dissociation constant Kd relative to the wild-type 
interaction (Table 3.7). The Kd values obtained from the equilibrium phase of the biosensor 
experiments were used where it was possible. For variants which retained high binding affinity 
and the equilibrium dissociation constant could not be directly evaluated were used the Kd ratios 
from kinetic measurements.  
 
Table 3.7: Relative Kd and loss of binding free energy of the IL-4BP variants included in the alanine mutational 
analysis. 
 
Receptor variant 
Relative Kd 
(Mut/Wild-type) 
∆∆G 
[kcal/mol] 
Y13A 10300 5.5 
L39A 210 3.2 
F41A 110 2.8 
L42A 1.6 0.3 
L43A 3.3 0.7 
D66A 7.2 1.2 
D67A 120 2.8 
V69A 80 2.6 
D72A 2600 4.7 
K91A 4.2 0.8 
S93A 2 0.4 
D125A 10 1.4 
N126A 6.1 1.1 
Y127A 80 2.6 
L128A 20 1.7 
Y183A 800 4.0 
 
The most significant loss of binding free energy after alanine substitution was observed for Y13. 
The alanine mutant contributes 5.5 kcal/mol, which accounts for 40 % of the total binding energy. 
The most important polar residue in the functional epitope is D72, which provides over 33 % (4.7 
kcal/mol) to the total binding energy. Another tyrosine residue, at position 183, also makes a 
large apparent contribution with loss of free binding energy of 4 kcal/mol during the alanine scan. 
The sum of the reductions in free energy caused only by the alanine substitutions at these 
particular positions already exceeds the total binding energy for the complex with IL-4. Five 
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additional residues included in the study, L39, F41, D67, V69, and Y127, produced a loss of 2.5 
to 3.5 kcal/mol each after they were replaced by alanine residues. The summed contribution of 
these amino acids is comparable with the total binding energy characterizing the complex. Lesser 
contributions demonstrated D66, D125, N126, and L128 when they were replaced by alanine (1 
to 2.1 kcal/mol). The rest of the examined amino acid side chains showed negligible energetic 
contribution (under 1 kcal/mol). No one of the alanine variants showed a negative value for ∆∆G, 
suggesting that all analyzed residues directly or indirectly stabilize the complex.  
The energetic contribution of single amino acid side chains from IL-4BP to the high-affinity 
interaction with the ligand, according the results obtained from the alanine scanning mutagenesis, 
is indicated the space-filling IL-4 BP model presented in Figure 3.27. The largest contribution 
was established for Y13, D72, and Y183 (colored in red) surrounded by residues of less 
importance. The mixed character of the functional important amino acids suggests mixed 
character of the contacts with IL-4, in contrast to the other well studied receptor-ligand system of 
hGH, where two tryptophan residues form a central hydrophobic patch (Clackson & Wells, 1995; 
Clackson et al., 1998). Furthermore, the present model is in agreement with the crystal structure 
of the complex with IL-4, which proposed a mosaic binding interface (Hage et al., 1999). 
Mutations of amino acids from cluster I and II clearly affected the dissociation rate constant. 
They resulted in greater loss of free binding energy supporting the idea that the residues from 
those clusters have the main role for the stability of the complex with IL-4. The three tyrosine 
residues Y13, Y127, and Y183, with properties for forming hydrogen bonds, have shown 
significant energetic contribution which implies their central role within the first cluster. The 
primary contact residue in the second cluster seems to be D72, surrounded by the hydrophobic 
side chains of L39, F41, and V69, which also have important energetic contribution. In contrast, 
the mutation analysis of residues within cluster III indicates that they have less energetic 
contribution and therefore confirms their minor functional role for complex stability. Their 
binding affinity is altered mainly due to slower association phases (especially for D67) which 
determines the amino acids from this cluster as kon determinants.  
The sum of the apparent binding free energy contributions for the amino acids included in the 
alanine mutational analysis accounts for 35.8 kcal/mol. This value considerably exceeds the 
calculated binding free energy for the complex. The high cumulative loss might indicate that 
some of the examined mutations are not completely independent, but interact with each other 
directly or indirectly. Furthermore, the additivity could be broken down if a mutation causes a 
change in the mechanism or rate-limiting step of the reaction. Another possibility is that some of 
the main binding determinants contribute to more than one single contact. A large loss of binding 
free energy in particular variants, and thereby in the total sum might be explained also with great 
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structural perturbations due to the alanine substitution. Such effects would be rather structural 
than functional. This does not seem to be the case for D72, since the variant D72N, which struct- 
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Figure 3.27: Loss of binding free energy of residues from IL-4BP due to alanine substitution. Residues have been 
color-coded as indicated to denote their apparent contributions to the loss of binding free energy, as determined by 
alanine scanning mutagenesis. Data from a previous study have been used for residues M14, S15, V68, S70, N73, 
Y74, P92, E94, and Y129. 
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urally should be highly similar to the wild-type protein demonstrated as well a large loss of 
binding free energy as D72A. However, structural consequences from the replacement of Y13 
and Y183 by alanine could not be ignored. 
 
 
3.3.3.3 Analysis of the binding of IL-4 to the IL-4BP tyrosine variants 
 
The three phenylalanine side chains which indicated the largest contribution to the loss of binding 
free energy during the alanine scan (Y13, Y127, and Y183) were replaced by tyrosine residues. 
Due to the conservative substitution, these variants were expected to be structurally very similar 
to the wild-type receptor, however without properties to form hydrogen bonds. Therefore the 
tyrosine variants were used to find out whether structural changes were the reason for the 
significant energetic alterations in the corresponding alanine mutant forms, or the effect was 
caused only because of disrupted binding contacts. 
The IL-4BP variants Y13F, Y127F and Y183F were expressed in SF9 insect cells following the 
described procedure (see 2.11). They were easily purified by an IL-4 affinity column, which was 
the first indication that they would retain much higher affinity to IL-4 then the parallel alanine 
variants. Furthermore, this expectation was confirmed by the BIAcore analyses. The sensograms 
(Figure 3.28) revealed a different pattern of interaction compared to the observed within the 
alanine scan. Variant Y127F showed a model of interaction very similar to the wild-type IL-4BP 
(Figure 3.28 B). Although IL-4 was used in a very low concentration rate (2.5, 5, 7.5 nM), fast 
association phase occurred followed by a very slow dissociation. Both the association and 
dissociation constants showed values very similar to the wild-type interaction (Table 3.8). The 
equilibrium dissociation constant could not be evaluated due to the high binding affinity of the 
variant. The calculated Kd based on the kinetic constants is negligibly different from Kd of IL-
4BP, which corresponds to loss of binding free energy of 0.1 kcal/mol. 
 
Table 3.8: Kinetic and thermodynamic constants characterizing the binding of IL-4 to the tyrosine variants of IL-4BP 
Receptor n kon         (SE) koff        (SE) Kd [M] Rel. Kd ∆∆G 
variant  [x 106M-1s-1] [x 10-3s-1] Kd (kin.) Kd (equilib.) (Mut./WT) kcal/mol
Y13F 12 11         (1.4) 26         (2.7) 2.4 x 10–9  3.2 x 10-9  40 2.2 
Y127F 6 16         (1.0) 1.5        (0.4) 9.3 x 10-11   1.2 0.1 
Y183F 9 6.0        (1.0) 190       (12) 3.1 x 10-8  2.4 x 10-8 310 3.4 
  
n: number of measurements; SE: Standard error; Kd (kin.): Kd calculated from kinetic data. 
 Kd (equilib.): Kd calculated from steady state binding data. The mean standard error for this value was 4.2%. 
 Rel. Kd: relative value of Kd. 
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Variant Y13F showed more significant effect (Figure 3.28 A) but still not comparable to the 
alterations observed with Y13A. The association constant was almost not affected due to the 
amino acid substitution. The faster dissociation phase caused a decrease in binding affinity over 
40-fold. The energetic contribution of this variant counted for merely 2.2 kcal/mol in contrast to 
the large contribution of Y13A, implying that the IL-4BP binding properties were significantly  
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Figure 3.28: Overlay of the sensograms representing the interaction of IL-4 and the tyrosine variants of IL-4BP: (A) 
Y13F, (B) Y127F, (C) Y183F. 
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less affected by a phenylalanine substitution at this position than by an alanine replacement.  
The largest effect due to the phenylalanine substitution displayed variant Y183F. While the 
association constant was only slightly changed, the dissociation constant was over 190-fold faster 
compared to the wild-type receptor (Table 3.8). The binding affinity was reduced over 300-fold, 
corresponding to apparent binding energy contribution of 3.4 kcal/mol. In relation to the 
corresponding alanine variant, Y183F still retained an about 2-fold higher binding affinity. 
However, both variants revealed comparable energetic contribution (Table 3.7). 
In summary, the substitution of the mentioned tyrosine side chains with the structurally similar 
phenylalanine dropped down significantly the energetic contribution of the analyzed variants to 
the overall loss of binding free energy. It seems that the hydroxyl group of the tyrosine at this 
position does not take part in hydrogen bonds to IL-4 that are critical for the binding. It is more 
likely that this tyrosine is involved in hydrophobic interactions through its aromatic ring. The 
replacement of Y13 and Y183 by phenylalanine caused considerable effects which suggests that 
their hydroxyl groups contribute to binding contacts. However, comparing the energetic 
contribution of both variants Y13A and Y13F implies that Y13 has rather structural than 
functional importance for the interaction between IL-4 and IL-4BP. It is also possible that Y183 
is involved in more hydrogen bonds than Y13 and therefore the loss of its hydroxyl group results 
in a greater functional effect. In addition, the results obtained from the phenylalanine variants to 
some extent give an explanation for the enormously large sum of binding free energy determined 
within the alanine mutational analysis. 
 
 
3.3.4 Analysis of IL-4BP Double Mutants 
 
Since proteins are highly cooperative structures, it has to be considered that the contribution of a 
particular residue might involve effects of multiple order. In many cases, interactions of several 
amino acids are coupled to one another and may not be reduced simply to a sum of pairwise 
interactions. In order to study experimentally the interaction of a certain amino acid residue in a 
protein with other residues in that protein, it has become common practice to analyse the free 
energy changes of multiple mutants (Wells, 1990; Jin et al., 1994; Hilser et al., 1998; Clackson et 
al, 1998; Di Cera, 1998).  
The analysis of double mutants considers the changes of binding free energy characterizing two 
proteins mutated individually at the sites X and Y, respectively and the double mutant form, 
which is mutated at both sites X and Y. To asses whether the effects between the examined 
residues are cooperative or additive, the losses of binding free energies characterizing the two 
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individual mutations are theoretically summarized (∆∆Gadd) and compared to the value, which is 
estimated for the double mutant. If the effects of the mutations are independent (non-
cooperative), the change in free energy for the double mutant form is equal to the sum of those 
for the two site-specific mutations. If the two examined sites are coupled, then the change in free 
energy for the double mutant differs from the sum of the two single mutants (Carter et al., 1984; 
Di Cera, 1998). It is possible for ∆∆Gadd to be either lower or greater than the experimentally 
estimated value for the double mutant depending upon whether the interactions between the 
examined side chains reduce or enhance the functional properties measured (Wells, 1990). 
In order to study whether the contact residues within IL-4BP are involved in cooperative 
interactions or function in an independent manner, a series of double mutants was produced and 
examined by BIAcore technology. Amino acid side chains from the three IL-4BP clusters 
identified by the crystal structure of the complex were included in the analysis (Table 3.2). The 
double mutant forms were constructed for all residues whose binding affinity decreased during 
the alanine screening over 50 fold (Table 3.7), since they were considered to have significant 
contribution to the binding. In half of the variants the mutation, D72N was uniformly present, 
while the second mutated site was subsequently exchanged to L39A, F41A, D67A, V69A, 
Y127A, or Y183F. The second group of double mutants constantly was modified to Y13F and 
additionally the mutations L39A, F41A, D67A, V69A, Y127A, or Y183F were introduced. 
Furthermore, a variant containing both mutations D72N and Y13F was created. Considering the 
technical limitations of the used device, all the double mutated variants were constructed under 
the condition that the theoretical sum of the change in free energies (∆∆Gadd) for the two 
introduced mutations does not exceed 8 kcal/mol. 
As expected, all examined double mutants demonstrated very low binding affinity to IL-4 (Figure 
3.29). Initially, about 100 RU of receptor were immobilized on the biosensor chip and the IL-4 
concentration was increased to 750 nM. Under those conditions, binding was recorded only for 
variants Y13F/L39A, Y13F/F41A, and Y13F/D67A. To analyze variants Y13F/V69A, 
Y13F/Y127A, and Y13F/Y183F, it was necessary to increase the amount of immobilized 
receptor to 200 RU and the IL-4 concentration to 3000 nM. The experiments for the remaining 
variants were performed with 400 RU of receptor immobilized on the chip, and IL-4 
concentrations up to 3000 nM. Both kinetic constants for the interaction of IL-4 and the double 
mutant variants could not be evaluated due to the high concentration of ligand that was applied 
causing very fast association, on one side, and the extremely rapid dissociation phase, on the 
other. Values for the equilibrium dissociation constant Kd were derived from the plots 
representing the receptor saturation levels at different ligand concentrations (Figure 3.30). 
Generally, the double mutants showed high Kd (between 1.4 x 10-7 and 7.7 x 10-5 M), but as 
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expected the mutant forms containing Y13F were less affected than the variants carrying D72N 
(Table 3.9). Although the receptor variants Y13F/D72N and D72N/D67A were immobilized with 
high density on the chip and extremely high IL-4 concentration was used, saturating binding was  
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Figure 3.29: Overlay of sensograms which recorded the interaction between IL-4 and double mutants of IL-4BP: (A) 
Y13F/L39A, (B) Y13F/F41A, (C) D72N/V69A. 
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not obtained and the equilibrium binding constants could not be determined. It seems that their 
Kd values exceed the detection limits of the used technical device (typically for steady state 
analysis 10-4 – 10-9 M), considering the fact that Kd of 7.7 x 10-5 M was still successfully 
determined. Experiments with higher receptor density were not performed within the present 
study, since for reliable measurements it is recommended to keep the immobilized receptor at 
levels of 100-500 RU (BIAapplications Handbook, 1995). Furthermore, for the system of IL-
4/IL-4BP it was already reported that density above 50 pg/mm2 (1 RU corresponds to 1 pg/mm2) 
resulted in high bulk-phase signals and drift phenomena (Shen, et al., 1996).  
 
 
Table 3.9: Equilibrium dissociation constant and loss of binding free energies for the IL-4BP double mutant variants 
 
Receptor n Kd (equilib.) ∆∆G ∆∆Gadd 
variant  [M] [kcal/mol] [kcal/mol] 
Y13F/L39A 9 2.6 x 10-7 4.8 5.4 
Y13F/F41A 9 2.4 x 10-7 4.8 5.0 
Y13F/D67A 9 3.9 x 10-7 5.1 5.0 
Y13F/V69A 9 2.2 x 10-7 4.7 4.8 
Y13F/D72N 9 ND ND 8.2 
Y13F/Y127A 9 1.4 x 10-7 4.4 4.8 
Y13F/Y183F 9 4.9 x 10-7 5.2 5.6 
D72N/L39A 9 9.0 x 10-7 5.5 8.0 
D72N/F41A 9 2.3 x 10-6 6.1 7.6 
D72N/D67A 9 ND ND 7.6 
D72N/V69A 9 2.8 x 10-6 6.2 7.4 
D72N/Y127A 9 1.6 x 10-5 7.2 7.4 
D72N/Y183F 9 7.7 x 10-5 8.2 8.2 
 
 n: number of measurements. 
 Kd (equilib.): Kd calculated from steady state binding data. The mean standard error for this value was 30 %. 
 ∆∆Gadd: the sum of ∆∆G for the two individual mutations. 
 ND: the values could not be accurately determined because they exceeded the limitations of the instrument. 
 
 
The analysis of double mutants applied to IL-4BP revealed that most of the variants were 
characterized by values of ∆∆G very similar to the theoretically predicted ∆∆Gadd, implying that 
the examined amino acid residues are independent and the observed mutational effects are 
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additive. However, the variants D72N/F41A and D72N/V69A were found to have higher binding 
affinity than expected. From all double mutants of IL-4BP, which were successfully analyzed 
variant D72N/L39A showed the largest difference between the theoretically predicted binding 
free energy and the experimental value. The residues L39, F41, V69, and D72, examined through 
the mentioned variants, were shown to be part from one and the same structural cluster (Hage et 
al., 1999). Therefore, it is likely that they are involved in cooperative contacts, especially 
considering the fact that the present data suggests a favorable kind of interactions. 
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Figure 3.30: Equilibrium phase ofsome double mutants. (A)Y13F/L39A, (B) Y13F/F41A, (C)  Y13F/D67A, (D) 
Y13F/Y183F D72N/V69A. 
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3.4 Biosensor Analysis of the Kinetics of Binding of IL-4 Variants to the IL-
4BP 
 
To further investigate the binding mechanisms of IL-4 to IL-4BP, two additional alanine IL-4 
variants were constructed and the kinetics of their interaction with the receptor was examined. 
The investigation on the IL-4 binding epitope was extended and the both IL-4 variants R53A and 
Y56A were studied in the framework of the current project, since the crystal structure of the 
complex demonstrated that those amino acids were part of the second contact cluster assembled 
around IL-4 R88 (Hage et al., 1999). 
The kinetics of the interaction between the both IL-4 variants and IL-4BP was analyzed using 
biosensor technology (Figure 3.31). The wild-type IL-4BP was immobilized on the streptavidin- 
coated chip with density of 90 RU and perfusion with each IL-4 variant in the concentration 
range of 2.5 to 60 nM was performed. The introduced mutations in the IL-4 molecule nearly did 
not affect the association phase and the evaluated corresponding rate constants remained very 
similar to the wild-type interaction (Table 3.10). A larger effect on the dissociation rate constant 
was observed particularly for the variant R53A, which increased over 20-fold compared to the 
wild-type. The off-rate of the IL-4 variant Y56A was 6-fold faster. The Kd levels of R53A, 
determined independently from the steady-state binding and from the ratio koff/kon, were in good 
agreement. Due to the high binding affinity, which variant Y56A retained it was not possible to 
evaluate its dissociation equilibrium constant and the presented value was calculated based on the 
kinetic constants. Overall, as an effect from the alanine substitution both variants showed 
decreased binding affinity to IL-4BP which was especially noticeable in the case of R53A (over 
30-fold) and merely modest (8-fold) for Y56A. 
 
Table 3.10: Constants and loss in binding free energy representing the interaction of the IL-4 variants to the IL-4BP. 
 
IL-4  n kon         (SE) koff        (SE) Kd [M] Relative Kd ∆∆G 
variant  [x 106M-1s-1] [x 10-3s-1] Kd (kin.) Kd (eq.) (Mut./WT) [kcal/mol] 
R53A 9 8.6        (0.7) 21         (1.6) 2.5 x 10-9 2.7 x 10-9 36 2.1 
Y56A 9 9.9        (0.8) 6.3        (0.9) 6.4 x 10-10  8 1.2 
 
 n: number of measurements. 
 SE: Standard error. 
 Kd (kin.): Kd calculated from kinetic data. 
 Kd (eq.): Data for Kd from equilibrium binding. The mean standard error for this value was 5 %. 
 ∆∆G: loss in free binding energy. 
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The corresponding values of ∆∆G suggest that the examined residues from the IL-4 contact 
epitope should be considered as functionally significant, since the energetic contribution of R53A 
was counted for 2.1 kcal/mol, and this of Y56A for 1.2 kcal/mol. Generally, an introduction of a 
mutation within IL-4 was followed by more moderate alterations of functional properties 
compared to IL-4BP (Wang et al., 1997). Therefore, even though the demonstrated effects were 
less pronounced, they imply that the mentioned amino acids are of importance for the interaction 
with the receptor, and are part of the binding epitope. Furthermore, the data obtained from the 
association and dissociation phases is in agreement with the proposal that the amino acids from 
the second contact cluster stabilize the complex with the receptor (Hage et al., 1999) and in this 
respect they are consistent with results from earlier mutational studies of other residues from the 
same cluster (Wang et al., 1997). 
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Figure 3.31: Sensograms representing the interaction of IL-4 variants R53A (A) and Y56A (B) with IL-4BP. 
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4. Discussion 
 
 
Human IL-4, as most cytokines, has pleiotropic functions and exhibits a wide range of biological 
effects on various tissues and cells. Responses are induced after IL-4 binds to its receptor. A 
central goal of receptor research is to understand, at molecular level, how receptors allow cells to 
sense and to respond to their external environment. A possible approach to this issue is to 
elucidate the binding determinants within both the ligand and the receptor, and to identify the 
molecular recognition mechanisms of the interaction between them. Improving the knowledge of 
the features characterizing the binding mechanisms is not only of theoretical interest, but as well 
is important for the drug development. Extensive information about the binding epitope of the α 
chain of the IL-4 receptor is of special benefit for drug design. With regard to the fact that this 
receptor component is implicated in the binding of two cytokines, which are involved in allergic 
responses (IL-4 and IL-13), a blocking agent directed against its binding epitope would be of 
advantage for both IL-4- and IL-13- mediated allergic diseases. 
Usually, two powerful methods, structural analysis and mutational analysis, are exploited to 
characterize sufficiently the interactions occurring within a receptor-ligand system. Only in 
combination they can explain how energetics and regulatory contacts are encoded into structure, 
and to provide comprehensive understanding of structure-functional correlations. Structural 
analysis reveals the contacts that contribute to protein-protein recognition in atomic details (Jones 
& Thornton, 1996). However, it alone cannot show how these contacts contribute to overall 
affinity and specificity. Ideally, the high-resolution structure of a complex is used to guide an 
extensive functional survey of residues present at the interface using site-directed mutagenesis, to 
allow their individual contributions to be assessed. Furthermore, construction and analyses of 
double mutants provides additional information about cooperative interactions, which link the 
behavior of different amino acid residues within the protein molecule.  
 
 
4.1 Structural Features and Binding Site of Human IL-4BP 
 
Since at the beginning of the presented study there was no structural data about the ligand-
binding epitope of IL-4BP, the initial selection of amino acids subjected to alanine substitution 
relied on two theoretical models of the complex between IL-4 and its receptor, which were 
available at that time (Bamborough et al., 1994; Gustchina et al., 1995). Both models were built, 
using as a starting point the extracellular portion of human growth hormone receptor (hGHbp), 
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since the structural and functional epitopes of the receptor and the ligand have been well 
characterized (De Vos et al., 1992; Cunningham & Wells, 1993). Based on sequence 
conservation and the predicted common structural organization for cytokine receptors, the amino 
acid sequences of a few different extracellular domains of cytokine receptors, including IL-4BP 
were aligned and examined for similarities to hGHbp. 
Although in the hGH/hGHbp complex the major contribution is provided by hydrophobic side 
chains, the IL-4BP interface proposed by the two models contains several polar and charged 
residues. Agreeably, as most prominent contact determinants from the receptor side were defined 
D72 and K91, which were suggested to form ion pairs with IL-4 R88 and E9, respectively. This 
assumption was supported also by the results from the mutagenesis study of human IL-4, which 
showed that charged and polar determinants predominate in its high-affinity binding epitope 
(Wang et al., 1997). According to the alignment of amino acid sequences of hGHbp with IL-4BP 
A71 and Y129 of IL-4BP superimpose the two most important binding determinants of hGHbp, 
W104 and W169, respectively. Therefore, those amino acids and their close surrounding from the 
same loop regions were of principle interest for the mutagenesis study of IL-4BP. Besides this, 
the models implicated particularly residues D66, D67, V69, S70, N126, Y127, and L128 of IL-
4BP in direct contacts with amino acids from the ligand. Additionally, in the mutational analysis 
were included residues M14 and S15, as well as P92, S93, and E94, since they correlate in the 
frame of the sequence alignment to amino acids of hGHbp, which have shown certain functional 
importance for the binding with hGH.  
At a later step, when the crystal structure of the complex between human IL-4 and IL-4BP was 
determined, the set of examined amino acids from IL-4BP interface was extended. Generally, the 
structure revealed an organization similar to the already observed for other hematopoietic 
receptors (Hage et al., 1999). IL-4BP consists of two covalently linked domains (D1 and D2). 
The domains are related to the overall topology of fibronectin type III (FN III) modules and fold 
into a sandwich comprising seven antiparallel β sheets. Moreover, it contains the strictly 
conserved four cysteine residues in the N-terminal domain and the strongly conserved 
“WSXWS” motif near the C-terminus of the second domain, which are distinctive characteristics 
of the cytokine receptor homology (CRH) region, as defined by Bazan, 1990. 
The structural epitope of IL-4BP was shown to be assembled by residues of five loops and has a 
midline of hydrophobic side chains with patches of tyrosine and serine residues situated on one 
side and a patch of aspartic acid side chains on the other side (Figure 4.1). An analysis of the 
possible hydrogen bonds and van der Waals contacts between IL-4 and its receptor revealed that 
their binding epitopes consist of three structurally independent subunits. Two of them (designated 
as cluster I and cluster II) were compared to an “avocado fruit”, since they exhibit a conspicuous 
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amphipathic structure with an outer mantle of hydrophobic side chain moieties and an inner core 
of polar groups. The third assemblage of trans-interacting side chains was demonstrated to have 
completely different design. The main characteristic of this cluster is the domination of 
electrostatic interactions. 
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Figure 4.1: Structural epitope of IL-4BP. Contact residues are colored according to their physicochemical properties 
(red, negatively charged; dark blue, positively charged; light blue, histidine; cyan; glutamine/ asparagine; magenta, 
tyrosine; orange, serine/threonine, green, hydrophobic) (Hage et al., 1999).  
              
 
Considering the structure of the above-mentioned clusters, the contacts formed within them 
between receptor and ligand side chains and the data about the loss of solvent-accessible surface 
area upon the binding (Table 4.1), a few additional amino acids of IL-4BP were submitted to site-
directed mutational analysis. Some of the side chains, which apparently demonstrated 
considerable change of the accessible surface, were already successfully predicted based on the 
 114
  __________________________________________________________________4. Discussion 
theoretical models and included in the study. Since the accessible surface of receptor F41, L42, 
L43 and Y183 showed a large decrease upon association, they were converted to alanine. 
Although L39 does not appear to change its solvent accessibility upon the complex formation to 
the same extent, it is a part of the hydrophobic shell within the second cluster and therefore it was 
included in the alanine scanning mutagenesis. The solvent-accessible surface area of Y13 does 
not change upon IL-4 binding. Nevertheless, according to the crystal structure this amino acid is 
implicated in a hydrogen bond with IL-4 E9 and was of particular interest for the mutational 
analysis. 
 
Table 4.1: Change in the accessible surface of amino acids within IL-4BP upon formation of the 1:1 complex 
between IL-4 and IL-4BP (Hage, 1999). 
 
IL-4BP amino acid ∆ Accessible surface [Å2] 
L39 12 
V40 2 
F41 106 
L42 32 
L43 58 
D66 23 
D67 95 
V69 50 
S70 71 
A71 54 
D72 21 
K91 1 
S93 8 
P123 3 
D125 98 
N126 7 
Y127 119 
N130 12 
H131 27 
A182 24 
Y183 47 
 
Altogether, in the frame of the entire project, 25 different side chains of IL-4BP distributed over 
all six loops of the receptor molecule were individually mutated to alanine (Figure 4.2). To refine 
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the functional epitope, substitutions by more conservative residues were performed, where it was 
necessary. The binding affinity of the mutated variants to IL-4 was examined by the use of a 
biosensor-based technology.  
 
              
Y13 M14
S15
L39
F41
L42
L43
D66
D67
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V69S70
D72
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Y129
Y183
E94
Y74
 
 
Figure 4.2: Side chains within IL-4BP subjected to site-directed mutagenesis. The colour scheme is according to 
traditional amino acid properties. Roughly, polar amino acids are presented in bright colours and non-polar in darker. 
(aspartic acid and glutamic acid, bright red; lysine, mid blue; methionine, yellow; serine, orange; phenylalanine and 
tyrosine, blue; asparagine, cyan; valine, leucine, green; proline, flesh). 
              
 
 
4.2 Defining Functional Important Residues from The Interface of Human IL-
4BP for the Interaction with IL-4 
 
The present study has identified all amino acid side chains within the extracellular domain of the 
IL-4 receptor α chain that are engaged in the high-affinity binding of the ligand. A scanning 
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mutagenesis strategy was used to dissect the contribution of the particular IL-4BP residues to the 
binding energy. Such approaches typically assume that no structural disturbances are caused by 
the mutations, so that the energetic consequences are entirely attributable to the deletion of the 
contacts. 
Undeniably, the site-directed mutational analysis defined the side chain of D72 as one of the 
major functional determinants for the interaction with the ligand. A mutation at this site to alanine 
caused 2600-fold decrease of binding affinity, corresponding to energetic contribution of 4.7 
kcal/mol. Such an effect definitely indicates affected functional properties and cannot be 
attributed to structural perturbation due to the introduced mutation. The assumption is based on 
the analysis of the additional variant D72N. The exchange of the aspartic acid by the structurally 
similar asparagine is followed by the loss of a negative charge, but generally is not expected to 
have disruptive effect on the structure. Despite the conservative character of the substitution 
made, variant D72N demonstrated decrease of binding affinity that basically was the same as the 
observed for the alanine variant. Thus, the original side-chain D72 and especially its negative 
charge is directly implicated in a contact to the ligand. The conclusion about the functional 
importance of D72 for the interaction with IL-4 is consistent with the findings of independent 
experiments using a cell-based selection strategy (Friedrich et al., 1999; Wietek, 1999). Two 
different receptor constructs carrying the receptor mutants D72A and D72R, respectively, were 
expressed in the murine pro-B cell line (Ba/F3) and examined for interaction with IL-4. 
Proliferation assays verified that cells expressing the charge reverse mutation D72R completely 
failed to proliferate in the presence of IL-4, while cell populations carrying D72A showed a weak 
response after treatment with IL-4. In addition, radioligand binding experiments revealed a 
complete loss of specific IL-4 binding by cells expressing D72R receptors, confirming that D72R 
receptors are incapable of productive interaction with IL-4. Furthermore, the results from the 
mutational analysis are in perfect agreement with the crystal structure of the IL-4/IL-4BP 
complex (Figure 4.3 B), which revealed that a salt pair links the side chain of D72 to IL-4 R88 
(Hage et al., 1999). 
The results from the alanine scanning mutagenesis pointed three tyrosine residues, Y13, Y127, 
and Y183, as prominent binding determinants from the receptor side. The mutant variant Y13A 
showed reduction of binding affinity over 10000-fold compared to the wild-type interaction. Its 
contribution to the loss of binding free energy counts 5.5 kcal/mol, which is the largest effect 
observed in the course of the alanine scan for IL-4BP. Further experiments were performed to 
assess if this effect is functional or structural. Replacement of Y13 by a phenylalanine residue 
resulted in merely 40-fold decreased binding affinity in comparison with the wild-type. Since the 
phenylalanine is a structural analog of the originally present amino acid, but without properties 
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for forming hydrogen bonds, it seems that the reason for the large effect demonstrated by Y13A 
is rather structural than functional. The alanine variant could still be recognized by the anti-IL-
4BP monoclonal antibody and therefore overall structural disruption could be excluded. It is more 
likely that the substitution caused only local perturbations within the contact cluster, but was not 
sufficient to destroy the structure as a whole. If Y13 is a structurally important residue for the 
entire cluster such a substitution will affect not only the contact properties of Y13, but of all 
amino acids within the cluster and will give an explanation for the large loss of binding free 
energy demonstrated by Y13A. Further, it has to be considered that in some cases, especially if 
much smaller amino acid replaces a large one, solvent can occupy the place of the missing side 
chain. Regarding the crystal structure (Hage at al., 1999), it seems that the effect shown by Y13F 
represents totally the functional importance of Y13. The hydroxyl group of this residue is 
implicated in a hydrogen bond with IL-4 E9 (Figure 4.3 A), and on that base it is reasonable to 
expect a modest functional effect by variant Y13F. 
Even more dramatic differences between affinity of the alanine and phenylalanine mutant form 
were observed in the case of Y127. Variant Y127A was characterized by 80-fold lower binding 
affinity to IL-4 than IL-4BP, while Y127F did not demonstrate considerable effect (1.2-fold) on 
the binding and in fact behaved as a wild-type receptor. However, the effect of the alanine 
substitution is by far not as large as in the case of Y13A and does not support the idea that 
Y127A is a structurally affected mutant. The structural data suggest that Y127 takes part in a 
series of hydrophobic interactions with the aliphatic side chain of IL-4 E9 (Hage, 1999). 
Therefore, it is likely that the reduced binding affinity of variant Y127A represents the 
contribution of those contacts and they are perhaps not disrupted when variant Y127F plays a part 
in the interaction with IL-4. According to the structure of the complex with IL-4, the hydroxyl 
group of receptor Y127 is involved in a hydrogen bond to IL-4 T13 (Figure 4.3 A) and 
additionally is bridged by a single ordered water molecule to IL-4 N89 (Hage et al., 1999). 
Nevertheless, the analysis of the mutant form Y127F, which is not able to form such contacts, 
indicates that they do not have significant contribution to the binding and should not be 
considered as functionally important for the complex stability. 
Replacement of receptor Y183 by alanine and phenylalanine revealed that both variants Y183A 
and Y183F bound IL-4 with low affinity. The alanine substitution caused a larger effect and the 
binding affinity of Y183A to IL-4 was reduced 800-fold compared to the wild-type interaction. 
Due to the introduced mutation, variant Y183F demonstrated an over 300-fold decrease in 
binding affinity corresponding to 3.4 kcal/mol loss of binding free energy. Definitely, the large 
energetic effect of mutation Y183F is an indication about the important functional role, which the 
hydroxyl group of Y183 takes in the interaction with the ligand. The crystal structure of IL-4/IL-
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4BP complex showed that this group is involved in a hydrogen bond to IL-4 E9 (Figure 4.3 A), 
one of the major binding determinants within the ligand (Hage et al., 1999). Another hydrogen 
bond was suggested to link Y183 to IL-4 K12. Apparently, those are contacts of great 
significance, which have a crucial role for the stability of the complex with IL-4, since their 
destruction was followed by a large functional effect. Furthermore, the side chain of receptor 
Y183 was implicated in van der Waals contacts to IL-4 I5 (Hage, 1999), which might explain to 
some extent the fact that a substitution by alanine has a greater effect on ligand binding. Small 
structural perturbations in variant Y183A cannot be excluded to be partially the reason for the 
reduced binding affinity to IL-4. However, if the mutation Y183A caused some disruptions in the 
receptor structure they certainly were minor and cannot be compared to the case observed with 
variant Y13A. Therefore, it seems that within contact cluster I of IL-4BP the residue Y183 
provides the largest functional contribution to the ligand binding. Moreover, the site-directed 
mutational analysis of IL-4BP established the side chain of Y183 as one of the main binding 
determinants from the receptor side for the high-affinity interaction with IL-4.  
Aspartic acids at positions 66, 67, and 125 were converted to alanine and examined for effects on 
the interaction, as they were determined to be engaged within the third structural cluster of IL-
4BP (Hage et al., 1999). The largest reduction in affinity (120-fold) occurred in variant D67A, 
which energetic contribution was estimated to be 2.8 kcal/mol. Mutations D66A and D125A 
decreased the affinity to a minor degree: 7- and 10-fold, respectively. The lower effects observed 
with these variants are in agreement with the suggestion that the third contact cluster is not 
important for the complex stability (Hage et al., 1999). The amino acids from the cluster were 
supposed to accelerate complex formation through electrostatic steering. Due to an alanine 
mutation certainly was affected the association phase of variant D67A, which appeared to be 4-
fold slower compared to the wild-type interaction. Apparently, the other two alanine mutants 
demonstrated negligible changes in association. However, the overall contribution of D125 to the 
affinity and also to the association of the complex might be partially underestimated, since some 
contacts to the ligand in which this amino acid is involved are built by its main chain. 
The analysis of the hydrophobic sequence of amino acids localized on loop L2 revealed that only 
L39 and F41 are of certain functional importance for the highly-affinity binding between IL-4 
and its receptor. Variant L39A bound IL-4 with over 200-fold lower binding affinity than IL-4BP 
did, while the binding affinity of F41A decreased over 100-fold. The association phase of both 
mutant forms was about 2-fold slower than the wild-type exhibited, but their dissociation was 
significantly affected due to the introduced mutation. Substitution of L42 and L43 by alanine did 
not result in considerable effects on the binding kinetics. As long as the properties of the alanine 
variants from this sequence were affected, the effects did not suggest a direct contribution to the 
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binding, but a supporting function of the original amino acids. Such an assumption is in 
accordance with the crystal structure, which showed that these amino acids are the main part of a 
hydrophobic shell surrounding D72 (Figure 4.3 B), and are involved in a number of van der 
Waals contacts with residues from IL-4 (Hage, 1999). The side chain of V69 localized on another 
loop (L3) in the receptor molecule completes the hydrophobic cluster around D72. Variant V69A 
behaved in a similar way to variants L39A and F41A; since it showed a 2-fold slower association 
and a modest effect on binding affinity (80-fold reduction). Besides the disruption of weak 
contacts, the substitution of large residues by alanine might be followed by penetration of water 
molecules in the hydrophobic cluster. Although no one of those residues demonstrated 
characteristics of a major binding determinant, disorder in the proper hydrophobic environment, 
which they provide alters to some degree the functional properties of IL-4BP as it affects the 
complex stability and to a minor extent concerns the association phase.  
No one of the residues K91, P92, S93, and E94, which are situated on loop L4 of IL-4BP, 
indicated significant contribution to the binding when they were exchanged by alanine. The 
corresponding variants reduced the binding affinity between 2- and 17-fold. In the absence of 
structural data receptor K91 was of special interest for the study, since a theoretical model of IL-
4/IL-4BP complex suggested this residue to be one of the main contact determinants, taking part 
in electrostatic interactions to IL-4 E9 (Bamborough et al., 1994). For that reason an additional 
variant K91D was produced and examined, although the analogous alanine variant showed 
negligible energetic contribution (0.8 kcal/mol). Despite the fact that the charge reversal mutation 
was expected to cause a grate effect on binding, the affinity in this case was reduced merely 30-
fold. Thus, the charge of receptor K91 is not involved in functionally important contacts to the 
ligand and the residue is not considered as a binding determinant. The site-directed mutagenesis 
of K91 should be seen as an example for the limited potential and accuracy of the molecular 
modelling as an approach for defining structural and functional epitopes. Later, in agreement with 
the above-mentioned findings, the structure of the complex confirmed that the entire loop L4 is 
not implicated in contacts to the ligand (Hage et al., 1999).  
The alanine scanning muatgenesis of IL-4BP did not reveal that some of the remaining amino 
acids included in the study provide important contribution to binding. Interestingly, variant S70A 
showed virtually the same binding affinity to IL-4 as the wild-type receptor. This amino acid is 
involved by its main chain in a hydrogen bond to IL-4 E9 (Figure 4.3 A) and additionally by its 
side chain forms a second with IL-4 T6 (Hage, 1999). Disruption of the hydrogen bond, in which 
the side chain of S70 plays a part, clearly showed that this contact is of no functional importance 
for the stability of the complex. This is supported by the fact that mutations of IL-4 T6, caused 
just negligible changes on binding affinity (Wang et al., 1997). It is likely that only the contact 
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made by the main chain of S70 is significant for the interaction with the ligand, but due to 
limitations of the used method that could not be assessed. 
 
              
C 
B 
A 
 
Figure 4.3: Details of the IL-4/IL-4BP contact: A, contact cluster I; B, contact cluster II; C, contact cluster III (Hage 
et al., 1999). 
              
 
In conclusion, the site-directed mutagenesis of IL-4PB residues defined clearly its functional 
epitope for the interaction with IL-4 (Figure 4.4). As major binding determinants were 
established the side chains of Y183 and D72 from binding clusters I and II, respectively. The 
contacts made by the side chain of D72 are strongly enhanced by the hydrophobic shell that 
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encircles it, as it was shown for residues L39, F41, and V69. Meanwhile Y183 is functionally 
supported by the other two tyrosine side chains, Y13 and Y127, localized within the same cluster. 
The amino acids included in the third cluster generally indicated lesser contribution to binding. 
However, D67 certainly is involved in contacts to IL-4 and perhaps is supported in this function 
by D125. 
The existence of further binding determinants is unlikely, but cannot be definitely excluded. Due 
to restrictions of the applied approach, contributions from alanine could not be analyzed. For 
instance, the functional importance of A71, which is involved in contacts with ligand residues 
within the first cluster of IL-4BP and shows relatively large change of accessible surface area 
upon association, could not be assessed. Furthermore, the site-directed mutational analysis is not 
able to detect contributions provided by the backbone parts of the amino acids.  
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Figure 4.4: Functional epitope of IL-4BP. Residues have been color-coded according to the loss of binding free 
energy due to alanine substitutions. Mutant variant Y13F has been used to estimated the energetic contribution of 
Y13, as the alanine form represents a structural mutant. 
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Based on the results from the alanine scan, the sum of the apparent binding free energy 
contributions (> 36 kcal/mol) considerably exceeds the estimated binding free energy for the 
complex (13.8 kcal/mol, corresponding to Kd=77 pM). The contributions made only by the 
residues included in the functional epitope of IL-4BP already give a sum of over 26 kcal/mol. 
Certainly, some contributions were overestimated due to structural perturbations caused by the 
introduced alanine residue. Nevertheless, this is only partially the reason for the high sum. The 
most pronounced instance of structural perturbations is presumably variant Y13A, but even in 
this case it seems that only approximately 3 kcal/mol from the loss of binding free energy can be 
attributed to structural effects, while the remaining 2.2 kcal/mol represent disrupted functional 
properties. Likewise, some alanine variants demonstrated large energetic contributions probably 
because the side chains of the original amino acids are involved in more than one single contact 
to the ligand. For example, the crystal structure revealed that the side chain of receptor Y183 
takes part in hydrogen bonds to both IL-4 E9 and K12. Furthermore, high loss of binding free 
energy implies that some of the examined mutations are not independent in their effects. That can 
be explained by the fact that particular side chains are involved not only in interactions to the 
ligand but also in intramolecular contacts. If interactions among residues within the receptor 
molecule are present, as a result the effect of the mutation will be propagated to other residues. In 
such cases the alanine scanning muatagenesis cannot assess properly the real contribution of the 
single side chains because the observed effect depends on the state of other residues (Di Cera, 
1998). Cooperativity is supposed to take place between residues within the binding epitope of IL-
4 (Wang et al., 1997). The small number of amino acids identified in the functional epitope of IL-
4BP and the large energetic contribution which they indicate, suggest that cooperative 
interactions might exist also in IL-4BP. 
In summary, the approach based on an alanine scanning mutagenesis is in principle powerful and 
informative. However, in the course of practical applications some limitations should be 
considered. Substitution by alanine, although is not supposed to introduce additional new 
contacts, might cause structural changes and subsequently large energetic consequences. Such 
effects might be wrongly assessed as functional. Therefore, the residues, which revealed great 
apparent contribution in the present study, were further mutated to produce structurally similar 
variants to the wild-type receptor. Furthermore, results might be misinterpreted in cases when 
interactions of several amino acids are coupled to one another and are not reduced simply to a 
sum of pairwise interactions. To identify if the effects from the site directed mutagenesis of IL-
4BP are independent or not, the present study was completed by analyses of receptor double 
mutant forms. 
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4.3 Additivity and Cooperativity in the Functional Epitope of IL-4BP 
 
Additive and cooperative mutational effects between the residues from the functional IL-4BP 
epitope were examined by applying double mutants. The side chains of amino acids L39, F41, 
D67, V69, Y127, and Y183 were analyzed for potential intramolecular interactions with Y13 and 
D72, respectively. In addition, a variant containing mutations at both sites, D72 and Y13, was 
created.  
Comparison of the theoretically predicted ∆∆Gadd and the estimated change of binding free 
energy (Table 3.9) for variants Y13F/Y127A and Y13F/Y183F indicates that the effects between 
the residues from contact cluster I are additive. This suggests not only that the sites act 
functionally independent, but also that no one of the introduced mutations caused structural 
perturbations. Indirectly this fact confirmed the assumption that mutation Y127A in the 
corresponding single variant was not disruptive to the structure and the observed effect 
represented basically the functional contribution of this residue to binding. Further, the analysis 
of double mutants indicated that the hydroxyl group from the side chain of Y13 is not involved in 
contacts to other residues from the cluster, but just in the interaction with IL-4. Therefore the 
mutational effect demonstrated by variant Y13F (2.2 kcal/mol) should be seen as the entire 
contribution of Y13 to ligand binding. The site-directed mutational analysis revealed that Y13 is 
important probably for the structure of the whole cluster. Since in these double mutated forms of 
the receptor Y13 was exchanged by the similar phenylalanine residue, which clearly did not 
affect the structure, it seems that the aromatic ring of Y13 is a crucial structural element 
supporting the conformation and the integrity of the cluster.  
Independent contributions to binding were shown from the side of Y13 and the hydrophobic shell 
surrounding D72, since the binding free energies of variants Y13F/L39A, Y13F/F41A, and 
Y13F/V69A negligibly differ from the corresponding ∆∆Gadd values. Likewise, additivity was 
established between the effects of Y13F and the binding determinant from cluster III D67. The 
binding free energies characterizing the double mutants, which carry the mutations D72N/Y127A 
and D72N/Y183F were very close to the values predicted by adding the energies of the single 
mutants. This is a clear indication that the main functional determinant D72 behaves in a 
completely independent manner from the two tyrosine residues from cluster I.  
The analyses of variants D72N/L39A, D72N/F41A, and D72N/V69A suggested that the 
examined sites in those double mutants are not independent in their effects. As those residues are 
parts from one and the same binding cluster it is likely that they cooperate and the effects from 
the individual substitutions are not additive. Further, the values of ∆∆Gadd are greater than the 
estimated ∆∆G for the three variants suggesting favorable interactions between the side chains 
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(Wells, 1990). The conclusion that the contacts to the ligand in which D72 is involved are 
enhanced by the hydrophobic shell including L39, F41, and V69 is in agreement with the results 
from the alanine scan of IL-4BP. Accordingly, the structural analysis defined the contact clusters 
as assemblies of trans-interacting residues and did not exclude the possibility that within a cluster 
certain amino acids cooperate (Hage et al., 1999). 
The equilibrium dissociation constants and subsequently the binding free energies for two double 
mutants, Y13F/D72N and D72N/D67A, could not be determined due to their extremely low 
binding affinity to the ligand. If the effects of the individual substitutions in variants Y13F and 
D72N were independent, than the change in binding energy caused due to the simultaneous 
mutation of these sites in variant Y13F/D72N, would be ∆∆Gadd = 7.0 kcal/mol. Correspondingly, 
the equilibrium dissociation constant of the double mutated variant would be Kd = 1.0 x 10-5 M, 
in a case of additivity. Assuming that the mutational effects in sites D72 and D67 are 
independent, a loss of binding free energy ∆∆Gadd = 7.6 kcal/mol and Kd = 2.9 x 10-5 M are 
expected for the interaction between variant D72N/D67A and IL-4. Certainly, those values 
indicate such a low affinity to the ligand which is at the detection limits of the used BIAcore 
system. Nevertheless, considering the fact that binding was recorded even for a variant with Kd = 
7.7 x 10-5 M (variant D72N/Y183F), detection of interaction also in the case of Y13F/D72N and 
D72N/D67A should be still possible. Thus, variants Y13F/D72N and D72N/D67A are 
characterized by considerably lower binding affinity to IL-4 than the theoretically estimated 
values presuming additive mutational effects. However, this does not necessarily indicate 
cooperativity between the examined sites. The structural analysis of IL-4BP strongly suggests 
that the three contact clusters are discrete and independent in their interactions (Hage et al., 
1999). Furthermore, if the low binding affinity is seen as a sign for cooperative interactions, the 
change of binding free energy for those mutants will be grater than the values of the theoretic 
sum ∆∆Gadd. This is not very likely, since such values would suggest that the mutant side chains 
reduce functional properties and the individual substitutions underestimated the contributions of 
the original residues. Considering the high cumulative loss of binding free energies, which was 
assessed in the frame of the alanine scan, effects were probably overestimated but not 
underestimated. Hence, the idea that cooperative interactions between the mutated sites in 
variants Y13F/D72N and D72N/D67A caused the extremely low binding affinity is not in 
agreement neither with the results from the alanine site-directed mutagenesis, nor with the 
structural data. It is more likely that due to the substitutions in the case of D72N/D67A the 
electrostatic steering between receptor and ligand was affected to a great degree. It was shown 
that the extraordinarily fast association rate constant, which is the main reason for the high-
affinity binding of IL-4 to IL-4BP, is caused by complementary electrostatic potentials of both 
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interfaces (Shen et al., 1996; Wang et al., 1997). Accordingly, variant D67A demonstrated the 
slowest association rate constant in the site-directed mutational analysis. The association phase of 
D72N could not be examined. In addition, alanine substitutions of the hydrophobic side chains 
surrounding D72 in cluster II revealed small but systematic reduction of the on-rate for L39, F41, 
and V69, suggesting that perhaps the entire cluster is recognized early in association. The third 
charged residue within the functional epitope of IL-4BP (D125) did not indicate significant effect 
on the association. It is likely that the charges of D72 and D67 are critical for the initiation of 
electrostatic steering between receptor and ligand and therefore their simultaneous loss in variant 
D72N/D67A results in such low electrostatic potential in the receptor that is under the point, 
which allows the complex formation. This suggestion is in agreement with the mechanism of 
association proposed for the complex of hGH and its receptor (Cunningham & Wells, 1993). 
Accordingly, the association is a multi-step process that starts with the formation of an initial 
weak complex, which undergoes further desolvation and cooperative rearrangement.  
Not all amino acids from IL-4BP examined by site-directed mutagenesis were included in the 
analysis of double mutants and therefore perhaps not all cases of cooperativity were identified. 
However, cooperative effects clearly were demonstrated to take part at least between amino acids 
within contact cluster II. This fact gives to some degree an explanation for the high cumulative 
loss of binding free energy, which was calculated according to the contribution of alanine 
variants. 
 
 
4.4 Comparison of the Structural and the Functional IL-4BP Epitopes 
 
Generally, the functional epitope of IL-4BP defined by mutational analyses is in a good 
agreement with the structural data. Similarly to the structural epitope, the functional important 
residues of IL-4BP are assembled in three differentiated clusters. The crystal structure of the IL-
4/IL-4BP complex proposed that the clusters are independent, but did not exclude the possibility 
that cooperative interactions take place in the same contact cluster (Hage et al., 1999). 
Respectively, the present analysis did not show a clear indication for interactions between the 
defined clusters. Furthermore, cooperativity was demonstrated to occur between side chains 
within one and the same cluster. 
The structure revealed that 835 Å2 of the receptor surface area are buried upon complex 
formation (Hage et al., 1999). This indicates that the high-affinity interaction between IL-4 and 
IL-4BP is generated from a relatively small contact area and that its size is not directly connected 
to binding affinity. Accordingly, amino acids localized out of the structural epitope did not appear 
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to have significant effects on binding affinity when they were mutated. Although segregation in 
the contribution of the examined residues present in the structural epitope of IL-4BP was 
observed, nearly all of them showed considerable effect on binding. Thus, the modest size of the 
IL-4BP structural epitope determines a corresponding functional epitope, which has a similar 
size.  
The structure of contact clusters I and II was compared to an “avocado fruit” and was suggested 
to be highly relevant to binding because polar interactions are enhanced in a hydrophobic 
environment (Hage et al., 1999). Agreeably, the mutational analysis indicated as main binding 
determinants residues from the central core of IL-4BP clusters I and II. Particularly large 
contribution to binding demonstrated the side chains of Y183 and D72, respectively. Most of the 
residues from their close surrounding certainly are implicated in the interaction with IL-4, 
although the mutations at those sites caused a loss in binding affinity to a lesser extent. Contact 
clusters I and II were proposed to have the same contribution to binding (Hage et al., 1999). 
However, based on the findings from the mutagenesis study of IL-4BP it seems that, comparing 
functional contributions, cluster II has slight prevalence over cluster I. Estimated from the loss of 
free binding energy in the mutant proteins, the entire cluster II (13.3 kcal/mol) accounts 
approximately for 95 % of binding energy, while the energetic contribution of cluster I 
corresponds to around 60 % (8.8 kcal/mol)1. In agreement with the suggestions based on 
structural data, the mutational analysis indicated that the residues from the third contact cluster 
have minor functional role in complex stability and the entire cluster contributes with 30 % (4.2 
kcal/mol) to binding energy. Additionally, the importance of this cluster, and particularly of the 
side chain of D67, for the association phase was confirmed. Alanine substitutions of a few 
residues present in the defined structural epitope did not produce considerable effect on binding 
affinity. Those are amino acids localized in the periphery of the binding epitope, and it is likely 
that the contacts made by their side chains are not of importance for the high-affinity interaction 
with IL-4. It is possible that some of them are directly involved in binding by their main chains, 
but due to limitations of the used approach such a suggestion could not be verified. Furthermore, 
it cannot be excluded that the periphery of the interface has another important role. For instance, 
it might contribute substantially to the specificity of binding by repulsion of non-target molecules 
through unfavorable electrostatic or steric interactions, or both. 
Comparison between the change of buried surface area upon binding and the change in the free 
energy of binding when the particular side chain was mutated revealed a very poor correlation 
                                                 
1  The contribution of cluster I was estimated considering the loss of binding affinity of variants Y13F, Y127A, and 
Y183A. Variant Y13F was favoured, since it represents better the functional properties of Y13 than the analogous 
alanine variant. Data about variants L39A, F41A, V69A, and D72A, was used for cluster II. Other variants were not 
included, as they demonstrated negligible contribution to binding. 
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(Figure 4.5). The largest decrease of accessible surface upon association was shown to occur for 
Y127 and F41 (Hage et al., 1999). Substitution of both residues by alanine was followed by 
modest effect on binding affinity and therefore they were suggested to have basically a 
supporting role for the interaction with IL-4. Likewise, amino acids L43 and S70 indicated high 
decrease of accessible surface, but did not affect any binding properties of the receptor when they 
were mutated. Meanwhile, the two main functional determinants D72 and Y183 are characterized 
by far lower change in buried surface area. Thus, although the decrease of accessible surface 
upon binding is useful when the entire epitope is defined, this parameter alone is not sufficient to 
assess the role of the individual side chains. Presumably, for the nonfunctional residues the 
energetic cost of desolvation and side chain rearrangement compensates the energy gained 
through the intermolecular interaction and therefore they do not stabilize the complex.  
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Figure 4.5: Decrease in solvent accessibility on complex formation for IL-4BP (data was taken from Hage, 1999) and 
loss of binding free energy when the individual side chains were converted to alanine. 
              
 
In the IL-4BP, molecule is observed a clear hierarchy regarding the functional significance of the 
particular clusters. The mosaic design of the structural epitope of IL-4BP predetermines the 
independent functional behaviors of the clusters in the process of binding. Possibly, this fact 
opens perspectives for drug design based on the mimicry of the assemblies. Compounds with low 
molecular weight might act as antagonists of IL-4, if significant affinity is assured. The most 
promising in this sense seems to be cluster II. Mimicry of cluster I might additionally increase the 
effect. 
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4.5 Complementarity between the Functional Epitopes of Human IL-4 and IL-
4BP  
 
Site-directed mutagenesis has previously been used as a strategy to determine the functional 
epitope on the ligand side of the interface (Wang et al., 1997). A set of alanine, glutamine, and 
charge reversed mutant forms of IL-4 were studied for effects on the interaction with IL-4BP by 
means of the BIAcore technology. The similar approaches used in the previous and current study 
give a reliable basis to compare the functional epitopes of ligand and receptor. In the framework 
of the present project two additional IL-4 variants R53A and Y56A were produced and analyzed. 
The original side chains were shown by the structure to be a part of contact cluster II and were 
implicated in contacts to residues from IL-4BP.  
The results of the systematic mutational analysis of IL-4 contact residues (Wang et al., 1997) 
confirmed that the functional important residues are localized on the helix AC face of the ligand 
(Figure 4.6). Furthermore, they are in agreement with the functional significance of the tree 
clusters of trans-interacting residues identified in the structure of the complex and support the 
existence of a mosaic binding (Wang et al., 1997, Hage et al., 1999). In like manner to the IL-
4BP structure, the contact clusters I and II of IL-4 were shown to resemble an “avocado fruit”. 
Mutations of the central amino acids within those two clusters, namely E9 and R88, had the 
largest effects on binding affinity observed among the IL-4 mutant forms. Their energetic 
contribution to the complex stability was estimated to be over 3.5 kcal/mol for each. Both 
residues are implicated in direct contacts to the corresponding main binding determinants from 
the IL-4BP interface. Accordingly, the carboxylate of E9 accepts three bonds from receptor Y13, 
Y183, and S70, while R88 is linked by a salt pair to the receptor D72. The energetic effect 
resulting from the substitution of receptor D72 by alanine is greater than from an analogous 
replacement of IL-4 R88. Since those residues were not demonstrated to take part in other 
contacts, it is likely that the higher effect in the receptor alanine variant represents the cooperative 
interactions within IL-4BP cluster II where D72 is localized. Mutations of residues from the 
periphery of IL-4 clusters I and II indicated modest contributions of the original side chains to the 
binding. Agreeably, the conversion to alanine of IL-4 residues R53 and Y56, which are parts 
from the shell of cluster II, was followed by 36- and 8-fold reduction in binding affinity. 
Similarly, the mutagenesis analysis of IL-4BP amino acids, which surround the main 
determinants, indicated that their side chains have only indirect but not main functions for the 
interaction.  
The results from substitutions performed in the corresponding clusters III of IL-4 and IL-4BP 
revealed that the residues from the both sides of the interface are important for the association 
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phase rather than to contribute significantly to the stability of the complex. Thus, comparison 
between the energetic effects of mutations introduced in the analogous functional epitopes of IL-
4 and IL-4BP demonstrates a striking complementarity: energetically critical and unimportant 
regions on one molecule match those on the other (Figures 4.4 and 4.6). As a result, the two 
proteins are able to interact with high affinity and specificity and to form a stable complex 
through relatively small functional epitopes. 
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Figure 4.6: The functional epitope of IL-4. Residues are color-coded according to the loss of binding free energy 
upon site directed mutagenesis. Data from Wang et al., 1997 is taken. 
              
 
Additivity analysis shows that summation of the disruptive effects of the alanine mutations of 
amino acids present in the IL-4BP functional epitope produces a value in excess of 26 kcal/mol. 
By comparison, for the mutations performed within the IL-4 functional epitope this value counts 
for over 15.5 kcal/mol. The cumulative loss of binding free energy for IL-4 might be slightly 
higher than the value mentioned above, since data for IL-4 variant E9A is not available and 
therefore the contribution of variant E9Q was used in this calculation (Wang et al., 1997). The 
summations of the energetic effects seen for IL-4 and IL-4BP mutant forms, respectively exceed 
the total change in binding free energy for the interaction of the wild-type ligand and receptor 
(13.8 kcal/mol). Based on this fact, it was assumed that the individual mutations in both proteins 
are not completely independent. However, the cumulative loss of binding free energy estimated 
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for IL-4BP certainly exceeds a lot this for IL-4. This difference cannot be explained with the 
implication of more main-chain interactions from one side of the interface than from the other, 
because both proteins, IL-4 and IL-4BP, were shown to build contacts mainly through side chains 
(Hage, 1999). The substantially greater cumulative loss of binding free energy for the receptor 
molecule is consistent with the findings that some of the residues within the functional epitope of 
IL-4BP are involved in cooperative interactions. It seems that the main functional side chains in 
IL-4 act in a more independent way and if cooperative effects within the epitope exist, they are of 
minor importance. In part, this probably reflects the rigidity of secondary structural scaffolds on 
which the complementary epitopes are presented: the major binding determinants from IL-4 are 
localized on helices whereas those of IL-4BP are displayed from loops.  
 
 
4.6 Comparison of the IL-4BP Functional Epitope to Other Cytokine 
Receptors  
 
Structurally the human IL-4BP is similar to the extracellular domains of other type I cytokine 
receptors that interact with short or long chain helical cytokines (Hage et al., 1999). Based on the 
structural homology and the established pattern of interaction between hGH and hGHbp 
(Clackson & Wells, 1995), hydrophobic contacts were suggested to dominate in the complexes of 
four-helix bundle cytokines (Kossiakoff & De Voss, 1999). However, the present results put 
together with the mutational analysis of IL-4 and the structure of IL-4/IL-4BP complex indicate 
that this is not universally the case, since within the epitopes of both the ligand and the receptor, a 
mixture of charged, polar, and hydrophobic side chains has been identified.  
In contrast to IL-4BP, the functional epitope of hGHbp is represented by a compact patch in the 
center of the contact region in which the hydrophobic residues form a core flanked by charged 
groups. Two tryptophans of the core (W104 and W169), constituting a “hot spot” for the 
interaction with hGH, were shown to account for the majority of the binding free energy. A 
structure-based sequence alignment reveals that IL-4BP Y127 is the direct homologue of W169 
in hGHbp (Figure 4.7). Furthermore, M150 in EPB (Middletone et al., 1999) and V230 in gp130 
(Horsten et al, 1997; Bravo et al, 1998), which superimpose to the same position, are important 
binding determinants for the interactions with their corresponding ligands. Similar to hGHbp 
W169, V230 from gp130 and M150 from EPB are parts of the hydrophobic surface forming the 
functional epitopes of those receptors. Although reduction in binding affinity was seen when 
Y127 in IL-4BP was substituted by alanine, the effect indicates rather supporting than major 
functions of this residue in binding.  
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The other major binding determinant of hGHbp, W104, according to the sequence alignment 
corresponds directly to S70 of IL-4BP (Figure 4.7). Mutational analysis clearly demonstrated that 
the side chain of S70 has no functional importance for the interaction with IL-4. However, the 
same receptor loop (L3) contains the major binding determinant D72 from the second binding 
cluster of IL-4BP that is involved in tight interaction with IL-4 R88. It approximately resembles 
not only W104 of hGHbp, but also F93 of EPB, which is a critical determinant of erythropoietin 
binding (Barbone et al, 1997). Likewise, the position of IL-4BP D72 correlates to Y172 of 
GCSF-R that has been suggested to take part in functionally very important hydrogen bonds to 
residues from the ligand (Layton et al, 1997; Aritomi et al, 1999). Thus, it seems that the 
presence of residues critical for binding in loop L3 might be a common feature of class I cytokine 
receptors. 
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Figure 4.7: Structure-based sequence alignment of different extracellular domains of cytokine receptors (IL-4BP, 
hGHbp, EBP, and gp130). Amino acid sequences are given in one letter code; deletions are marked “-“, sequence 
numbering and secondary structure designations are given for IL-4BP. β strands and α/310 helices are depicted by 
black and red boxes, respectively. A gray background indicates structural superposition (Hage et al., 1999).   
              
 
In accordance with the sequence alignment, no important side chains of hGHpb and EPB 
correspond to IL-4BP Y183. Nevertheless, the structurally guided mutagenesis of IL-4BP 
residues revealed that Y183 is the main binding component of cluster I engaged in interaction 
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with the ligand. Comparison with GCSF-R shows that within the same receptor loop where IL-
4BP Y183 is localized (L6), is positioned residue R287, which obtained the greatest effect on 
binding after alanine substitution (Layton et al., 1997). Another residue Y13, which is also 
present in the first contact cluster of IL-4BP has as a structural homologue R43 from hGHbp. 
Structurally Y13 is a part from the hydrophobic shell surrounding the main binding determinant 
Y183 of IL-4BP and in like manner L43 is a peripheral element from the functional epitope of 
hGHbp. Agreeably, both side chains are characterized by modest effects on binding, when 
replaced in a structurally non-disruptive way.  
The aspartic acid at position 67 from the third contact cluster of IL-4BP appears to be 
homologous to D89 in EBP that has been implicated in contacts to EPO at site 2 (Syed et al., 
1998). Although data from mutagenesis of EPB D89 currently is not available, generally it is 
known that the interactions between EPB and EPO at site 2 are less extensive than at site 1. 
Similarly, the present analysis indicates that the residues within cluster III of IL-4BP provide 
lesser contribution to the stability of the complex with IL-4. The other aspartic acid present in the 
same cluster of IL-4BP D125 resembles D164 in hGHbp. Substitution by alanine of both side 
chains was followed by relatively small effects on binding affinity (Clackson et al., 1998). 
The functions in binding of the hydrophobic sequence localized within loop L2 and comprising 
L39, F41, L42, and L43 is unique for the IL-4/IL-4BP receptor complex. This sequence 
represents the main part of the hydrophobic shell in cluster II, which is completed by V69 from 
loop L3. According to the structural alignment, IL-4BP V69 superimposes I103 from hGHbp and 
L171 from GCSF-R. The effects on binding affinity observed after the hydrophobic residues at 
this position were mutated to alanine suggest that in all receptors they have indirect functional 
contribution to the binding (Clackson & Wells, 1995; Layton et al., 1997). 
In summary, the functional epitope of IL-4BP significantly differs from other structurally well-
characterized cytokine receptors, such as hGHbp and EBP, for which the majority of binding 
energy is attributed to a few hydrophobic residues. In contrast, both the present study and the 
mutational analysis of IL-4 indicate that the critical contacts in the IL-4/IL-4BP complex are 
provided by polar and charged residues. Correspondingly, the crystal structure of IL-4/IL-4BP 
complex revealed that the relative position of IL-4BP is remarkably altered compared to hGHbp 
(Hage et al., 1999). Thus, both the spatial orientation of IL-4 and IL-4BP in the complex and the 
functional properties of the contact establish novel features different from the binding in the 
homodimeric hGH receptor complex. The molecular arrangement of GCSF and its receptor was 
shown to be similar to that of IL-4/IL-4BP complex (Aritomi et al., 1999). Furthermore, the 
distribution of hydrophobic and polar contacts found in the two complexes is comparable. The 
importance of charged residues and polar contacts was demonstrated also for the interaction 
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between p35 and p40, the two subunits of IL-12, which is a heterodimeric cytokine similar to the 
class I cytokine-receptor complexes in its overall architecture (Yoon et al., 2000). Based on these 
data, two distinct models of interactions seem to exist for the binding between cytokines and their 
receptors. In the first case, the interfaces are dominated by hydrophobic residues, as it has been 
established for the receptor systems of hGH and EPO. In the second, charged and polar contacts 
are dominating, while the hydrophobic have only indirect contribution to the binding, as it was 
shown for the complexes of IL-4, GCSF and the two subunits of IL-12. Moreover, the binding 
epitope of IL-4BP is further distinguished from those receptors by its unique mosaic-like 
topography consisting of three discrete contact clusters. 
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5. Summary 
 
 
The cytokine IL-4 is a basic regulator of immune responses that plays a pivotal role in the 
pathophysiology of allergic diseases. Its effects depend upon binding to and signaling through a 
receptor complex composed of the IL-4Rα chain and the common gamma chain (γ ). A first and 
crucial event in receptor activation is the interaction between IL-4Rα chain and IL-4, which is 
characterized by high affinity (K  ≈ 100 pM) and specificity. Signal transduction pathways are 
mediated after the subsequent recruitment of γ . Therefore the IL-4 receptor complex is seen as a 
promising therapeutic target for treatment of allergic disorders.  
c
d
c
The aim of the present study was to define the functional epitope of IL-4BP that is engaged in the 
high-affinity interaction with IL-4. Side chains of IL-4BP amino acids, implicated in contacts to 
the ligand, were analyzed systematically by the means of site-directed mutagenesis. In a first step, 
all residues of interest were replaced by alanine. To verify whether the observed effects in the 
alanine variants were functional or structural, in a few cases, the original amino acids were 
further substituted by structurally similar residues. Moreover, double mutants were constructed 
with the purpose to examine cooperative and additive interactions between residues within the 
functional epitope of IL-4BP. All IL-4BP mutant variants were expressed in an eukaryotic 
expression system (Sf9 insect cells). Variants, which retained relatively high binding affinity to 
the ligand, were successfully purified by IL-4 affinity chromatography. An alternative 
purification procedure using a monoclonal antibody against IL-4BP was established for low-
affinity variants. The effects on binding kinetics, due to the introduced mutations, were measured 
employing biosensor technology. 
The mutagenesis analysis revealed that IL-4BP takes part in the high-affinity interaction with IL-
4 through a relatively small functional epitope. As major binding determinants were identified the 
side chains of two amino acids localized within contact clusters I and II, respectively. The 
residues of six additional amino acids contribute to the binding to a minor extent. In contrast to 
other cytokine receptors, in which the major contributions to binding are from hydrophobic side 
chains, the IL-4BP functional epitope is assembled from charged, polar, and hydrophobic 
residues. Furthermore, the critical contacts for binding to IL-4 are provided by charged and polar 
residues, while the hydrophobic side chains have only supporting functions in the interaction. The 
energetic segregation observed within the IL-4BP binding interface is highly relevant and 
complementary to the already described IL-4 functional epitope. 
The mosaic design of the binding epitope proposed by the crystal structure of the IL-4/IL-4BP 
complex was confirmed in this study. The three contact clusters were demonstrated to act in an 
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independent manner. However, cooperative interactions between residues present in one and the 
same cluster were observed. Moreover, the clusters could be distinguished according to their 
apparent contribution and functional importance for the binding. Estimated from the loss of free 
binding energy in the affected mutant variants, contact cluster II has the greatest contribution to 
binding followed by cluster I and cluster III, respectively. Both clusters I and II appear to have 
important functions in stabilizing the complex between IL-4 and its receptor, since mutations 
introduced in those assembles resulted in considerably affected binding properties. In contrast, 
substitutions of residues from cluster III caused merely small effects on binding affinity, 
indicating that the cluster plays a role mainly in electrostatic steering in order to accelerate 
complex formation. 
The mutational analysis presented in this thesis, together with the already established IL-4 
functional epitope and the structure of the intermediate complex between IL-4 and IL-4BP, 
improves the understanding of the molecular mechanisms of receptor binding and activation for 
members of the cytokine receptor family. Detailed knowledge about the molecular recognition 
between cytokines and their receptors is not only of theoretical interest, but is also important as a 
base for drug design.  
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Appendix 1 Kinetic and equilibrium theory for the evolution of data 
obtained from BIAcore experiments 
 
For the association of an analyte A with an immobilized ligand B 
 
 
a kinetic of first order is assumed: 
 
 
   k : association rate constant a
d: 
 
For the starting concentration of free B,  is valid: 
          ( 3 ) 
 
Equation ( 2 ) can therefore be rearranged to give: 
      ( 4 ) 
 
If one equates [  with the maximal signal of the BIAcore experiment R ,  with the 
actually measured signal R and  with the used concentration of analyte C, equation ( 4 ) can 
be written as: 
 
      ( 5 ) 
 
 
[ABBA ⇔+ ]         ( 1 ) 
      ( 2 ) [ ] [ ] [ ] [ ]AB  x k    B  x  A  x kdt / ABd da −=
   k dissociation rate constant 
[ ]0B
 
[ ] [ ] [AB    B    B0 += ]
 
[ ] [ ] [ ] [ ] [ ]AB xk) ABB ( A xkdt / ABd d0a −−=
] ]0B [AB
[ ]A
max
R  x  
k
)k    C  x (k
y
R x C x kdtdR / 
s
damaxa +−=
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Equation ( 5 ) is the equation of a straight line with k  as gradient. s
 
          ( 6 ) 
s s
d
By measurement at different analyte concentrations C through this graphical representation k  as 
well as k  can be determined. In practice, the determination of k  by graphical representa-tion is 
not very accurate, because in general is valid: 
a
d
 
  
 
d
 
For the dissociation a time law of first order is assumed: 
  
 
This can be transformed into 
  
 
A graphical representation of ln  against  results in a straight line with k  as 
gradient. 
das k    C  x k  k +=
The graphical representation of k  against C results also in a straight line with k  as gradient and 
the k  as ordinate segment. 
 
d
da k    C  x k >>
The determination of k  therefore is achieved according to another method. 
 
)t(t k
0t
0de x R  R −−=
 
)t(t x k    )/R(R ln 0dt0 −=
)/R(R t0 )t(t 0− d
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Appendix 2  Vector pRPR9IL-4FD 
(with IL-4BP cDNA 1278-1970 bp) 
 
 
5’TTCTCATGTTTGACAGCTTATCATCGATTTTATGAATATACAAATAATTGGAGCCAACC  3’ 
5’GCAGGTGATGATTATCAGCCAGCAGAGAATTAAGGAAAACAGACAGGTTTATTGAGCGCT 3´ 
 120 
T
 180 
5’CCATTTACTATGTTATGTTCTGAGGGGAGTGAAAATTCCCCTAATTCGATGAAGATTCTT 3´ 
5’GCTCAATTGTTATCAGCTATGCGCCGACCAGAACACCTTGCCGATCAGCCAAACGTCTCT 3´ 
 300 
5’TCAGGCCACTGACTAGCGATAACTTTCCCCACAACGGAACAACTCTCATTGCATGGGAT  3´ 
 360 
5’ATTGGGTACTGTGGGTTTAGTGGTTGTAAAAACACCTGACCGCTATCCCTGATCAGTTTC 3´ 
 420 
C
 480 
5’TGCTCAGGGTCAACGAGAATTAACATTCCGTCAGGAAAGCTTGGCTTGGAGCCTGTTGGT 3´ 
5’GCGGTCATGGAATTACCTTCAACCTCAAGCCAGAATGCAGAATCACTGGCTTTTTTGGTT 3´ 
 600 
5’GTGCTTACCCATCTCTCCGCATCACCTTTGGTAAAGGTTCTAAGCTTAGGTGAGAACAT  3´ 
 660 
5’CCTGCCTGAACATGAGAAAAAACAGGGTACTCATACTCACTTCTAAGTGACGGCTGCATA 3´ 
 720 
G
 780 
5’CTAACTTTGAGAATTTTTGTAAGCAATGCGGCGTTATAAGCATTTAATGCATTGATGCCA 3´ 
5’TTAAATAAAGCACCAACGCCTGACTGCCCCATCCCCATCTTGTCTGCGACAGATTCCTGG 3´ 
 900 
5’GATAAGCCAAGTTCATTTTTCTTTTTTTCATAAATTGCTTTAAGGCGACGTGCGTCCTC  3´ 
 960 
5’AGCTGCTCTTGTGTTAATGGTTTCTTTTTTGTGCTCATACGTTAAATCTATCACCGCAAG 3´ 
 1020 
C
 1080 
5’ATGTACTAAGGAGGTTGTATGGAACAACGCATAACCCTGAAAGATTATGCAATGCGCTTT 3´ 
5’GGGCAAACCAAGACAGCTAAAGATCAAGAATGTTGATCTTCAGTGTTTCGCCTGTCTGTT 3´ 
 1200 
5’TTGCACCGGAATTTTTGAGTTCTGCCTCGAGCTGGTATAAGTTTTATTGCTTATAGCAA  3´ 
 1260 
5’AAGGTTGAGGTGATTTTATGAAAAAGAATATCGCATTTCTTCTTGCATCTATGTTCGTTT 3´ 
 1320 
G
 1380 
5’ACTACATGAGCATCTCTACTTGCGAGTGGAAGATGAATGGTCCCACCAATTGCAGCACCG 3´ 
T
   1 60 
5’TATCTTTCCCTTTATTTTTGCTGCGGTAAGTCGCATAAAAACCATTCTTCATAATTCAA  3´ 
 240 
C
5’TTGAAGGTAAACTCATCACCCCCAAGTCTGGCTATGCAGAAATCACCTGGCTCAACAGC  3´ 
 540 
C
5’CTAACCGCTTCATACATCTCGTAGATTTCTCTGGCGATTGAAGGGCTAAATTCTTCAAC  3´ 
 840 
A
5’GGATAAATATCTAACACCGTGCGTGTTGACTATTTTACCTCTGGCGGTGATAATGGTTG  3´ 
 1140 
T
5’TTTCTATTGCTACAAATGCCTATGCATTTAAGGTCTTGCAGGAGCCCACCTGCGTCTCC  3´ 
 1440 
5’AGCTCCGCCTGTTGTACCAGCTGGTTTTTCTGCTCTCCGAAGCCCACACGTGTATCCCT  3´ G
 1500 
5’AGAACAACGGAGGCGCGGGGTGCGTGTGCCACCTGCTCATGGATGACGTGGTCAGTGCG  3´ G
 1560 
5’ATAACTATACACTGGACCTGTGGGCTGGGCAGCAGCTGCTGTGGAAGGGCTCCTTCAAG  3´ C
 1620 
5’CCAGCGAGCATGTGAAACCCAGGGCCCCAGGAAACCTGACAGTTCACACCAATGTCTCC  3´ G
 1680 
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5’ACACTCTGCTGCTGACCTGGAGCAACCCGTATCCCCCTGACAATTACCTGTATAATCATC 3´ 
 1740 
5’TCACCTATGCAGTCAACATTTGGAGTGAAAACGACCCGGCAGATTTCAGAATCTATAACG 3´ 
 1800 
5’TGACCTACCTAGAACCCTCCCTCCGCATCGCAGCCAGCACCCTGAAGTCTGGGATTTCC  3´ T
 1860 
5’ACAGGGCACGGGTGAGGGCCTGGGCTCAGGCCTATAACACCACCTGGAGTGAGTGGAGC  3´ C
 1920 
5’CCAGCACCAAGTGGCACAACTCCTACAGGGAGCCCTTCGAGCAGCACTAGGATCCCGCAA 3´ 
 BamHI 1980 
5’AAGCGGCCTTTGACTCCCTGCAAGCCTCAGCGACCGAATATATCGGTTATGCGTGGGCGA 3´ 
 2040 
5’TGGTTGTTGTCATTGTCGGCGCAACTATCGGTATCAAGCTGTTTAAGAAATTCACCTCG  3´ A
 2100 
5’AAGCAAGCTGATAAACCGATACAATTAAAGGCTCCTTTTGGAGCCTTTTTTTTTGGAGAT 3´ 
 2160 
5’TTTCAACGTGAAAAAATTATTATTCGCAATTCCTTTAGTTGTTCCTTTCTATTCTCACTC 3´ 
 2220 
5’CGCTGAAACTGTTGAAAGTTGTTTAGCAAAACCTCATACAGAAAATTCATTTACTAACG  3´ T
 2280 
5’CTGGAAAGACGACAAAACTTTAGATCCGGCCAAGCTTCGTCGACCCTGCCTCGCGCGTT  3´ T
 2340 
5’CGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCT 3´ 
 2400 
5’GTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTG 3´ 
 2460 
5’TCGGGGCGCAGCCATGACCCAGTCACGTAGCGATAGCGGAGTGTATACTGGCTTAACTA  3´ T
 2520 
5’GCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAG  3´ A
 2580 
5’TGCGTAAGGAGAAAATACCGCATCAGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTG 3´ 
 2640 
5’CGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTA 3´ 
 2700 
5’TCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGC  3´ C
 2760 
5’AGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAG 3´ 
 2820 
5’CATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATAC 3´ 
 2880 
5’CAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTAC  3´ C
 2940 
5’GGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTG  3´ T
 3000 
5’AGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCC 3´ 
 3060 
5’GTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGA 3´ 
 3120 
5’CACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGT  3´ A
 3180 
5’GGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGT  3´ A
 3240 
5’TTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGA 3´ 
 3300 
5’TCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACG 3´ 
 3360 
5’CGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCA  3´ G
 3420 
5’TGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACC 3´ 
 3480 
5’TAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACT 3´ 
 3540 
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5’TGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATT  3´ T
 3600 
5’CGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTA 3´ 
 3660 
5’CCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTA 3´ 
 3720 
5’TCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATC  3´ C
 3780 
5’GCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAA  3´ T
 3840 
5’AGTTTGCGCAACGTTGTTGCCATTGCTGCAGGCATCGTGGTGTCACGCTCGTCGTTTGGT 3´ 
 3900 
5’ATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTT  3´ G
 3960 
5’TGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGC  3´ A
 4020 
5’GTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGT  3´ A
 4080 
5’TTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACC  3´ G
 4140 
5’CTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTT 3´ 
 4200 
5’ACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGG  3´ A
 4260 
5’AGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCG  3´ G
 4320 
5’CGACCGAGTTGCTCTTGCCCGGCGTCAACACGGGATAATACCGCGCCACATAGCAGAAC  3´ T
 4380 
5’ATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAG  3´ C
 4440 
5’ATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAA  3´ A
 4500 
5’CAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCAT  3´ T
 4560 
5’ATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCAAGA  3´ A
 4620 
 
150 
                                                                                                                                 7. Appendices 
 Appendix 3 A Part of the Expression Vector pAcGP67B 
(with IL-4BP cDNA 4267-4887 bp) 
 
 
5´GATAACCATCTCGCAAATAAATAAGTATTTTACTGTTTTCGTAACAGTTTTGTAATAAA  3´ A
  4020              4080 
5´AAACCTATAAATATTCCGGATTATTCATACCGTCCCACCATCGGGCGCGGATCTATGCT  3´ A
              4140 
5´CTAGTAAATCAGTCACACCAAGGCTTCAATAAGGAACACACAAGCAAGATGGTAAGCGC  3´ T
              4200 
5´ATTGTTTTATATGTGCTTTTGGCGGCGGCGGCGCATTCTGCCTTTGCGGCGGATCTTGG  3´ A
              4260 
5´TCCATGAAGGTCTTGCAGGAGCCCACCTGCGTCTCCGACTACATGAGCATCTCTACTTG  3´ C
              4320 
5´GAGTGGAAGATGAATGGTCCCACCAATTGCAGCACCGAGCTCCGCCTGTTGTACCAGCTG 3´ 
              4380 
5´GTTTTTCTGCTCTCCGAAGCCCACACGTGTATCCCTGAGAACAACGGAGGCGCGGGGTG  3´ C
              4440 
5´GTGTGCCACCTGCTCATGGATGACGTGGTCAGTGCGGATAACTATACACTGGACCTGTGG 3´ 
              4500 
5´GCTGGGCAGCAGCTGCTGTGGAAGGGCTCCTTCAAGCCCAGCGAGCATGTGAAACCCAGG 3´ 
              4560 
5´GCCCCAGGAAACCTGACAGTTCACACCAATGTCTCCGACACTCTGCTGCTGACCTGGAGC 3´ 
              4620 
5´AACCCGTATCCCCCTGACAATTACCTGTATAATCATCTCACCTATGCAGTCAACATTTG  3´ G
              4680 
5´AGTGAAAACGACCCGGCAGATTTCAGAATCTATAACGTGACCTACCTAGAACCCTCCCT  3´ C
              4740 
5´CGCATCGCAGCCAGCACCCTGAAGTCTGGGATTTCCTACAGGGCACGGGTGAGGGCCTG  3´ G
              4800 
5´GCTCAGGCCTATAACACCACCTGGAGTGAGTGGAGCCCCAGCACCAAGTGGCACAACTCC 3´ 
              4860 
5´TACAGGGAGCCCTTCGAGCAGCACTAGGATCCCGGGCCATGGGAATTCCGGAGCGGCCG  3´ C
              4920 
5´TGCAGATCTGATCCTTTCCTGGGACCCGGCAAGAACCAAAAACTCACTCTCTTCAAGGA  3´ A
              4980 
5´ATCCGTAATGTTAAACCCGACACGATGAAGCTTGTCGTTGGATGGAAAGGAAAAGAGTT  3´ C
              5060 
5´TACAGGGAAACTTGGACCCGCTTCATGGAAGACAGCTTCCCCATTGTTAACGACCAAGA  3´ A
              5120 
5´GTGATGGATGTTTTCCTTGTTGTCAACATGCGTCCCACTAGACCCAACCGTTGTTACAA  3´ A
              5180 
5´GCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCA 3´ 
              5240 
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Appendix 4  Sequence of the Expression Vector R pRC109 
(with IL-4 cDNA 1281-1673 bp) 
 
 
5´TTCTCATGTTTGACAGCTTATCATCGATTTTATGAATATACAAATAATTGGAGCCAACC  3´ 
1  60 
5´GCAGGTGATGATTATCAGCCAGCAGAGAATTAAGGAAAACAGACAGGTTTATTGAGCGCT 3´ 
120 
5´TATCTTTCCCTTTATTTTTGCTGCGGTAAGTCGCATAAAAACCATTCTTCATAATTCAAT 3´ 
180 
5´CCATTTACTATGTTATGTTCTGAGGGGAGTGAAAATTCCCCTAATTCGATGAAGATTCT  3´ 
240 
5´GCTCAATTGTTATCAGCTATGCGCCGACCAGAACACCTTGCCGATCAGCCAAACGTCTCT 3´ 
300 
5´TCAGGCCACTGACTAGCGATAACTTTCCCCACAACGGAACAACTCTCATTGCATGGGATC 3´ 
360 
5´ATTGGGTACTGTGGGTTTAGTGGTTGTAAAAACACCTGACCGCTATCCCTGATCAGTTT  3´ 
420 
5´TTGAAGGTAAACTCATCACCCCCAAGTCTGGCTATGCAGAAATCACCTGGCTCAACAGCC 3´ 
480 
5´TGCTCAGGGTCAACGAGAATTAACATTCCGTCAGGAAAGCTTGGCTTGGAGCCTGTTGGT 3´ 
540 
5´GCGGTCATGGAATTACCTTCAACCTCAAGCCAGAATGCAGAATCACTGGCTTTTTTGGT  3´ 
600 
5´GTGCTTACCCATCTCTCCGCATCACCTTTGGTAAAGGTTCTAAGCTTAGGTGAGAACATC 3´ 
660 
5´CCTGCCTGAACATGAGAAAAAACAGGGTACTCATACTCACTTCTAAGTGACGGCTGCATA 3´ 
720 
5´CTAACCGCTTCATACATCTCGTAGATTTCTCTGGCGATTGAAGGGCTAAATTCTTCAAC  3´ 
780 
5´CTAACTTTGAGAATTTTTGTAAGCAATGCGGCGTTATAAGCATTTAATGCATTGATGCCA 3´ 
840 
5´TTAAATAAAGCACCAACGCCTGACTGCCCCATCCCCATCTTGTCTGCGACAGATTCCTGG 3´ 
900 
5´GATAAGCCAAGTTCATTTTTCTTTTTTTCATAAATTGCTTTAAGGCGACGTGCGTCCTC  3´ 
960 
5´AGCTGCTCTTGTGTTAATGGTTTCTTTTTTGTGCTCATACGTTAAATCTATCACCGCAAG 3´ 
1020 
5´GGATAAATATCTAACACCGTGCGTGTTGACTATTTTACCTCTGGCGGTGATAATGGTTGC 3´ 
1080 
5´ATGTACTAAGGAGGTTGTATGGAACAACGCATAACCCTGAAAGATTATGCAATGCGCTT  3´ 
1140 
5´GGGCAAACCAAGACAGCTAAAGATCAAGAATGTTGATCTTCAGTGTTTCGCCTGTCTGTT 3´ 
1200 
5´TTGCACCGGAATTTTTGAGTTCTGCCTCGAGTAATTTACCAACACTACTACGTTTTAACT 3´ 
1260 
5´GAAACAAACTGGAGACTGCCATGCACAAGTGCGATATCACCTTACAGGAGATCATCAAA  3´ 
1320 
5´CTTTGAACAGCCTCACAGAGCAGAAGACTCTGTGCACCGAGTTGACCGTAACAGACATCT 3´ 
1380 
5´TTGCTGCCTCCAAGAACACAACTGAGAAGGAAACCTTCTGCAGGGCTGCGACTGTGCTCC 3´ 
1440 
5´GGCAGTTCTACAGCCACCATGAGAAGGACACTCGCTGCCTGGGTGCGACTGCACAGCAG  3´ 
1500 
5´TCCACAGGCACAAGCAGCTGATCCGATTCCTGAAACGGCTCGACAGGAACCTCTGGGGCC 3´ 
1560 
5´TGGCGGGCTTGAATTCCTGTCCTGTGAAGGAAGCCAACCAGAGTACGTTGGAAAACTTCT 3´ 
1620 
5´TGGAAAGGCTAAAGACGATCATGAGAGAGAAATATTCAAAGTGTTCGAGCTGATAAGGA  3´ 
1680 
TS
T
T
C
T
G
A
T
A
T
T
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5´CCCGCAAAAGCGGCCTTTGACTCCCTGCAAGCCTCAGCGACCGAATATATCGGTTATGCG 3´ 
1740 
5´TGGGCGATGGTTGTTGTCATTGTCGGCGCAACTATCGGTATCAAGCTGTTTAAGAAATTC 3´ 
1800 
5´ACCTCGAAAGCAAGCTGATAAACCGATACAATTAAAGGCTCCTTTTGGAGCCTTTTTTT  3´ 
1860 
5´TGGAGATTTTCAACGTGAAAAAATTATTATTCGCAATTCCTTTAGTTGTTCCTTTCTATT 3´ 
1920 
5´CTCACTCCGCTGAAACTGTTGAAAGTTGTTTAGCAAAACCTCATACAGAAAATTCATTTA 3´ 
1980 
5´CTAACGTCTGGAAAGACGACAAAACTTTAGATCCGGCCAAGCTTCGTCGACCCTGCCTC  3´ 
2040 
5´CGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAG 3´ 
2100 
5´CTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTG 3´ 
2160 
5´GCGGGTGTCGGGGCGCAGCCATGACCCAGTCACGTAGCGATAGCGGAGTGTATACTGGC  3´ 
2220 
5´TAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACC 3´ 
2280 
5´GCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCTCTTCCGCTTCCTCGCTCACTGA 3´ 
2340 
5´CTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAA  3´ 
2400 
5´ACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCA 3´ 
2460 
5´AAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCC 3´ 
2520 
5´TGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTAT  3´ 
2580 
5´AAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCC 3´ 
2640 
5´GCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTC 3´ 
2700 
5´ACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACG  3´ 
2760 
5´ACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCC 3´ 
2820 
5´GGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAG 3´ 
2880 
5´GTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAA  3´ 
2940 
5´GACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAG 3´ 
3000 
5´CTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCA 3´ 
3060 
5´GATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTG  3´ 
3120 
5´CGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGAT 3´ 
3180 
5´CTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGA 3´ 
3240 
5´GTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCT  3´ 
3300 
5´TCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGA 3´ 
3360 
5´GGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCC 3´ 
3420 
5´AGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAA  3´ 
3480 
5´TTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCC 3´ 
3540 
T
G
T
T
A
A
G
A
G
C
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5´AGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTGCAGGCATCGTGGTGTCACGCTCGTC 3´ 
3600 
5´GTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCC 3´ 
3660 
5´CATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGT  3´ 
3720 
T
5´GGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCC 3´ 
3780 
5´ATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTG 3´ 
3840 
5´TATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAACACGGGATAATACCGCGCCACATAG 3´ 
3900 
5´CAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGAT 3´ 
3960 
5´CTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGC 3´ 
4020 
5´ATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAA 3´ 
4080 
5´AAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTA 3´ 
4140 
5´TTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAA 3´ 
4200 
5´AAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGA 3´ 
4260 
5´AACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCT 3´ 
4320 
5´TCAAGAA 3´ 
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